---
document_datetime: 2024-09-16 16:12:21
document_pages: 98
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0082-epar-assessment-report-variation_en.pdf
document_name: tecentriq-h-c-004143-ii-0082-epar-assessment-report-variation_en.pdf
version: success
processing_time: 240.5600705
conversion_datetime: 2025-12-20 18:35:15.522216
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 July 2024 EMA/CHMP/111305/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Tecentriq

International non-proprietary name: Atezolizumab

Procedure No. EMEA/H/C/004143/II/0082

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................6                                                          |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................ | 6                                                                                                        |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 7                                                |
| 2. Scientific discussion                                                                                                | ................................................................................7                        |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 7 |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 8             |
| 2.1.2. About the product                                                                                                | ........................................................................................... 9            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                        | ....... 9                                                                                                |
| 2.1.4. General comments on compliance with GCP                                                                          | ...................................................... 10                                                |
| 2.2. Non-clinical aspects..........................................................................................     | 10                                                                                                       |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                | 10                                                                                                       |
| 2.3. Clinical aspects ................................................................................................  | 10                                                                                                       |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 10     |
| 2.3.2. Pharmacokinetics                                                                                                 | .......................................................................................... 12            |
| 2.3.3. Pharmacodynamics........................................................................................         | 14                                                                                                       |
| 2.3.4. PK/PD modelling............................................................................................      | 17                                                                                                       |
| 2.3.5. Discussion on clinical pharmacology                                                                              | ................................................................. 17                                     |
| 2.3.6. Conclusions on clinical pharmacology                                                                             | ............................................................... 18                                       |
| 2.4. Clinical efficacy                                                                                                  | ................................................................................................ 18      |
| 2.4.1. Dose response study(ies)                                                                                         | ............................................................................... 18                       |
| 2.4.2. Main study                                                                                                       | ................................................................................................... 19   |
| 2.4.3. Discussion on clinical efficacy ..........................................................................       | 56                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy...................................................................          | 59                                                                                                       |
| 2.5. Clinical safety                                                                                                    | .................................................................................................. 59    |
| 2.5.1. Discussion on clinical safety ............................................................................       | 86                                                                                                       |
| 2.5.2. Conclusions on clinical safety ..........................................................................        | 90                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                       | ................................................................................................... 90   |
| 2.6. Risk management plan......................................................................................         | 90                                                                                                       |
| 2.7. Update of the Product information                                                                                  | ...................................................................... 93                                |
| 2.7.1. User consultation...........................................................................................     | 93                                                                                                       |
| 3. Benefit-Risk Balance..............................................................................93                 |                                                                                                          |
| 3.1. Therapeutic Context .........................................................................................      | 93                                                                                                       |
| 3.1.1. Disease or condition.......................................................................................      | 93                                                                                                       |
| 3.1.2. Available therapies and unmet medical need .....................................................                 | 93                                                                                                       |
| 3.1.3. Main clinical studies                                                                                            | ....................................................................................... 94               |
| 3.2. Favourable effects............................................................................................     | 94                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ........................................... 94                                                           |
| 3.4. Unfavourable effects.........................................................................................      | 95                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | ........................................ 95                                                              |
| 3.6. Effects Table                                                                                                      | ................................................................................................... 96   |
| 3.7. Benefit-risk assessment and discussion                                                                             | ............................................................... 96                                       |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ............................................ 96                                                          |
| 3.7.2. Balance of benefits and risks...........................................................................         | 97                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 3.7.3. Additional considerations on the benefit-risk balance ..........................................               |   97 |
|-----------------------------------------------------------------------------------------------------------------------|------|
| 3.8. Conclusions..................................................................................................... |   97 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADA                                                                                | Anti-drug antibody                                                                 |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| ADR                                                                                | Adverse drug reaction                                                              |
| AJCC                                                                               | American Joint Committee on Cancer                                                 |
| AE                                                                                 | Adverse event                                                                      |
| AESI                                                                               | Adverse event of special interest                                                  |
| ALK                                                                                | Anaplastic lymphoma kinase                                                         |
| BSC                                                                                | Best supportive care                                                               |
| CCOD                                                                               | Clinical cutoff date                                                               |
| CNS                                                                                | Central nervous system                                                             |
| CR                                                                                 | Complete response                                                                  |
| CSR                                                                                | Clinical study report                                                              |
| DOR                                                                                | Duration of response                                                               |
| ECOG                                                                               | Eastern Cooperative Oncology Group                                                 |
| eCRF                                                                               | Electronic case report form                                                        |
| EGFR                                                                               | Epidermal growth factor receptor                                                   |
| EMA                                                                                | European Medicines Agency                                                          |
| EORTC                                                                              | European Organisation for Research and treatment of Cancer                         |
| ESMO                                                                               | European Society for Medical Oncology                                              |
| ES-SCLC End-stage small cell lung cancer                                           | ES-SCLC End-stage small cell lung cancer                                           |
| EU                                                                                 | European Union                                                                     |
| FDA                                                                                | Food and Drug Administration                                                       |
| GCP                                                                                | Good Clinical Practice                                                             |
| HA                                                                                 | Health Authority                                                                   |
| HR                                                                                 | Hazard ratio                                                                       |
| HRQoL                                                                              | Health-related quality of life                                                     |
| IC                                                                                 | Tumor-infiltrating immune cells                                                    |
| ICH                                                                                | International Conference on Harmonization                                          |
| ICI                                                                                | Immune checkpoint inhibitor                                                        |
| IDCC                                                                               | Independent data coordinating centre                                               |
| IDMC                                                                               | Independent Data Monitoring Committee                                              |
| Ig                                                                                 | Immunoglobulin                                                                     |
| IHC                                                                                | Immunohistochemistry                                                               |
| IV                                                                                 | Intravenous                                                                        |
| ITT                                                                                | Intent-to-treat                                                                    |
| IxRS                                                                               | Interactive voice/web response system                                              |
| KM                                                                                 | Kaplan-Meier                                                                       |
| MedDRA Medical Dictionary for Regulatory Activities                                | MedDRA Medical Dictionary for Regulatory Activities                                |
| MRI                                                                                | Magnetic resonance imaging                                                         |
| NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events | NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events |
| NCCN                                                                               | National Comprehensive Cancer Network                                              |

<div style=\"page-break-after: always\"></div>

| NSCLC                                                        | Non-small cell lung cancer                                   |
|--------------------------------------------------------------|--------------------------------------------------------------|
| ORR                                                          | Objective response rate                                      |
| OS                                                           | Overall survival                                             |
| PD-1                                                         | Programmed death-1                                           |
| PD-L1                                                        | Programmed death-ligand 1                                    |
| PI                                                           | Product information                                          |
| PK                                                           | Pharmacokinetic                                              |
| PFS                                                          | Progression-free survival                                    |
| PR                                                           | Partial response                                             |
| PRO                                                          | Patient-reported outcome                                     |
| PS                                                           | Performance status                                           |
| q2w                                                          | Every 2 weeks                                                |
| q3w                                                          | Every 3 weeks                                                |
| q4w                                                          | Every 4 weeks                                                |
| QLQ-C30 Quality of life Questionnaire Core 30                | QLQ-C30 Quality of life Questionnaire Core 30                |
| QLQ-LC13 Quality of life Questionnaire Lung Cancer Module 13 | QLQ-LC13 Quality of life Questionnaire Lung Cancer Module 13 |
| RCT                                                          | Randomized controlled trial                                  |
| RECIST Response Evaluation Criteria in Solid Tumors          | RECIST Response Evaluation Criteria in Solid Tumors          |
| SAE                                                          | Serious adverse event                                        |
| SAP                                                          | Statistical analysis plan                                    |
| SC                                                           | Subcutaneous                                                 |
| SCE                                                          | Summary of Clinical Efficacy                                 |
| SCLC                                                         | Small cell lung cancer                                       |
| SOC                                                          | System organ class                                           |
| TC                                                           | Tumor cell                                                   |
| TNBC                                                         | Triple-negative breast cancer                                |
| TTCD                                                         | Time to confirmed deterioration                              |
| UC                                                           | Urothelial carcinoma                                         |
| U.K.                                                         | United Kingdom                                               |
| ULN                                                          | Upper limit of normal                                        |
| U.S.                                                         | United States                                                |
| 1L                                                           | First-line                                                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 24 August 2023 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I                  |

Extension of indication to include first-line treatment of adult patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy and who do not have EGFR mutant or ALK-positive disease, who have: locally advanced unresectable NSCLC not amenable for definitive chemoradiotherapy, or metastatic NSCLC, for TECENTRIQ, based on final results from study MO29872 (IPSOS); this is a phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment naive advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic (stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. Version 29.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.

The variation requested amendments to the Summary of Product Characteristics and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/0207/2019 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0207/2019 was completed.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Aaron Sosa Mejia

| Timetable                                                                       | Actual dates      |
|---------------------------------------------------------------------------------|-------------------|
| Submission date                                                                 | 24 August 2023    |
| Start of procedure:                                                             | 16 September 2023 |
| CHMP Rapporteur Assessment Report                                               | 9 November 2023   |
| PRAC Rapporteur Assessment Report                                               | 20 November 2023  |
| Updated PRAC Rapporteur Assessment Report                                       | 24 November 2023  |
| PRAC Outcome                                                                    | 30 November 2023  |
| CHMP members comments                                                           | 4 December 2023   |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                            | 8 December 2023   |
| Request for supplementary information (RSI)                                     | 14 December 2023  |
| Rapporteur's preliminary assessment report on the MAH's responses circulated on | 27 March 2024     |
| Rapporteur's updated assessment report on the MAH's responses circulated on     | 18 April 2024     |
| 2 nd request for supplementary information                                      | 25 April 2024     |
| Rapporteur's preliminary assessment report on the MAH's responses circulated on | 27 June 2024      |
| Rapporteur's updated assessment report on the MAH's responses circulated on     | 19 July 2024      |
| CHMP opinion                                                                    | 25 July 2024      |

## 2. Scientific discussion

## 2.1. Introduction

This application seeks marketing authorisation for Tecentriq (atezolizumab) monotherapy for the firstline  (1L)  treatment  of  adult  patients  with  non-small  cell  lung  cancer  (NSCLC)  who  are  ineligible  for platinum-based chemotherapy and who do not have epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive disease, who have locally advanced, unresectable NSCLC not amenable for definitive chemoradiotherapy, or metastatic NSCLC based on results from Study MO29872 (hereafter referred to as IPSOS). This study is a Roche-sponsored, global, randomized controlled Phase III  trial  that  compared  the  efficacy  and  safety  of  atezolizumab  monotherapy  versus  single-agent chemotherapy (gemcitabine or vinorelbine as per investigator's choice) in patients with treatment-naïve locally  advanced  or  metastatic  NSCLC  not  harboring  an  EGFR  mutation  or  ALK  translocation  and regardless of programmed death-ligand 1 (PD-L1) expression status who were deemed unsuitable for platinum-doublet  chemotherapy.  IPSOS  enrolled  453 patients  across  23  countries  in  North  America, Central and South America, Asia Pacific, Europe and the Middle East.

<div style=\"page-break-after: always\"></div>

## 2.1.1. Problem statement

## Disease or condition

The MAH applied for the following indication: Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with NSCLC who are ineligible for platinum-based chemotherapy, and who do not have EGFR-mutant or ALK-positive NSCLC, who have:

- locally advanced, unresectable NSCLC not amenable for definitive chemoradiotherapy, or
- metastatic NSCLC (see section 5.1)

## Epidemiology

Lung cancer remains the leading cause of cancer deaths worldwide; it is the most common cancer in men (together with prostate cancer) and the third most common cancer in women (after breast and colorectal cancer). It accounted for approximately 11% of all new cancers in 2020 with an estimated 2.2 million new cancer cases and 1.8 million death (Sung et al. 2021).

Half of all newly diagnosed NSCLC patients present with advanced disease (Stage IIIb or IV) (SEER 2023). In addition to advanced disease at diagnosis, patients could present with poor performance status (PS), advanced age and a history of unintentional weight loss (Bailey et al. 2023).

Platinum-based chemotherapy regimens are an efficacious standard of care, but can in some patients with substantial comorbidities or specific contraindications not be tolerated and therefore not an available treatment option (Quoix et al. 2011). For this reason, treatment tolerability is an important factor in treatment decisions for patients.

## Management

The current European Society for Medical Oncology (ESMO) treatment guidelines point out the lack of evidence for cancer immunotherapies in NSCLC patients with an Eastern Cooperative Oncology Group (ECOG) PS of ≥2 due to the exclusion of this patient popula tion from clinical trials. The United Kingdom (U.K.) based, single arm, Phase II PePS2 trial studied pembrolizumab monotherapy in patients with advanced NSCLC and an ECOG PS of 2, regardless of PD-L1 expression level and number of previous lines  of  treatment.  Based  on  these  data,  the  ESMO  panel  states  that  this  treatment  option  can  be considered in patients with ECOG PS 2. Recommended therapies for the 1L treatment of patients with advanced NSCLC and an ECOG PS ≥2 are platinum based doublets in eligible pat ients,  single  agent chemotherapy with gemcitabine, vinorelbine, docetaxel or pemetrexed (for non-squamous NSCLC only), and best supportive care (BSC) in patients with an ECOG PS of 3 or 4. Similar to patients with an ECOG PS of 2, in elderly patients, single agent chemotherapy is superior to BSC (The Elderly Lung Cancer Vinorelbine Italian Study Group 1999) and carboplatin-based chemotherapy combinations are superior to  non-platinum-based  combinations  or  single-agent  chemotherapy,  though  with  increased  toxicity (without  significantly  compromising  QoL).  Platinum  based  chemotherapy  is  the  preferred  option  for elderly  patients  with  PS  0-2  with  adequate  end  organ  function,  while  a  single  agent  approach  is recommended for the treatment of unfit or co-morbid patients.

Despite  the  limited  survival  benefit  conferred  by  cytotoxic  chemotherapy,  platinum-based  regimens remain the standard first-line option for most patients with locally advanced and metastatic NSCLC not harbouring an activating epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement. In particular, for newly diagnosed advanced stage non-squamous NSCLC, standard of care is a platinum-

Assessment report

Error! Unknown document property name.

<div style=\"page-break-after: always\"></div>

doublet with either cisplatin or carboplatin and a taxane or pemetrexed, with or without bevacizumab. The  combination  of  gemcitabine  and  a  platinum  analogue  (either  carboplatin  or  cisplatin)  has  also demonstrated efficacy as first-line treatment for NSCLC. Additionally, both vinorelbine and gemcitabine have been considered to have demonstrated improvement over BSC and are well tolerated.

In recent years, the use of immune checkpoint inhibitors (ICIs) has radically changed clinical practice and treatment paradigms in locally advanced, metastatic, and early-stage resectable NSCLC. Clinicians and researchers have pointed towards the lack of evidence-based treatment options for single-agent cancer immunotherapy in patients with poor PS and those ineligible for platinum-based therapy. These gaps provided the rationale for evaluating the benefits and risks of atezolizumab monotherapy in patients ineligible for platinum-based chemotherapy. Due to atezolizumab's well-established efficacy, safety, and pharmacokinetic (PK) profile, single agent atezolizumab was chosen to study its impact on OS in patients with 1L advanced or metastatic NSCLC deemed ineligible for platinum doublet therapy in the Phase III IPSOS trial.

## 2.1.2. About the product

Tecentriq  (hereinafter  atezolizumab)  is  a  humanized  immunoglobulin  (Ig)  G1  monoclonal  antibody consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster ovary cells. Atezolizumab targets human programmed death-ligand 1 (PD L1) on tumor infiltrating immune cells (ICs) and tumor cells (TCs) and inhibits its interaction with its receptors, programmed death-1 (PD 1) and B7.1, both of which can provide inhibitory signals to T cells.

Atezolizumab is globally approved for the treatment of patients with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC) as first-line (1L) therapy if their tumors are PD-L1 high (≥50%) or after prior chemotherapy (regardless of PD -L1 expression level), as well as 1L treatment of metastatic non-squamous NSCLC in combination with chemotherapy with or without bevacizumab. In addition,  atezolizumab  monotherapy  is  approved  for  adjuvant  treatment  of  Stage  II  to  IIIA  NSCLC following resection and platinum-based chemotherapy in patients whose tumors have PD-L1 expression of ≥50%.

Atezolizumab  is  also  globally  approved  for  the  treatment  of  a  variety  of  other  cancers,  including extensive-stage small-cell lung cancer (ES-SCLC), urothelial cancer (UC), triple negative breast cancer (TNBC), melanoma, and hepatocellular carcinoma (HCC). In the US, atezolizumab is also approved for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

## Table 1. Summary of Key Discussions with EMA and (Co-)Rapporteurs

| Key request/agreements (if relevant)                                                                                                                                            | Comment                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| The (Co-)Rapporteurs expressed concerns regarding the lack of PK sample collection in this fragile population and recommended preparing a robust justification to address this. | A rationale for not collecting PK data in IPSOS is provided in Section 2.3.2. |

<div style=\"page-break-after: always\"></div>

| The (Co-)Rapporteurs raised concerns regarding the definition of platinum-ineligibility and the adequacy of the choice of chemotherapy for the comparator arm. They recommended investigating efficacy endpoints according to chemotherapy.   | Rationale for the population enrolled in IPSOS and for the choice of chemotherapy for the comparator arm is provided in Section 2.4.3.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| The (Co-)Rapporteurs expressed interest in additional analyses by PD-L1 subgroups with both SP142 and SP263 assays to confirm the consistency of the treatment effect across PD-L1 subgroups.                                                 | The requested analyses are provided in Section 2.4.2.                                                                                    |
| The (Co-)Rapporteurs raised concerns regarding the safety data, in particular the higher proportion of SAEs and fatal AEs observed in the atezolizumab arm.                                                                                   | These data are discussed in Section 2.5.1.                                                                                               |

AE = adverse  event;  PD-L1 = programmed  death-ligand  1;  PK = pharmacokinetic;  ORR = objective  response  rate;  OS = overall survival; PFS = progression-free survival; SAE = serious adverse event;

## 2.1.4. General comments on compliance with GCP

Phase III Study IPSOS was conducted in accordance with the principles of the 'Declaration of Helsinki' and GCP. The appropriate Ethics Committees and Institutional Review Boards reviewed and approved the study.

No audits were conducted for this study.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Tecentriq (atezolizumab) is a protein and is therefore exempt from the Environmental Risk Assessment (ERA) requirements. This is compliant with the current Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00).

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has confirmed that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Assessment report

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

Table 2. A summary of atezolizumab studies utilised to support the summary of clinical pharmacology

| Atezolizumab Monotherapy Studies   | Phase   | Indication            | N Enrolled/PKevaluable (Total 3135/3079)b   | Design/Dose/Primary Clinical Endpoint                                                                                                                         | Howthestudywasutilizedto support the SCP                                                                                                                                                     |
|------------------------------------|---------|-----------------------|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PCD4989g (GO27831)                 |         | Multiple solid tumors | 481/473                                     | Dose-escalation/ up to 20 mg/kg q3w/ PK and safety                                                                                                            | Phase 1 popPKa (Section 3.2) Pooled monotherapy ER (Section 3.5) Age assessment (Section 3.3.2) Renal impaiment assessment(Section 3.3.1.1) Hepatic impairment assessmenta (Section 3.3.1.2) |
| JO28944                            |         | Multiple solid tumors | 6/6                                         | Dose-escalation/ 10 mg/kg and 20 mg/kg q3w/ PK and safety                                                                                                     | Phase 1 popPKa (Section 3.2) Pooled monotherapy ER (Section 3.5) Age assessment (Section 3.3.2) Renal impaiment assessment?(Section 3.3.1.1) Hepatic impairment assessment(Section 3.3.1.2)  |
| IMvigor211 (GO29294)               | III     | 2L/3L mUC             | 467/455                                     | 2-arm study/ 1200 mg q3w vs. vinflunine, paclitaxel,ordocetaxel/os                                                                                            | Age assessment (Section 3.3.2)                                                                                                                                                               |
| POPLAR (GO28753)                   | II      | 2L/3L NSCLC           | 144/142                                     | 2-arm study/ 1200 mg q3w vs. docetaxel/ OS                                                                                                                    | Age assessment(Section 3.3.2)                                                                                                                                                                |
| OAK (GO28915)                      | III     | 2L/3L NSCLC           | 613/606                                     | 2-arm study/ 1200 mg q3w vs.docetaxel/ OS                                                                                                                     | Age assessment (Section 3.3.2)                                                                                                                                                               |
| IMpower110 (GO29431)               | III     | 1L NSCLC              | 285/284                                     | 2-arm study/1200 mg q3w vs. cisplatin/carboplatin + pemetrexed/gemcitabine/Os                                                                                 | Simulation comparison with IPSOS (Section 3.2.1)                                                                                                                                             |
| IMvigor130 (WO30070)               | III     | 1L mUC                | 803/789                                     | 3-am study/1200 mg q3w vs. 1200mgq3w+carboplatin+ gemcitabine or cisplatin + gemcitabine vs. placebo + carboplatin+ gemcitabine or cisplatin + gemcitabine/OS | BaselineECOGPS assessment (Section 3.4.1)                                                                                                                                                    |
| IMbrave150 (YO40245)               | III     | 1L mHCC               | 336/324                                     | 2-arm study/1200 mg q3w + bevacizumab 15 mg/kg q3w vs. sorafenib400mgBID/OS                                                                                   | Hepatic impairment assessment(Section 3.3.1.2)                                                                                                                                               |

1L=first-line; 2L=second-line; 2L +=second-line and beyond; BID=twice per day; CSR=Clinical Study Report; DFS=disease-free survival; mHCC=metastatic hepatocellularcarcinoma;mRcC=metastaticrenal cell carcinoma;mUC=metastaticurothelial carcinoma;NSCLC=non-smallcallungcancer,ORR=overall response rate; q3w=every 3 weeks; OS=overall survival; PK=pharmacokinetic.

a The atezolizumab Phase 1 popPK(Report No. 1066935) also included assessments for renal and hepatic impaiment

bFor randomized studies (i.e., IMvigor211, POPLAR, OAK, IMpower110, IMvigor130, and IMbrave150), number enrolled corresponds to the number of patients enrolled into the arm that includes atezolizumab therapy.

Study MO29872 (IPSOS) is a global, randomised controlled Phase III trial that compared the efficacy and safety of atezolizumab monotherapy versus single-agent chemotherapy (gemcitabine or vinorelbine as per investigator's choice) in patients with treatment-naïve locally advanced or metastatic NSCLC, who were  deemed  unsuitable  for  platinum  doublet  chemotherapy.  The  main  focus  of  this  study  was  to evaluate  efficacy  and  safety  of  atezolizumab  monotherapy  in  this  patient  population  and  given  the extensive information on pharmacokinetics (PK) and anti-drug antibodies (ADA) already available for

<div style=\"page-break-after: always\"></div>

atezolizumab, PK and ADA samples were not collected in IPSOS.

## 2.3.2. Pharmacokinetics

## Estimation of PK in IPSOS

Atezolizumab PK and ADA samples were not collected in IPSOS and thus, no bioanalysis information is available  and  no  population  PK  analysis  was  conducted  for  IPSOS.  Instead,  atezolizumab  popPK simulated  concentrations  using  selected  observed  median  covariate  values  from  the  IPSOS  patient population were compared to atezolizumab simulations using observed median covariate values from the IMpower110 patient population in order to demonstrate PK similarity. The IMpower110 study was a study  evaluating  monotherapy  atezolizumab  in  1L  NSCLC  patients,  similar  to  the  IPSOS  study,  and chosen as the reference population.

The popPK model developed in Phase I patients (Atezolizumab Phase I PopPK Report 1066935) showed that  albumin,  body  weight,  tumour  burden  (sum  of  longest  diameters  of  target  lesions),  sex,  and presence of ADA are significant covariates of atezolizumab PK.

Two sets of  median  covariates  representing  IMpower110  and  IPSOS  were  used  to  predict  exposure metrics for each study. For IMpower110 median values of albumin, body weight and tumour burden were 40 g/L, 70 kg, and 80 mm; for IPSOS median values albumin, body weight and tumour burden were 38 g/L, 65 kg, and 83 mm for, respectively. The popPK simulations were done for male and ADA-negative patients at an atezolizumab dose of 1200 mg q3w at Cycle 1 and at steady-state (Table 3).

Table 3. Typical exposures in IMpower110 and IPSOS after simulations using median covariates (in male with ADA negative patients) at 1200 mg Q3W

|                  | IMpower110   | IPSOS   |
|------------------|--------------|---------|
| Cycle 1          |              |         |
| Typical CL (L/d) | 0.191        | 0.191   |
| Cmax (μg/mL)     | 440          | 451     |
| Cmin (μg/mL)     | 94.1         | 94.0    |
| AUC (μg-d/mL)    | 3399         | 3422    |
| Steady-state     |              |         |
| Cmax (μg/mL)     | 631          | 640     |
| Cmin (μg/mL)     | 190          | 188     |
| AUC (μg·d/mL)    | 6282         | 6268    |

ADA= anti-drug antibody; AUC = area under the concentration-time curve; Cmin = minimum concentration;Cmax=maximumconcentration

Note: Median albumin, body weight and tumor burden of 40 g/L, 70 kg and 80 mm, respectively, in IMpower110 and38g/L,65kg and 83 mm, respectively,in IPS0S.

## ADME characteristics

Atezolizumab in both monotherapy and combination has been evaluated across a number of indications and has exhibited similar PK across all of these studies.

<div style=\"page-break-after: always\"></div>

Figure 1. Cross-study Box Plot of atezolizumab 1200 mg Q3W observed Ctrough (right) and Model-predicted weekly AUC (left) at Cycle 1

<!-- image -->

AUC=area under the concentration-time curve; Ctrough =pre-dose trough concentration. For observed Ctrough, X-axis is capped at 300 μg/ml, actual data extends to ~600 μg/mL. Included in the plot are the studies of approved Tecentriq indications for mUC: IMvigor210, IMvigor211; IMpassion130;NSCLC:POPLAR;melanoma:IMsipre150;HCC:IMbrave150;RCC:IMmotion151.In addition, the 1200 mg Q3W cohort from FIH study PCD4989g was included. Observed Cycle 1 Ctrough (μg/mL) is not available for IMpassion130.

Model predicted CL for IMpower110 and IPSOS of 0.191 L/d were similar to the CL in the atezolizumab SmPC of 0.2 L/d.

## Special populations

## Organ impairment

There are no clinically important differences in atezolizumab clearance in patients with mild or moderate hepatic or renal impairment compared with patients with normal hepatic/renal function. Overall, 69% (208/300) of patients who received treatment with atezolizumab in IPSOS had renal impairment (51% [n =154] mild, 18% [n = 53] moderate and &lt;1% [n = 1] severe). Overall, 9% (26/300) of patients who received  treatment  with  atezolizumab  in  the  IPSOS  study  had  hepatic  impairment  as  defined  using National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria (8% [n =24] mild, &lt;1% [n =2] moderate).

## Age

The IPSOS median age was 75 years versus atezolizumab monotherapy pooled median age of 64 years which was also the median age of IMpower110 population. No dose adjustment of Tecentriq is required in patients ≥ 65 years of age. In the atezolizumab arm of IP SOS, 15% of patients were &lt;65 years of

<div style=\"page-break-after: always\"></div>

age, 33% of patients were 65 - 74 years of age, 46% of patients were 75 - 84 years of age, and 5% of patients were ≥ 85 years of age.

## Baseline ECOG

In the IPSOS patient population, there were more patients with baseline ECOG performance status 2 and 3, as compared to other atezolizumab monotherapy studies to date. The IMpower110 reference population included only 1L NSCLC patients with ECOG 0 or 1. Based on data from IMvigor130 which included patients with ECOG 2 status and sub-group analysis of safety data from IPSOS, baseline ECOG status is not expected to impact PK.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Programmed  death-ligand  1  (PD-L1)  may  be  expressed  on  tumour  cells  and/or  tumour-infiltrating immune cells, and can contribute to the inhibition of the antitumour immune response in the tumour microenvironment.  Binding  of  PD-L1  to  the  PD-1  and  B7.1  receptors  found  on  T-cells  and  antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.

Atezolizumab  is  an  Fc-engineered,  humanised  immunoglobulin  G1  (IgG1)  monoclonal  antibody  that directly  binds  to  PD-L1  and  provides  a  dual  blockade  of  the  PD-1  and  B7.1  receptors,  releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity. Atezolizumab spares the PD-L2/PD-1 interaction allowing PD-L2/PD-1 mediated inhibitory signals to persist.

## Primary and secondary pharmacology

No pharmacodynamics studies were conducted for the current application. No PK and PD samples were collected in the IPSOS trial.

## Analyses of exposure-response in the monotherapy setting

Exposure-response (ER) analyses were not conducted for the IPSOS study since no PK samples were collected;  however,  pooled  ER  analyses  have  been  conducted  for  atezolizumab  monotherapy  across various indications (Atezolizumab pooled ER Report 1087176) submitted to the EMA as part of the Type II variation EMEA/H/C/004143/II/0022.

Figure 2 and Figure 3 represent the ER analysis conducted for safety from the pooled atezolizumab monotherapy ER analysis ,  evaluating the relationship between atezolizumab Cycle 1 AUC and the proportion of patients experiencing Grade ≥ 3 AEs, and atezolizumab Cycle 1 AUC and the proportion of patients experiencing AEs of special interest (AESI) of any grade, respectively.

Figure 4 represents the ER  analysis conducted  for efficacy from the pooled  atezolizumab monotherapy ER analysis ,  evaluating the relationship between atezolizumab Cycle 1 AUC and the objective response rate. Figure 5 presents the ER analysis conducted for efficacy, which presents the overall survival distribution stratified over atezolizumab Cycle 1 AUC quartiles. The doses tested in the ER  safety  and  efficacy  analyses  included  patients  who  received  atezolizumab  1200  mg  q3w  in PCD4989g, IMvigor211 and OAK (N=1056); patients from PCD4989g who received 10 to 20 mg/kg q3w (N=172); and one patient who received 1 mg/kg atezolizumab q3w from study PCD4989g .

<div style=\"page-break-after: always\"></div>

Figure 2. Proportion of Patients Experiencing AE of Grade ≥ 3 vs. Cycle 1 AUC from Patients with NSCLC or UBC in Studies PCD4989g (NSCLC and mUC Cohorts), IMvigor211, and OAK

<!-- image -->

AUC = area under the concentration-time curve; AE = adverse event; AEG35 = adverse events of Grade 3 to 5; CI = confidence interval; N = number of patients; NSCLC = non -small cell lung cancer; UBC = urothelial bladder cancer; p = p-value of Wald test in logistic regression of incidence versus exposure.

Notes: For legibility, two extreme AUC values (&gt;15000 μ g.day/mL) are not displayed on the plot. The data cutoff dates are 2 December 2014, 13 March 2017, and 7 July 2016 for Studies PCD4989g, IMvigor211 and OAK, respectively. The thick solid line and shaded area represent the logistic regression slope model and 95% prediction interval.  The filled circles and error bar represent the incidence in exposure quartiles and 95% CI. The vertical lines are the limits of the exposure quartiles.  The cross is AE events (0: No, 1: Yes).  The triangle and two-headed arrow represent the mean exposure and exposure interval between the 10th and the 90th percentile for patients receiving 1200 mg atezolizumab, respectively.

Figure 3. Proportion of Patients Experiencing AESI vs Cycle 1 AUC from Patients with NSCLC or mUC in Study PCD4989g (NSCLC and UBC cohorts), IMvigor211 and OAK

<!-- image -->

<div style=\"page-break-after: always\"></div>

AUC = area under the concentration-time curve; AESI = adverse events of special interest of any grade; CI = confidence interval; N = number of patients; NSCLC = non -small cell lung cancer; UBC = urothelial bladder cancer; p = p value of Wald test in logistic regression of incidence versus exposure.

Notes: For legibility, two extreme AUC values (&gt;15000 μ g.day/mL) are not displayed on the plot. The data cutoff dates are 2 December 2014, 13 March 2017 and 7 July 2016 for PCD4989g, IMvigor211 and OAK, respectively. The thick solid line and shaded area represent the logistic regression slope model and 95% prediction interval. The filled circles and error bar represent the incidence in exposure quartiles and 95% CI. The vertical lines are the limits of the exposure quartiles. The cross is AE events (0: No, 1: Yes). The triangle and two-headed arrow represent the mean exposure and exposure interval between the 10th and the 90th percentile for patients receiving 1200 mg atezolizumab, respectively.

Figure 4. Objective Response Rate vs. Atezolizumab AUC at Cycle 1- mUC and NSCLC Patients

<!-- image -->

AUC = area under the curve; CI = confidence interval; CR = complete response; N = number of patients; p = p value of Wald test in logistic regression of proportion of responders versus exposure; PR = partial response; q3w = every three weeks

Notes: For legibility, one extreme AUC value (&gt;15000 μ g.day/mL) is not displayed on the plot.

The data cutoff dates are 2 December 2014, 13 March 2017 and 7 July 2016 for PCD4989g, IMvigor211 and OAK, respectively. The grey solid line and shaded area represent the logistic regression slope model and 95% prediction interval. The filled circles and error bar represent the proportion of responders in exposure quartiles and 95% CI. The vertical lines are the limits of the exposure quartiles.  The crosses are the patient response events (0: No, 1: Yes). The triangle and two-headed arrow represent the mean exposure and exposure interval between the 10th and the 90th percentile for patients receiving 1200 mg atezolizumab, respectively.

<div style=\"page-break-after: always\"></div>

Figure 5. Evaluation of the Overall Survival Model in mUC and NSCLC Patients in Study IMvigor211 and OAK: Overall Survival Distribution Stratified by Quartile of AUC Cycle 1

<!-- image -->

<!-- image -->

Notes: AUC Cycle 1 in µ g/mL; [a, b) interval notation, a is included and b is excluded, (a ≤ x &lt; b); bottom left panel: 1 st  quartile of AUC in atezolizumab arm N=191, bottom right panel: 2 nd  quartile of AUC in atezolizumab arm N=191, top left panel: 3 rd  quartile of AUC in atezolizumab arm N=191, upper right panel 4th quartile of AUC in atezolizumab arm N=191; Areas: 95% prediction interval of survival distributions; Line: Observed Kaplan-Meier distributions with censored data (crosses).

## 2.3.4. PK/PD modelling

Not applicable.

## 2.3.5. Discussion on clinical pharmacology

No PK or ADA samples were collected in Study IPSOS in 1L NSCLC patients. The patient population was similar to the patient population in IMpower110, which was used as reference. Exposure metrics for IMpower110 and IPSOS were predicted using the Phase I pop PK model using the study specific median values  of  covariates  identified  in  the  Phase  I  popPK  model  (baseline  body  weight,  albumin,  tumour burden, ADA, and gender) except for ADA status and gender. The median values of albumin, body weight and tumour burden from each study were highly comparable. The simulations were carried out in ADA negative male patients and were, as expected, highly comparable.

No difference in ADME parameters are expected in the IPSOS patient population compared to other patients receiving atezolizumab monotherapy.

No study specific intrinsic factors of  the IPSOS patient population are expected to have impact on atezolizumab PK.

<div style=\"page-break-after: always\"></div>

No statistically significant atezolizumab ER relationship was identified with any of the tested efficacy and safety endpoints. Therefore, while it is expected that IPSOS patients have similar atezolizumab PK as the already characterised atezolizumab PK across different monotherapy indications, slight increases (or decreases) in atezolizumab exposure are not expected to be clinically meaningful due to the lack of ER (for both safety and efficacy) for atezolizumab monotherapy.

Overall, the atezolizumab monotherapy PK has been extensively characterised and is not expected to be different in the IPSOS patient population.  In addition, because no statistically significant ER relationship has been identified, any potential minor differences in atezolizumab PK is not expected to be clinically meaningful.

The  following  four dosing  regimens are  recommended  for  atezolizumab  when  administered  as  a monotherapy:

- Atezolizumab 1200 mg q3w administered intravenously (IV); or
- Atezolizumab 840 mg q2w administered intravenously; or
- Atezolizumab 1680 mg q4w administered intravenously; or
- Atezolizumab 1875 mg q3w administered subcutaneously (SC).

The rationale to support the 1200 mg q3w regimen is based on the clinical data from the IPSOS study showing a positive benefit-risk of atezolizumab 1200 mg q3w in patients with treatment-naïve locally advanced or metastatic NSCLC who were deemed unsuitable for platinum-doublet chemotherapy (see Clinical Efficacy section).  The rationale to support the 840 mg q2w and 1680 mg q4w dosing regimens is based on PK modeling and simulation, ER assessments, and safety analyses submitted to the EMA as part of the Type II variation EMEA/H/C/004143/II/0022.  In the EU, these dosing regimens have been approved for the 1L NSCLC, 2L NSCLC, and UC monotherapy indications (Tecentriq SmPC).

Following the positive outcome of the Tecentriq X-76 procedure (CHMP positive opinion 09 Nov 2023 and EC decision 11 Jan 2024), Tecentriq 1875 mg SC q3w demonstrated non-inferiority when compared with the dose regimen of Tecentriq 1200 mg IV q3w. Consequently, it was concluded that the line extension for atezolizumab SC would include all current and future approved indications for atezolizumab IV (see EPAR Tecentriq X/76).

## 2.3.6. Conclusions on clinical pharmacology

The clinical pharmacology data supports the use of atezolizumab in the applied indication, by means of PK determined in other studies.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

Please see 'Pharmacodynamics' section above.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

## Title of Study

IPSOS (MO29872). A Phase III, open-label, multicentre, randomised study to investigate the  efficacy  and  safety  of  atezolizumab  compared  with  chemotherapy  in  patients  with treatment  naive  advanced  or  recurrent  (Stage  IIIB  not  amenable  for  multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed ineligible for platinum-containing therapy.

Figure 6. IPSOS (MO29872) - Study Design

<!-- image -->

IHC = immunohistochemistry; NSCLC = non-small cell lung cancer; PD = disease progression; PD-L1 = programmed cell death-ligand 1; q3w = every 3 weeks

a  Patients in the experimental arm with atezolizumab who show evidence of clinical benefit, could continue atezolizumab treatment after disease progression (RECIST v 1.1).

b  Single-agent chemotherapy (vinorelbine, oral or intravenous, or gemcitabine, intravenous) based on investigator's choice was administered per relevant local guidelines and SmPC management. Chemotherapy cycles could be 3weekly or 4-weekly.

c  Follow-up information, including subsequent anticancer therapies and any treatment related adverse events, was collected via telephone calls and/or clinic visits every 2 months (± 5 days) until death, withdrawal of consent, loss to follow-up, study termination by the Sponsor, or protocol-defined end of study, whichever came first

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

## Key Inclusion and Exclusion Criteria

Patients who were treatment-naïve for locally advanced or metastatic NSCLC and who were deemed unsuitable  for  any  platinum-doublet  chemotherapy  were  enrolled  in  IPSOS.  Key  criteria  relevant  to efficacy are summarized below.

## Key Inclusion Criteria Relevant for Efficacy

- Histologically  or  cytologically  confirmed  diagnosis  of  advanced  or  recurrent  (Stage IIIB  not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC as per the American Joint Committee on Cancer (AJCC) 7th edition.
- No sensitizing EGFR mutation (L858R or exon 19 deletions) or ALK fusion oncogene detected.
- No  prior  systemic  treatment  for  advanced  or  recurrent  (Stage  IIIB  not  amenable  for multimodality treatment) or metastatic (Stage IV) NSCLC.
- Life expectancy ≥ 8 weeks
- Deemed unsuitable  by  the  investigator  for  any  platinum-doublet  chemotherapy  due  to  poor performance status (ECOG PS of 2 or 3). However, patients ≥ 70 years of age who had an ECOG PS of 0 or 1 could be included due to:
- a) substantial comorbidities
- b) contraindication(s) for any platinum-doublet chemotherapy.
- Patients with treated, asymptomatic central nervous system (CNS) metastases were eligible, provided they met all of the following criteria:
- a) Measurable disease outside CNS

b)  Only  supratentorial  and  cerebellar  metastases  allowed  (i.e.,  no  metastases  to midbrain, pons, medulla or spinal cord)

c) No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose allowed d) No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to randomization

e) No evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study

Patients with new asymptomatic CNS metastases detected at screening had to receive radiation therapy and/or surgery for CNS metastases. Following treatment, these patients could then be eligible without the need for an additional brain scan prior to randomization, if all other criteria were met, including clinical confirmation of no evidence of interim disease progression

- Measurable disease (by RECIST v1.1)
- o Previously irradiated lesions could only be considered as measurable disease if disease progression  had  been  unequivocally  documented  at  that  site  since  radiation  and  the previously irradiated lesion was not the only site of disease.

<div style=\"page-break-after: always\"></div>

## Key Exclusion Criteria

- Patients younger than 70 years who had an ECOG PS of 0 or 1
- Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation of the brain during screening and prior radiographic assessments

a)  Spinal  cord  compression  not  definitively  treated  with  surgery  and/or  radiation  or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for &gt;2 weeks prior to randomization

- b) Leptomeningeal disease
- c) History of CNS metastases intracranial haemorrhage
- Uncontrolled or symptomatic hypercalcemia (ionized calcium &gt; 1.5 mmol/L or calcium &gt; 12 mg/dL or corrected serum calcium &gt; ULN)
- Patients  who  had  received  prior  neo-adjuvant,  adjuvant  chemotherapy,  radiotherapy,  or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last chemotherapy, radiotherapy, or chemoradiotherapy.
- Administration of a live, attenuated vaccine within 4 weeks before randomisation or anticipation that such a live attenuated vaccine would be required during the study.
- Treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin-2 [IL-2]) within 4 weeks or 5 half-lives of the drug, whichever was shorter, prior to randomisation.
- Treatment with systemic corticosteroids or other immunosuppressive medications (including but not  limited  to  prednisone,  dexamethasone,  cyclophosphamide,  azathioprine,  methotrexate, thalidomide, and anti-tumor necrosis factor [anti -TNF] agents)

## PD-L1 testing

Eligible patients had to provide a tumour tissue specimen for central assessment of PD-L1 expression by IHC at a central laboratory. Patients were tested prospectively using the SP142 assay for stratification and retrospectively by the SP263 assay. PD-L1 subgroup analyses by SP263 is a secondary endpoint introduced in Protocol amendment v5. The study enrolled all patients regardless of PD-L1 expression status.

Randomisation was stratified by PD-L1 expression levels determined in human formalin fixed, paraffinembedded tumour tissue, using a specific anti-PD-L1 (SP142) rabbit monoclonal primary antibody IHC assay system (VENTANA PD-L1 SP142 Assay); efficacy analyses based on this assay were exploratory in nature.

The PD-L1 IHC assay and scoring criteria were developed to measure PD-L1-specific signals on both TCs and ICs. Four levels of TC expression (TC0, TC1, TC2, TC3) and four levels of IC expression (IC0, IC1, IC2, IC3) were determined by trained pathologists and used for the assessment of PD-L1 expression in NSCLC patients.

The protocol and statistical analysis plan (SAP) used outdated terminology, namely 'PD-L1 positive' to define TC3 or IC3 which is now known as 'PD-L1 high', and 'PD-L1 negative' to define TC0/1/2 and IC0/1/2  which  is  now  known  as  'PD-L1  low  and  negative',  to  define  the  PD-L1  strata.  For  clarity,

<div style=\"page-break-after: always\"></div>

throughout the SCE, the use of the terms 'positive' and 'negative' has been replaced by the actual TC and IC cut-off levels for both PD-L1 assays used in the study.

Table 4. Criteria for PD-L1 Expression Assessment in NSCLC Studies for the VENTANA PD-L1 (SP142) Assay

| Description of IHC Scoring Criteria                                                                                                                                                                                                         | PD-L1 Expression Level   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Absence of any discernible PD-L1 staining OR presence of discernible PD-L1 staining of any intensity in ICs covering < 1% of tumour area occupied by tumour cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma | IC0                      |
| Presence of discernible PD-L1 staining of any intensity in ICs covering between ≥ 1% and < 5% of tumour area occupied by tumour cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma                             | IC1                      |
| Presence of discernible PD-L1 staining of any intensity in ICs covering between ≥ 5% and < 10% of tumour area occupied by tumour cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma                            | IC2                      |
| Presence of discernible PD-L1 staining of any intensity in ICs covering ≥ 10% of tumour area occupied by tumour cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma                                             | IC3                      |
| Absence of any discernible PD-L1 staining OR presence of discernible PD-L1 staining of any intensity in < 1% TCs                                                                                                                            | TC0                      |
| Presence of discernible PD-L1 staining of any intensity in ≥ 1% and < 5% TCs                                                                                                                                                                | TC1                      |
| Presence of discernible PD-L1 staining of any intensity in ≥ 5% and < 50% TCs                                                                                                                                                               | TC2                      |
| Presence of discernible PD-L1 staining of any intensity in ≥ 50% TCs                                                                                                                                                                        | TC3                      |

IC = tumour-infiltrating immune cell; IHC = immunohistochemistry; PD-L1 = programmed death -ligand 1; TC = tumour cell.

Protocol version 5 (19 December 2019) added the secondary endpoints of OS and PFS by RECIST v1.1 in patients with PD-L1 expression defined by the VENTANA PD-L1 SP263 IHC assay. To assess PD-L1 status,  sections  from  tumour  specimens  were  stained  using  the  PD-L1  SP263  assay  and  trained pathologists scored these tumour specimens for tumour cell expression according to a scoring algorithm measuring PD-L1 on tumour cells (TC &lt;1%, TC ≥ 1%, TC 1-49%, or TC ≥ 50% of tumour cells with membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control).

Table 5. Nomenclature of PD-L1 Subgroups

| PD-L1 subgroup         | Categories/cut-off by PD-L1 SP142 assay   | Categories/cut-off by PD-L1 SP263 assay   |
|------------------------|-------------------------------------------|-------------------------------------------|
| PD-L1 negative         | TC0 and IC0                               | < 1%                                      |
| PD-L1 positive         | TC1/2/3 or IC1/2/3                        | ≥ 1%                                      |
| PD-L1 low              | [TC1/2 and IC0/1/2] or [TC0 and IC1/2]    | 1 - 49%                                   |
| PD-L1 low and negative | TC0/1/2 and IC0/1/2                       | < 50%                                     |

<div style=\"page-break-after: always\"></div>

| PD-L1 subgroup   | Categories/cut-off by PD-L1 SP142 assay   | Categories/cut-off by PD-L1 SP263 assay   |
|------------------|-------------------------------------------|-------------------------------------------|
| PD-L1 high       | TC3 or IC3                                | ≥ 50%                                     |

IC = tumor-infiltrating immune cells; PD-L1 = programmed death-ligand 1; TC = tumor cells

## Treatments

Atezolizumab was administered at a fixed dose of 1200 mg intravenously on Day 1 of each 21-day cycle.

Patients randomised to receive single-agent chemotherapy ( vinorelbine, oral or IV or gemcitabine IV based on investigator's choice) received chemotherapy per relevant local guidelines and prescribing information. Doses and dose modifications for the selected single-agent chemotherapy were according to local standard of care and SmPCs.

- Vinorelbine: IV infusion at 25-30 mg/m 2  or oral administration at 60-80 mg/m 2  on Days 1 and 8 of each 21-day cycle or on Days 1, 8 and 15 of each 28-day cycle or weekly administration or
- Gemcitabine: IV infusion at 1 000-1 250 mg/m 2  on Days 1 and 8 of each 21-day cycle or on Days 1, 8 and 15 of each 28-day cycle

## Table 6. Randomised First-Line Single-agent Chemotherapy Trials Including Patients Deemed Unsuitable for Platinum-based Chemotherapy

| Single-Agent Chemotherapy   | Reference (Trial name)           | Phase   |   Sample size | Region (Country)   | Keyeligibilitycriteriarelatedto platinum-unsuitability                                                                                                                                                                                                                                                                                                                 | PS0/1(%)5PS2(%)5                                                                                |   PS3 5(%) | Median Age (years)s   | mos (months)s        |
|-----------------------------|----------------------------------|---------|---------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------|-----------------------|----------------------|
| Gemcitabine                 | Cappuzzo et al.2006              | II      |           117 | Italy              | KPS≥50（ECOGPS0-2)* Furtherinclusion criteria detailsrelevant to platinum-ineligibilitypopulation:Presence ofneuropathy orkidneydiseaseor any other conditionforwhichtheuseof platinumcompoundswascontraindicated                                                                                                                                                       | KPS100:18(SIT)/16(LIT) KPS90-80:55(SIT)/51 KPS 70-60:23(SIT)/30 (LIT) (LIT) KPS50:4(SIT)/3(LIT) |          0 | 72 (SIT)/ 73(LIT)     | 9.8 (SIT)/ 9.8 (LIT) |
| Vinorelbine                 | Camerini et al.2021 (Tempo Lung) | II      |           167 | Europe             | ECOG PSof 0-1or 2;Patients unfit to receive platinum-based chemotherapyhad atleastone(or more)of thefollowing criteria:previous adjuvantplatinum-based chemotherapy，creatinine clearance<60 ml/min, heart failure New York Heart Association class II-III,hearing loss >grade2andmedical conditionimpairing platinum-basedchemotherapy according to physician'sopinion | 62(SOV)/ 66 (MOV) 38(SOV)/ 34 (MOV)                                                             |          0 | 77 (SOV)/ 77 (MOV)    | 7.6 (SOV)/ 7.1 (MOV) |
| Docetaxel                   | Hainsworth_et al. 2007           | III     |           350 | US                 | Patientswererequired tobeolder than65 yearsof ageor tobepoor candidatesfor standardplatinum-basedchemotherapy regimensbecauseofeither coexistent medicalillnessorpoorperformancestatus                                                                                                                                                                                 | 67 33                                                                                           |          0 | 74                    | 5.1°                 |
| Pemetrexed                  | Gridelli et al. 2007             | II      |            87 | Europe             | Age≥70yearsor<70yearsforpatients who,in the investigator's opinion,were ineligibleforplatinum-basedchemotherapy because of poor PSor comorbidities;an Eastern CooperativeOncology GroupPSof 0to2                                                                                                                                                                       | 68 32                                                                                           |          0 | 73                    | 4.7**                |

ECOG=Eastern Cooperative OncologyGroup;KPS=KarnofskyPerformanceScale;LIT=Lowinfusiontime;mQS=median overall survival;MOV=Metronomicoralvinorelbine; PS=performancestatus;SIT=Standardinfusion time;SOV=StandardOralVinorelbine;US=UnitedStates.

5PercentagesforPerformanceStatus,medianage and medianOSarereportedfortherespective single-agentchemotherapy arm(s),asindicated.

*Performancestatuswasreported asKarnofskyperformancestatus(KPs)for this trial;therangeinECoGPSisbasedontheperformancescalescomparisonofKarnofskyand ECOG Scores in theESMOPracticeTools.TheESMOpractice toolconsidersKPS 100-90asECOGPS0,KPS80-70as ECOGPS1,KPS60-50asECOGPS2,and aKPSof40-30 as ECOGPS3.

Thetrialinvestigateddocetaxelversusdocetaxel/gemcitabine(mos:5.5months)

**Thetrialinvestigatedpemetrexedversussequentialpemetrexed/gemcitabine(mOs:5.4months)

No crossover was allowed between treatment arms.

Tumour assessments were performed at baseline, every 6 weeks ( ± 5 days) following randomisation for 48  weeks,  and  every  9 weeks  ( ± 5  days)  thereafter,  with  additional  scans  as  clinically  indicated. Assessments continued until disease progression per RECIST v1.1.

Assessment report

<div style=\"page-break-after: always\"></div>

Patients  in  the  experimental  arm  with  atezolizumab  who  showed  evidence  of  clinical  benefit,  were permitted to continue treatment with atezolizumab beyond disease progression per RECIST v1.1 until loss of clinical benefit, unacceptable toxicity, patient or physician decision to discontinue, or death, if they met all of the following criteria:

- Evidence  of  clinical  benefit  (i.e.,  in  the  absence  of  symptomatic  deterioration  attributed  to disease  progression  as  determined  by  the  investigator  after  an  integrated  assessment  of radiographic data, biopsy results [if available], clinical status, and of laboratory values)
- Absence of unacceptable toxicity
- No decline in ECOG performance status that can be attributed to disease progression
- Absence of tumour progression at critical anatomical sites (e.g., leptomeningeal disease) that cannot be managed by protocol-allowed medical interventions

Patients for whom approved therapies exist must provide written consent to acknowledge deferring these treatment options in favour of continuing study treatment at the time of initial progression.

Patients  randomised  to  atezolizumab  who  continued  to  receive  atezolizumab  following  disease progression per RECIST v1.1 underwent tumour assessments until treatment discontinuation.

Tumour assessments were to continue regardless of whether patients discontinued study treatment or started new anti-cancer therapy in the absence of disease progression per RECIST v1.1 unless patients withdrew consent.

## Objectives

The primary efficacy objective was to evaluate the efficacy of atezolizumab compared with single-agent chemotherapy in patients with treatment-naïve locally advanced or metastatic NSCLC who are deemed unsuitable for any platinum-doublet chemotherapy, as measured by OS.

The  secondary  efficacy  objectives  of  the  study  were  to  evaluate  the  efficacy  of  atezolizumab monotherapy compared with chemotherapy on the basis of the following outcome measures:

- OS rates at 6, 12, 18 and 24 months
- Investigator-assessed ORR using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
- Investigator-assessed PFS using RECIST v1.1
- Investigator-assessed duration of response (DOR) using RECIST v1.1.
- OS and investigator-assessed PFS (using RECIST v1.1) in patients with PD-L1 expression defined by the VENTANA PD-L1 SP263 assay.

The patient-reported outcome (PRO) objective of the study was to evaluate and compare PROs of lung cancer symptoms, patient functioning, and health-related quality of life (HRQoL) between treatment arms as measured by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30).

Follow-up  data  capture,  including  subsequent  anticancer  therapies,  continued  for  each  patient  until death, withdrawal of consent, loss to follow-up, or study termination by Sponsor, whichever occurred first.

Safety assessments included the incidence, nature, and severity of adverse events (AEs) and laboratory abnormalities graded per the National Cancer Institute Common Terminology Criteria for Adverse Events

Error! Unknown document property name.

<div style=\"page-break-after: always\"></div>

(NCI CTCAE) v. 4.0. Laboratory safety assessments included the regular monitoring of haematology and blood chemistry.

An independent Data Monitoring Committee (IDMC) was employed to conduct periodic evaluations of safety data. In addition, the IDMC was also responsible for evaluating efficacy data at the pre-specified interim analysis prior to the Sponsor's unblinding. All analyses for the IDMC's review were prepared by an Independent Data Coordinating Centre (IDCC).

## Outcomes/endpoints

The primary efficacy outcome measure was the comparison of OS between the two treatment arms (atezolizumab versus chemotherapy) in the ITT population.

The secondary outcome measures were:

- OS rate at the 6-, 12-, 18-, and 24-month timepoints in the ITT population
- ORR in the ITT population, defined as a best overall response rate of confirmed CR or PR, as determined by the investigator with use of RECIST v1.1.
- PFS  in  the  ITT  population,  defined  as  the  time  from  randomization  to  the  first  documented disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first.
- DOR, in the ITT population defined as the time from the first tumor assessment that supports the patient's objective response (CR or PR, whichever is first reported) to documented disease progression  as  determined  by  the  investigator  according  to  RECIST  v1.1  or  death  from  any cause, whichever occurs first, among patients who have a best overall response as CR or PR.
- OS and investigator-assessed PFS in patients with PD-L1 expression defined by the Ventana PDL1 SP263 immunohistochemistry (IHC) assay (introduced in Protocol amendment v5).

The PRO measures were:

- Clinically meaningful change from baseline (defined as a ≥ 10-point change) in EORTC QLQ-C30 and  EORTC  QLQ-LC  scores  and  TTCD  defined  as  the  time  from  randomization  to  the  first confirmed  clinically  meaningful  deterioration  in  EORTC  QLQ-C30  and  LC13  symptom  scores. Confirmed clinically meaningful deterioration in lung cancer symptoms is defined as a ≥ 10-point increase  above  baseline  in  a  symptom  score  that  must  be  held  for  at  least  two  consecutive assessments or an initial ≥ 10-point increase above baseline followed by either death within 6 weeks  from  the  last  assessment  through  Week  48  or  death  within  9  weeks  from  the  last assessment from Week 48 thereafter.

## Sample size

Assuming a 10% withdrawal rate and accrual duration of 24 months, approximately 441 (in reality 453) patients will be randomised in a 2:1 ratio to atezolizumab (294 patients) or chemotherapy (147 patients). A total of 380 OS events will provide 90% power to detect a significant improvement in median OS with atezolizumab compared to chemotherapy from 7 months to 10 months (i.e. hazard ratio [HR] 0.7) using a log-rank test at an overall two-sided alpha level of 5% (using a two-look Lan-DeMets group sequential

<div style=\"page-break-after: always\"></div>

design with an interim analysis at 80% of information fraction and O'Brien-Fleming type boundary at two-sided 5% level of significance).

## Randomisation

Randomisation to atezolizumab and chemotherapy arms will occur in a 2:1 ratio using permuted-block randomisation method. Randomisation will be stratified by the following factors:

- Histologic subtype (non-squamous vs. squamous)
- PD-L1 IHC status (positive vs. negative vs. unknown) according to assay VENTANA PD-L1 SP142
- Brain metastases (yes vs. no)

## Blinding (masking)

Not applicable, this study was open label.

Given the unique toxicities associated with chemotherapy (i.e., alopecia, hematologic toxicities), the premedications required (i.e., steroid, anti-emetics, and potentially growth factor support), the different dosing  schedules  for  the  chemotherapies  and  the  option  to  administer  vinorelbine  either  orally  or intravenously, the study was open label.

## Statistical methods

## Analysis sets for the IPSOS study

Intent-to-treat  (ITT)  Population :  all  randomised  patients  irrespective  of  whether  the  assigned treatment was actually received. For analyses on ITT, patients will be grouped according to the treatment assigned  at  randomisation.  The  ITT  population  will  be  the  population  for  the  analysis  of  efficacy parameters.

Safety-Evaluable Population: all randomised patients who received any amount of study treatment. For analyses on Safety-Evaluable Population, patients will be grouped according to whether any amount of atezolizumab was received, including the case when atezolizumab was received in error. The SafetyEvaluable Population will be the population for the analysis of safety parameters.

Hypotheses: The overall type I error ( α) for this study is 0.05 (two-sided). There will be no multiplicity adjustments for testing of secondary endpoints.

## Statistical methods

Treatment comparisons for the primary OS analysis were based on the stratified log-rank test based on the predefined randomisation stratification factors (see 'Randomisation'). The hazard ratio (HR) was estimated with use of a stratified Cox regression model, including a two-sided 95% CI. Kaplan-Meier methodology was used to estimate the median OS for each treatment arm and Kaplan-Meier (KM) curves were produced. Brookmeyer-Crowley methodology was used to construct the two-sided 95% CI for the median OS for each treatment arm. OS rates for 6-, 12, 18- and 24-month landmark analyses were estimated by the Kaplan-Meier methodology for each treatment arm, with two-sided 95% CIs calculated using Greenwood's formula.

Analysis of the secondary endpoints of PFS and TTCD was performed using the same methodology as with OS.

<div style=\"page-break-after: always\"></div>

ORR and its 95% CI were estimated using the Clopper-Pearson method for each treatment arm. CIs for the difference in ORRs between the two arms were determined using the normal approximation to the binomial distribution. The ORR was compared between the two arms using a Chi-square test.

Because the determination of DOR is based on a non-randomized subset of patients, formal hypothesis testing was not performed. Comparisons between treatment arms were made for descriptive purposes. The same methodologies detailed for the OS analysis were used for the DOR analysis.

## Interim analysis and final analysis

There was one prespecified interim OS analysis performed by the iDMC after 304 deaths had occurred (CCOD: 15 May 2020), corresponding to 80% of the planned 380 events for the final analysis. The iDMC recommended that the study proceed to final analysis. To control the Type 1 error for OS, a LanDeMets group sequential design with an O'Brien Fleming type boundary was used. Final analysis of OS was conducted by the Sponsor when 379 OS events had been observed, 55 months after the first patient was randomised (CCOD: 30 April 2022). The planned information fraction and stopping boundaries at the time of each analysis were re-calculated using the actual number of events included in the analysis, and the nominal alpha level re-calculated accordingly so that the overall alpha level across both analyses was maintained at 5%. Boundaries can be seen below:

Table 7. Timing and Stopping Boundaries for Interim and Final Analyses for Overall Survival

<!-- image -->

| Interim and Final Analysis for OS   | Interim and Final Analysis for OS   | Interim and Final Analysis for OS    | Interim and Final Analysis for OS   |
|-------------------------------------|-------------------------------------|--------------------------------------|-------------------------------------|
| Analysis Timing                     | Time from First Patient in (months) | Information Fraction (No. of events) | Stopping Boundary HR (p-value1)     |
| Interim Analysis                    | 30                                  | 80% (304)                            | 0.76 (p ≤ 0.0244)                   |
| Final Analysis                      | 42                                  | 100% (380)                           | 0.80 (p ≤0.0428)                    |

Censoring rules for primary endpoint, OS: For OS, patients without a date of death will be censored on the date a patient was last known to be alive. If no post-baseline data are available, OS will be censored at the date of randomization plus 1 day.

## Censoring rules for key secondary time to event endpoints:

Progression-Free  Survival  (PFS),  defined  as  the  time  from  randomization  to  the  first  occurrence  of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. Patients who were alive and who had not experienced disease progression will be censored at the date of the last tumor assessment or the date of randomization plus 1 day if no postbaseline tumor assessment was available.

Duration of Response (DOR), defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. Patients who were alive and who had not experienced disease  progression  will  be  censored  at  the  date  of  the  last  tumor  assessment  or  the  date  of randomization plus 1 day if no post-baseline tumor assessment was available.

OS and Investigator-assessed PFS according to RECIST v1.1 in patients with PD-L1 expression defined by the SP142 and SP263 immunohistochemistry (IHC) assay

## Subgroup and Exploratory Analyses

<div style=\"page-break-after: always\"></div>

The  consistency  of  OS  and  PFS  results  was  investigated  in  pre-specified  subgroup  analyses  by demographic and baseline disease characteristics and by PD-L1 expression by IHC (SP263 assay and SP142 assay).

Additional post-hoc analyses in response to health authority feedback have also been performed and include:

- A  sensitivity  analysis  of  OS  performed  to  better  characterise  the  impact  of  treatment discontinuation based on the investigator's decision. For patients who discontinued treatment with the reason documented as 'Physician decision', overall survival was censored at the time of the treatment discontinuation.
- Subgroup analyses of OS, PFS and ORR as well as description of baseline demographics and disease characteristics were performed according to: PD-L1 expression by the SP263 and SP142 IHC assays and investigator's choice of preferred chemotherapy (vinorelbine vs. gemcitabine)

Furthermore,  a  number  of  other  sensitivity  analyses  were  conducted.  These  are  discussed  under assessor's comment.

Changes to the SAP: Only changes from version 2 and 3 are disclosed in the SAP.

## Results

## Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Recruitment

First Patient randomised: 11-Sep-2017. Last patient randomised: 23 September 2019. Data cut-off for Primary Analysis: 30-Apr-2022.

A total of 843 patients were screened for entry into the study and 390 patients failed screening based on information collected in the IxRS. The most common reasons for screen failure were failure to meet inclusion criteria, meeting one or more exclusion criteria, investigator or patient decision and insufficient tissue for analysis or lab result unavailable.

Patients were recruited from 85 centers across 23 countries. The number of patients randomized per region  and  country,  followed  by  the  number  of  centers  (in  parentheses),  is  summarized  below  in descending order:

- Europe and Middle East: Spain 48 patients (9 sites), United Kingdom 47 (7), Germany 42 (8), Poland 40 (2), Italy 30 (3), Switzerland 11 (3), Belgium 9 (4), Kazakhstan 8 (2), Romania 6 (3), Bulgaria 6 (2), Czech Republic 4 (1), Ireland 4 (2), Portugal 4 (2), Denmark 3 (1), Slovakia 3 (2).
- Asia Pacific: China 55 patients (7 sites), India 38 (7), Vietnam 15 (2).
- Central  and  South  America:  Brazil  20  patients  (3  sites),  Colombia  18  (4),  Mexico  16  (3), Argentina 7 (3).
- North America: Canada 19 patients (5 sites)

Of the 453 enrolled patients, 302 patients were randomised to the atezolizumab monotherapy arm and 151 patients were randomised to the chemotherapy (gemcitabine or vinorelbine) arm. Of these 453 randomized patients, 447 patients received at least one dose of study treatment and comprised the safety-evaluable population.

As of the CCOD (30 April 2022), 95% of patients [287/302] in the atezolizumab arm vs. 100% of patients [151/151] in the chemotherapy arm had discontinued the study. The remaining 5% of patients [15/302] in the atezolizumab arm on study at the time of the CCOD were still on study treatment.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

Table 8. Treatment discontinuation (Safety-Evaluable Population)

|                                               | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Total (N=447)   | Total (N=447)   |
|-----------------------------------------------|------------------------|------------------------|------------------------|------------------------|-----------------|-----------------|
| Received at least One Dose of Study Drug, n() |                        | 300(100.0)             |                        | 147 (100.0)            |                 | 447(100.0)      |
| Treatment Status, n(&)                        |                        |                        |                        |                        |                 |                 |
| Ongoing                                       |                        | 15 (5.0)               |                        | 0 ( 0.0)               |                 | 15 (3.4)        |
| Discontinued from Treatment                   |                        | 285(95.0)              |                        | 147(100.0)             |                 | 432(96.6)       |
| Primary Reason for Discontinuation            |                        |                        |                        |                        |                 |                 |
| from Treatment, n() Adverse Event             |                        | 38(12.7)               |                        | 20(13.6)               |                 | 58(13.0)        |
| Death                                         |                        | 60(20.0)               | 18                     | (12.2)                 |                 | 78(17.4)        |
| Progressive disease                           | 151                    | (50.3)                 | 75                     | 51.0)                  |                 | 226(50.6)       |
| Lost to follow-up                             | 1                      | ( 0.3)                 | 1                      | 0.7)                   |                 | 0.4)            |
| Non-compliance                                | 3                      | ( 1.0)                 | 0                      | 0.0)                   | 3               | ( 0.7)          |
| Withdrawal by subject                         | 27                     | 9.0)                   | 12                     | 8.2)                   | 39              | 8.7)            |
| Study terminated by sponsor                   | 1                      | ( 0.3)                 | 0                      | 0.0)                   | 1               | ( 0.2)          |
| Physician decision                            | 8                      | 1 1.0)                 | 17                     | 11.6)                  | 20              | 4.5)            |
| Other                                         | 1                      | ( 0.3)                 | 4                      | 2.7)                   | 5               | 1.1)            |
| Patients who Continued Treatment              |                        | 86(28.7)               | 0                      |                        |                 |                 |
| beyond Disease Progression, n(&)              |                        |                        |                        | 0.0)                   |                 | 86 (19.2)       |

Table 9. Study discontinuation (ITT Population)

|                                                        | (N=302)   | (N=302)    | Atezolizumab Chemotherapy (N=151)   | Atezolizumab Chemotherapy (N=151)   | Total (N=453)   | Total (N=453)   |
|--------------------------------------------------------|-----------|------------|-------------------------------------|-------------------------------------|-----------------|-----------------|
| Received at least One Dose of Study Drug, n(6)         |           | 300 (99.3) |                                     | 147(97.4)                           |                 | 447(98.7)       |
| On-study Status), n(&) Alive: On Treatment             |           | 15 (5.0)   |                                     | 0.0)                                |                 | 15 (3.3)        |
| Patients who Discontinued the Study, n(&)              |           | 287(95.0)  |                                     | 151 (100.0)                         |                 | 438(96.7)       |
| Primary Reason for Discontinuation from the Study, n() |           |            |                                     |                                     |                 |                 |
| Death                                                  |           | 236(78.1)  |                                     | 127( 84.1)                          |                 | 363(80.1)       |
| Lost to follow-up                                      | 6         | 3.0)       | 31                                  | 2.0)                                | 12              | 2.6)            |
| Withdrawal by subject                                  | 26        | 8.6)       |                                     | 16  ( 10.6)                         | 42              | 9.3)            |
| Study terminated by sponsor                            | 15        | 5.0)       | 5                                   | 3.3)                                | 20              | 4.4)            |
| Physician decision                                     | 1         | ( 0.3)     | 0                                   | 0.0)                                | 1               | 0.2)            |

<div style=\"page-break-after: always\"></div>

Table 10. Summary of Major Protocol Deviations (ITT Population)

| Protocol Deviation Category                                          | Atezolizumab (N=302)   | Atezolizumab (N=302)   | Chemotherapy Total (N=151) n (%) n ()   | Chemotherapy Total (N=151) n (%) n ()   | (N=453)   | (N=453)    |
|----------------------------------------------------------------------|------------------------|------------------------|-----------------------------------------|-----------------------------------------|-----------|------------|
| Protocol Deviation Subcategory                                       | n ()                   | n ()                   |                                         |                                         |           |            |
| Patients with Any Major Protocol Deviations                          |                        | 89( 29.5)              |                                         | 39( 25.8)                               |           | 128( 28.3) |
| Overall Total Number of Major                                        | 113                    | 113                    | 53                                      | 53                                      | 166       | 166        |
| Protocol Deviations                                                  |                        |                        |                                         |                                         |           |            |
| Exclusion Criteria                                                   | 13                     | ( 4.3)                 | 11                                      | [ 7.3)                                  | 24        | 5.3)       |
| Excluded CNs involvement                                             | 1                      | 0.3)                   | 3                                       | 2.0)                                    | 4         | 1 0.9)     |
| Excluded autoimmune disease                                          |                        | 0                      | 2                                       | 1 1.3)                                  | 2         | 0.4)       |
| Excluded concurrent or prior therapy                                 | 6                      | 2.0)                   | 5                                       | 3.3)                                    | 11        | 2.4)       |
| Excluded medical condition                                           | 6                      | 2.0)                   | 2                                       | 1 1.3)                                  | 8         | ( 1.8)     |
| Inclusion Criteria                                                   | 18                     | 6.0)                   | 7                                       | 1 4.6)                                  | 25        | 1 5.5)     |
| Failure to perform serum pregnancy test at screening                 | 1                      | 1 0.3)                 | 0                                       | 0                                       | 1         | 0.2)       |
| ICF deviation during screening                                       | 3                      | ( 1.0)                 | 4                                       | 2.6)                                    | 7         | ( 1.5)     |
| Inadequate hematologic and end organ function                        | 8                      | 2.6)                   | 3                                       | 2.0)                                    | 11        | 2.4)       |
| No tumor tissue at screening                                         | 1                      | 0.3)                   | 0                                       | 0                                       | 1         | 0.2)       |
| Prohibited prior systemic anticancer treatment                       | 2                      | ( 0.7)                 | 0                                       | 0                                       | 2         | 0.4)       |
| Symptomatic/untreated CNS mets                                       | 3                      | 1.0)                   | 0                                       | 0                                       | 3         | 0.7)       |
| Medication                                                           | 14                     | ( 4.6)                 | 6                                       | 4.0)                                    | 20        | 4.4)       |
| Overdosage of IMP                                                    |                        | 0                      | 4                                       | 1 2.6)                                  | 4         | 1 0.9)     |
| Use of prohibited concomitant therapy during the course of the study | 14                     | ( 4.6)                 | 2                                       | [ 1.3)                                  | 16        | 3.5)       |
| Procedural                                                           |                        | 56( 18.5)              |                                         | 24(15.9)                                | 80        | (17.7)     |
| Error with stratification                                            | 11                     | 3.6)                   | 4                                       | 2.6)                                    | 15        | 3.3)       |
| Incorrect drug handling                                              | 4                      | ( 1.3)                 |                                         | 0                                       | 4         | ( 0.9)     |
| Missed or incorrect study                                            | 35                     | (11.6)                 | 13                                      | 8.6)                                    | 48        | (10.6)     |
| procedure Missed or incorrect tumor assessment                       |                        | 12 (4.0)               | 7                                       | 4.6)                                    | 19        | 4.2)       |

## Protocol amendments

Version 1: 13 Feb 2017

Version 2: 29 Jun 2017

Exclusion criteria: Amended to exclude patients younger than 70 years with ECOG PS 0/1 in line with ESMO guidelines.

Amended to ensure exclusion of patients with illness or condition that may interfere with capacity or compliance with the study protocol.

Study population: Amended to include patients deemed 'unsuitable for any platinum doublet chemotherapy' as opposed to 'unsuitable for platinum containing therapy' to appropriately recruit cisplatin and carboplatin ineligible patients.

<div style=\"page-break-after: always\"></div>

Study procedures: Increased frequency of on-treatment pregnancy tests and regular postdiscontinuation visit pregnancy testing until at least 5 months after the last dose of atezolizumab or until at least 6 months after the last dose of chemotherapy.

## Version 3: 16 Jan 2018

Inclusion criteria: Requirement for male contraception for atezolizumab patients removed as atezolizumab is not genotoxic.

Study procedures: PRO assessment frequency aligned with tumor assessments. Optional tumor biopsy at time of progression removed and replaced with serum sample. Initial tumor assessments and baseline laboratory assessments to be performed with 14 days prior to randomization. EGFR/ALK testing made mandatory only for patients with non-squamous NSCLC and squamous NSCLC who are never smokers or have mixed histology. Serum sampling for EBV removed. Week 6 plasma biomarker sampling amended to Week 7.

Concomitant medications: Immunostimulatory and-suppressive agents added to list of prohibited therapy.

## Version 4: 14 Jan 2019

Inclusion criteria: Requirement for female patients of childbearing potential randomised to the atezolizumab arm to refrain from donating eggs was added.

Version 5: 19 Dec 2019

Inclusion criteria: Requirement for female patients of childbearing potential randomised to the atezolizumab arm to refrain from donating eggs was removed as study drug is not genotoxic.

Concomitant medications: Traditional herbal medicines used at investigator's discretion added.

Primary endpoints: Addition of interim analysis after 304 OS events (approximately 30 months from FPI). The final OS analysis will be conducted after 380 OS events (approximately 42 months after FPI) as opposed to after 372 OS events (approximately 40 months after FPI).

Secondary endpoints: Secondary objective to evaluate the efficacy (OS and INV-PFS [using RECIST v1.1]) of atezolizumab compared with single-agent chemotherapy in patients with PDL1 expression defined by SP263 IHC assay added.

## Version 6: 03 Feb 2021

Concomitant medications: Immunosuppressive medications removed from list of prohibited therapies and added to cautionary therapies section

Version 7: 22 Dec 2021

Primary endpoint: A time limit of at least 54 months after first patient enrolled was introduced as an alternative to the target 380 OS events for analysis of the primary endpoint, whichever should occur first.

## Follow-up

Duration of survival follow-up was calculated using the reverse Kaplan-Meier estimate of OS. In the ITT population, the median duration of survival follow-up was 41.0 months and was comparable between the treatment arms (41.4 months in the atezolizumab arm versus 39.9 months in the chemotherapy arm)

<div style=\"page-break-after: always\"></div>

Table 11. Duration of Survival Follow-up (ITT Population)

<!-- image -->

|                                                                 | Atesoligumab (N=302)   | Chemotherapy (N=151)   | Total (8S1=N)    |
|-----------------------------------------------------------------|------------------------|------------------------|------------------|
| Raplan-Meier Estimates ofDurationof Survival Follow-Vp (months) |                        |                        |                  |
| Events, n(e)                                                    | 53 (17.56) 249 (82.58) | 21 (13.90) 130 (86.10) | 74 (16.36)       |
| Censored, n(8)                                                  |                        |                        | 379 (83.76)      |
| 25th Pctl.(950 C1)                                              | 38.2 (33.9.40.1)       | 8\"18 (34.3,39.9)36.7   | (34.3,39.9)      |
| Median (95e C1l)                                                | (40.0,44.2)            | 6.68 (36.5.52.7)       | 41.0 (39.9,43.1) |
| 75th Petl.(95o C1l)                                             | (43.1.49.1)            | 52.7(36.8. NE)         | 47.8 (43.1.49.4) |
| Min, Max                                                        | 0.1,51.5               | 0.1.53.5               | 0.1.53.5         |

The inverse Kaplan-Meier methodology was used to estimate the duration of survival follow-up.

1  95% Confidence Interval (CI) computed using the Brookmeyer and Crowley method.

## Baseline data

In the following sections, two efficacy datasets are presented:

The intent-to-treat (ITT) population (N=453, 302 in the atezo arm and 151 in the chemo arm) is constituted by all randomised patients irrespective of whether the assigned treatment was actually received. This population (N=453, from which 302 were in the atezo arm and 151 in the chemotherapy arm) was used for all the efficacy analysis per protocol.

The platinum-ineligible population (N=405, 268 in the atezo arm and 137 in the chemo arm): Considering  the  lax  and  relatively  ambiguous  per-protocol  definition  of  platinum-ineligibility  in  the inclusion criteria from IPSOS, the CHMP questioned whether the observed results were robust enough to  represent  the  targeted fragile patient  population.  The  MAH  acknowledged  the  lack  of  detailed information  in  IPSOS  as  to  why  study  investigators  assessed  their  patients  to  be  ineligible  for  a platinum-based doublet and lack of severity grading for ongoing comorbidities and recognised that this information cannot be obtained in retrospect. Based on this, it was agreed with the MAH to assess which proportion  of  patients  from  IPSOS  could  meet  'directly  evaluable'  criteria  for  platinum  ineligibility according to De Marinis et al. 2015 , i.e., age &gt;80 years, Eastern Cooperative Oncology Group (ECOG) PS ≥3, and creatinine clearance &lt;45 mL/min. In addition, the MAH assessed the proportion of patients with any ongoing comorbidities if they did not meet any of the three 'directly evaluable' criteria.

After the assessment, the following selection criteria were defined to select an ad hoc dataset of patients ('platinum-ineligible population'):

1. Age &gt;80 years; and/or
2. ECOG PS 3; and/or
3. ECOG PS 2 in combination with relevant comorbidities; and/or
4. Age ≥70 years in combination with relevant comorbidities.

Relevant comorbidities are related to cardiac disorders, nervous system disorders, psychiatric disorders, vascular  disorders,  renal  disorders,  metabolism  and  nutrition  disorders,  or  pulmonary  disorders contraindicating treatment with platinum-based therapy, as assessed by the treating physician.

Efficacy results for the 'platinum ineligible population' are described in the Ancillary analyses section.

<div style=\"page-break-after: always\"></div>

Table 12. Summary of Baseline Demographic Characteristics (ITT Population)

|                                  | Ategolisumab   | Ategolisumab   | Chemotherapy   | Chemotherapy   | Total     | Total         |
|----------------------------------|----------------|----------------|----------------|----------------|-----------|---------------|
|                                  | (N=302)        | (N=302)        | (N=151)        | (N=151)        | (N=453)   | (N=453)       |
| Age (years)                      |                |                |                |                |           |               |
| n (missing)                      | 302(0)         | 302(0)         | 151(0)         | 151(0)         | 453(0)    | 453(0)        |
| Mean (SD)                        | 73.6(9.1)      | 73.6(9.1)      | 73.8(8.5)      | 73.8(8.5)      | 73.7(8.9) | 73.7(8.9)     |
| Median                           | 75.0           | 75.0           | 75.0           | 75.0           | 75.0      | 75.0          |
| HEH 'UTH                         | +6'88          | +6'88          | 37.89          | 37.89          | 33.94     | 33.94         |
| Age Category(years). n(e)        |                |                |                |                |           |               |
| 992                              |                | 46 ( 15.2)     |                | 19(12.6)       |           | 65(14.3)      |
| 65-74                            |                | 100(33.1)      | 51             | (33.8]         | 151       | [33.3]        |
| 75-84                            | 141            | (46.7)         | 72             | (47.7)         | 213       | 47.01         |
| >=85                             | 15             | 5.01           | 9              | 6.01           | 24        | 5.31          |
| Age Category (years), n(e)       |                |                |                |                |           |               |
| c70                              | 80             | (26.5]         |                | 43(28.5)       | 123       | (27.2)        |
| >=70                             | 222            | (73.5]         | 108            | (71.5)         | 330       | (72.8)        |
| Age Category (years), n(b)       |                |                |                |                |           |               |
| <80                              | 205            | (67.9)         | 108            | 71.51          | 313       | 69.11         |
| >=80                             | 97             | (32.1)         | 43             | (28.5)         | 140       | (30.9)        |
| Sen, n(8)                        |                |                |                |                |           |               |
| Male                             |                | 220(72.8)      |                | 108(71.5)      |           | 328(72.4)     |
| Female                           |                | 82(27.2)       |                | 43(28.5)       | 125       | (27.6)        |
| Ethnicity. n(t)                  |                |                |                |                |           |               |
| Hispanic or Latino               | 47             | (15.6)         | 23             | 15.21          | 70        | 15.51         |
| Not Hispanie or Latino           | 242            | 80.1)          | 125            | 82.81          | 367       | 81.01         |
| Not reported                     | 9              | 3.01           | 3              | 2.01           | 12        | 2.61          |
| Unknown                          | 4              | 1.3)           |                | 0              | 4         | 16*0          |
| Raee， n（o)                       |                |                |                |                |           |               |
| American Indian or Alagka Native | 12             | 4.01           | 9              | 6.01           | 21        | 4.61          |
| Aaian                            | 75             | 24.81          | 28             | 25.21          | 113       | 24.91         |
| Indian subcontinent              | 28             | 9.31           | 10             | 6.61           | 38        | 8.41          |
| Other than Indian                | 47             | 15.61          | 28             | 18.51          | 75        | 16.6)         |
| subcontinent                     |                |                |                |                |           |               |
| Black or African American        | 2              | 0.71           | 1              | 0.71           | 3         | 0.71          |
| White                            | 203            | 67.21          | 95             | 62.91          | 298       | 65.61         |
| Unknown                          | 4              | 1.31           | 2              | 1.31           | 6         | 1.31          |
| Hultiple                         | 6              | 2.01           | 6              | 4.01           | 12        | 2.61          |
| Weightl (kg) at baseline         |                |                |                |                |           |               |
| n (missing)                      |                | 302(0)         |                | 151 (0)        |           | 453(0)        |
| Mean (SD)                        |                | 65.72(15.29)   |                | 66.14(15.75)   |           | 65.86 (15.43) |
| Hedian                           |                | 65.00          |                | 65.00          |           | 65.00         |
|                                  |                | 31.0,130.7     |                | 35.0, 128.5    |           | 31.0,130.7    |
| EcoG Performance Btatus', n(o)   |                |                |                |                |           |               |
| 0                                | 7              | 2.31           |                | 0              | 7         | (1.5)         |
| 1                                | 49             | 16.21          | 19             | (12.6)         | 68        | 15.01         |
| 2                                | 228            | 75.51          | 116            | [8*91 )        | 344       | 75.91         |
| 3                                | 16             | 10:9           | 16             | (10.6)         | 34        | 7.51          |
| E00G 0/1 and Age 2 70, n(o)      |                | 56(18.5)       |                | 19(12.6)       |           | 75(16.6)      |
| Smoking Status, n(b)             |                |                |                |                |           |               |
| Never                            | 35             | 11.61          | 20             | 13.21          | 55        | 12.11         |
| Current                          | 58             | 19.2)          | 28             | 16.51          | 86        | 19.01         |
| Previous                         | 209            | 69.21          | 103            | 68.21          | 312       | 68.91         |

1  Baseline evaluation is defined as the latest evaluation performed prior to or on the first dosing date (i.e. at visit Day 1).

<div style=\"page-break-after: always\"></div>

Table 13. Summary of Baseline Demographic Characteristics (Platinum-ineligible Population)

|                                                                                                                            | Atezolizumab                                                                                                               | Chemotherapy                                                                                                               | Total                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                            | (N=268)                                                                                                                    | (N=137)                                                                                                                    | (N=405)                                                                                                                    |
| Age (years)                                                                                                                |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| n (missing)                                                                                                                | 268(0)                                                                                                                     | 137 (0)                                                                                                                    | 405(0)                                                                                                                     |
| Mean (SD)                                                                                                                  | 74.7 (8.0)                                                                                                                 | 74.4 (7.9)                                                                                                                 | 74.6 (7.9)                                                                                                                 |
| Median                                                                                                                     | 75.5                                                                                                                       | 76.0                                                                                                                       | 76.0                                                                                                                       |
| Min, Max                                                                                                                   | 47,94                                                                                                                      |                                                                                                                            | 47,94                                                                                                                      |
| Age Category (years),n(%)                                                                                                  |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| <65                                                                                                                        | 33 (12.3)                                                                                                                  | 15 (10.9)                                                                                                                  | 48 11.9)                                                                                                                   |
|                                                                                                                            | 87 32.5)                                                                                                                   | 4 4 32.1)                                                                                                                  | 131 32.3)                                                                                                                  |
| 65-74                                                                                                                      |                                                                                                                            |                                                                                                                            | 202 49.9)                                                                                                                  |
| 75-84                                                                                                                      | 133 49.6)                                                                                                                  | 69 50.4)                                                                                                                   |                                                                                                                            |
| >=85                                                                                                                       | 15 5.6)                                                                                                                    | 9 6.6)                                                                                                                     | 24 5.9)                                                                                                                    |
| Age Category (years), n() <70                                                                                              | 62 (23.1)                                                                                                                  | 38 (27.7)                                                                                                                  | 100 24.7)                                                                                                                  |
| >=70                                                                                                                       | 206 76.9)                                                                                                                  | 99 72.3)                                                                                                                   | 305 75.3)                                                                                                                  |
| Age Category (years),n()                                                                                                   |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| 08=>                                                                                                                       | 192 71.6)                                                                                                                  | 104 75.9)                                                                                                                  | 296 73.1)                                                                                                                  |
| >80                                                                                                                        | 76 28.4)                                                                                                                   | 33 24.1)                                                                                                                   | 109 26.9)                                                                                                                  |
| Sex,n()                                                                                                                    |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| Male                                                                                                                       | 194 72.4)                                                                                                                  | 96 (70.1)                                                                                                                  | 290 71.6)                                                                                                                  |
| Female                                                                                                                     | 74 (27.6)                                                                                                                  | 41 (29.9)                                                                                                                  | 115 (28.4)                                                                                                                 |
| Ethnicity,n()                                                                                                              |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| Hispanic or Latino                                                                                                         | 39 14.6)                                                                                                                   | 21 15.3)                                                                                                                   | 60 14.8)                                                                                                                   |
| Not Hispanic or Latino                                                                                                     | 217 81.0)                                                                                                                  | 113 82.5)                                                                                                                  | 330 81.5)                                                                                                                  |
| Not reported                                                                                                               | 8 3.0)                                                                                                                     | 3 2.2)                                                                                                                     | 11 2.7)                                                                                                                    |
| Unknown                                                                                                                    | 4 1.5)                                                                                                                     | 0                                                                                                                          | 4 1.0)                                                                                                                     |
| Race, n(%)                                                                                                                 |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| American Indian or Alaska Native                                                                                           | 10 3.7)                                                                                                                    | 8 5.8)                                                                                                                     | 18 4.4)                                                                                                                    |
| Asian                                                                                                                      | 52 19.4)                                                                                                                   | 31 22.6)                                                                                                                   | 83 20.5)                                                                                                                   |
| Indian subcontinent                                                                                                        | 14 5.2)                                                                                                                    | 5 3.6)                                                                                                                     | 19 4.7)                                                                                                                    |
| Other than Indian subcontinent                                                                                             | 38 14.2)                                                                                                                   | 26 19.0)                                                                                                                   | 64 15.8)                                                                                                                   |
| Black or African American                                                                                                  | 2 0.7)                                                                                                                     | 1 0.7)                                                                                                                     | 3 0.7)                                                                                                                     |
| White                                                                                                                      | 194 72.4)                                                                                                                  | 91 66.4)                                                                                                                   | 285 70.4)                                                                                                                  |
| Unknown                                                                                                                    | 4 1.5)                                                                                                                     | 2 1.5)                                                                                                                     | 6 1.5)                                                                                                                     |
| Multiple                                                                                                                   | 6 2.2)                                                                                                                     | 4 2.9)                                                                                                                     | 10 2.5)                                                                                                                    |
| Weight' (kg) at baseline                                                                                                   |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| n(missing)                                                                                                                 | 268(0)                                                                                                                     | 137 (0)                                                                                                                    | 405 (0)                                                                                                                    |
| Mean (SD)                                                                                                                  | 66.19 (15.79)                                                                                                              | 66.60 (15.81)                                                                                                              | 66.33 (15.78)                                                                                                              |
| Median                                                                                                                     | 65.00                                                                                                                      | 65.00                                                                                                                      | 65.00                                                                                                                      |
| Min, Max                                                                                                                   | 31.0,130.7                                                                                                                 | 35.0,128.5                                                                                                                 | 31.0,130.7                                                                                                                 |
| ECOG Performance Status²,n()                                                                                               |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| 0                                                                                                                          | 6 2.2)                                                                                                                     | 0                                                                                                                          | 6 1.5)                                                                                                                     |
| 1                                                                                                                          | 49 18.3)                                                                                                                   | 19 (13.9)                                                                                                                  | 68 16.8)                                                                                                                   |
| 2                                                                                                                          | 195 72.8)                                                                                                                  | 102 74.5)                                                                                                                  | 297 73.3)                                                                                                                  |
| 3                                                                                                                          | 18 6.7)                                                                                                                    | 16 11.7)                                                                                                                   | 34 8.4)                                                                                                                    |
| ECOG 0/1 and Age ≥ 70,n()                                                                                                  | 55 20.5)                                                                                                                   | 19 13.9)                                                                                                                   | 74 18.3)                                                                                                                   |
| Smoking Status,n()                                                                                                         |                                                                                                                            |                                                                                                                            |                                                                                                                            |
|                                                                                                                            |                                                                                                                            | 15                                                                                                                         |                                                                                                                            |
| Never                                                                                                                      | 30 11.2)                                                                                                                   | （ 10.9)                                                                                                                    | 45 （ 11.1) 81 20.0)                                                                                                        |
| Current Previous                                                                                                           | 56 20.9) 182 67.9)                                                                                                         | 25 18.2) 97 70.8)                                                                                                          | 279 68.9)                                                                                                                  |
| Baseline evaluation is defined as the latest evaluation performedprior to or on the first dosing                           | Baseline evaluation is defined as the latest evaluation performedprior to or on the first dosing                           | Baseline evaluation is defined as the latest evaluation performedprior to or on the first dosing                           | Baseline evaluation is defined as the latest evaluation performedprior to or on the first dosing                           |
| date (i.e.at visit Day 1).                                                                                                 | date (i.e.at visit Day 1).                                                                                                 | date (i.e.at visit Day 1).                                                                                                 | date (i.e.at visit Day 1).                                                                                                 |
| Relevant comorbidities defined as the following HLGTs: Cardiac arrhythmias,Coronary artery                                 | Relevant comorbidities defined as the following HLGTs: Cardiac arrhythmias,Coronary artery                                 | Relevant comorbidities defined as the following HLGTs: Cardiac arrhythmias,Coronary artery                                 | Relevant comorbidities defined as the following HLGTs: Cardiac arrhythmias,Coronary artery                                 |
| disorders, Heart failures, Myocardial disorders, Cardiac valve disorders, Arteriosclerosis,                                | disorders, Heart failures, Myocardial disorders, Cardiac valve disorders, Arteriosclerosis,                                | disorders, Heart failures, Myocardial disorders, Cardiac valve disorders, Arteriosclerosis,                                | disorders, Heart failures, Myocardial disorders, Cardiac valve disorders, Arteriosclerosis,                                |
| stenosis, vascular insufficiency and necrosis,                                                                             | stenosis, vascular insufficiency and necrosis,                                                                             | stenosis, vascular insufficiency and necrosis,                                                                             | stenosis, vascular insufficiency and necrosis,                                                                             |
| Vascular hypertensive disorders, Central nervous system vascular disorders, Mental impairment and                          | Vascular hypertensive disorders, Central nervous system vascular disorders, Mental impairment and                          | Vascular hypertensive disorders, Central nervous system vascular disorders, Mental impairment and                          | Vascular hypertensive disorders, Central nervous system vascular disorders, Mental impairment and                          |
| hydrocephalus, Encephalopathies,                                                                                           | hydrocephalus, Encephalopathies,                                                                                           | hydrocephalus, Encephalopathies,                                                                                           | hydrocephalus, Encephalopathies,                                                                                           |
| Deliria (incl confusion), Psychiatric disorders NEC, Dementia and amnestic conditions,                                     | Deliria (incl confusion), Psychiatric disorders NEC, Dementia and amnestic conditions,                                     | Deliria (incl confusion), Psychiatric disorders NEC, Dementia and amnestic conditions,                                     | Deliria (incl confusion), Psychiatric disorders NEC, Dementia and amnestic conditions,                                     |
| Nephropathies, Renal disorders nephropathies), Electrolyte and fluid balance conditions,                                   | Nephropathies, Renal disorders nephropathies), Electrolyte and fluid balance conditions,                                   | Nephropathies, Renal disorders nephropathies), Electrolyte and fluid balance conditions,                                   | Nephropathies, Renal disorders nephropathies), Electrolyte and fluid balance conditions,                                   |
| (incl diabetes mellitus), Appetite and general nutritional disorders,                                                      | (incl diabetes mellitus), Appetite and general nutritional disorders,                                                      | (incl diabetes mellitus), Appetite and general nutritional disorders,                                                      | (incl diabetes mellitus), Appetite and general nutritional disorders,                                                      |
| Glucose metabolism disorders Bronchial disorders (excl neoplasms), Lower respiratory tract disorders (excl obstruction and | Glucose metabolism disorders Bronchial disorders (excl neoplasms), Lower respiratory tract disorders (excl obstruction and | Glucose metabolism disorders Bronchial disorders (excl neoplasms), Lower respiratory tract disorders (excl obstruction and | Glucose metabolism disorders Bronchial disorders (excl neoplasms), Lower respiratory tract disorders (excl obstruction and |

<div style=\"page-break-after: always\"></div>

Table 14. Summary of Baseline Disease Characteristics (ITT Population)

|                                                      | Atesolisumab (N=302)   | Chemotherapy (N=151)   |          | Total    | (N=453)   |
|------------------------------------------------------|------------------------|------------------------|----------|----------|-----------|
| Histology', n(t)                                     |                        |                        |          |          |           |
| snowenbg                                             | 129                    | 42.71                  | 64 42.4) |          | 193 42.6) |
| Non-squamous                                         | 173                    | 57.31                  | 87       | 57.61    | 260 57.41 |
| Adenocareinoma                                       | 156                    | 90.21                  | 81       | 93.1)    | 237 91.21 |
| Adenosquamous                                        | 5                      | 2.91                   |          |          | 5 1.91    |
| Sarcomatoid                                          | 2                      | 1.2)                   | 0        | 2        | 0.81      |
| Large cell                                           | 1                      | 0.61                   | 0        |          | 1 0.41    |
| Large cell with neuroendocrine differentiation       | 0                      |                        | 1 (      | 1.1)     | 1 [ 0.41  |
| Poorly differentiated                                | 4                      | 2.31                   | 1        | 1.1)     | 5 1.91    |
| Mixed (not including small cell)                     | 1 1                    | 0.61                   | 0        |          | 1 0.41    |
| NSCLC/NOS                                            | 4                      | 2.3)                   |          | 4.6)     | 8 3.11    |
| Initial Diagnosis Staging. n[e]                      |                        |                        |          |          |           |
| Btage IA                                             | 12                     | 4.01                   | 4        | 2.6) 16  | 3.51      |
| Btage IB                                             | 4                      | 1.31                   | 4        | 2.6) 8   | 1.81      |
| Btage IIA                                            | 12                     | 4.01                   | 1        | 0.7) 13  | 2.91      |
| Stage IIB                                            | 14                     | 4.61                   | 2        | 1.3) 16  | 3.51      |
| Stage IIIA                                           | 13                     | 4.3)                   | 11 [     | 7.3) 24  | 5.31      |
| Stage IIIB                                           | 44                     | 14.61                  | 26       | 17.2)    | 70 15.51  |
| Stage IV                                             | 187                    | 61.91                  | 97       | 64.2)    | 284 62.71 |
| Not Done                                             | 1                      | 0.31                   | 0        | 1        | 0.21      |
| Unknown                                              | 15                     | 5.01 6                 | [        | 4.0)     | 21 4.6)   |
| Current Disease Stage at Enrollment， n（t)            |                        |                        |          |          |           |
| Stage IIIB                                           | 41                     | 13.61                  | 21       | 13.9)    | 62 (13.7) |
| Staqe IV                                             | 261                    | 86.41                  | 130      | 86.1)    | 391 86.31 |
| Locations of Metastatic Disease at Enrollment², n(e) |                        |                        |          |          |           |
| Adrenal gland                                        | 42                     | 13.9)                  | 16       | 10.6)    | 58 12.8)  |
| Bone                                                 | 68                     | 22.51                  | 23       | 15.2) 91 | 20.11     |
| Brain                                                | 27                     | 8.91                   | 13       | 8.61     | 40 8.81   |
| Liver                                                | 44                     | 14.6)                  | 26       | 17.2)    | 70 15.51  |
| Lung                                                 | 204                    | 67.51                  | 102      | 67.51    | 306 67.51 |
| Lymph node                                           | 175                    | 57.91                  | 90       | 59.6)    | 265 58.51 |
| Mediastinum                                          | 29                     | 9.61                   | 11       | 7.31     | 40 8.81   |
| Pleural cavity                                       | 70                     | 23.2)                  | 30       | 19.91    | 100 22.11 |
| Pericardial cavity                                   | 16                     | 5.31                   | 6        | 4.01     | 22 4.91   |
| Skin                                                 | 1                      | 0.31                   | 1        | 0.71 2   | 0.41      |
| Chest wall                                           | 6                      | 2.01                   | 2 (      | 1.31     | 8 1.81    |
| Bronchus                                             |                        | 0                      | 1        | 0.71 1   | [ 0.21    |
| Trachea                                              | 5                      | 1.71                   | 1 (      | 0.71     | 6 [ 1.31  |
| Abdominal cavity                                     | 6                      | 2.01                   | 9        | 3.31     | 11 2.41   |
| Abdominal wal1                                       | 1                      | 0.3)                   | 0        | 1        | 0.2) 9.31 |
| Other Missing                                        | 28 37 12.31            | 9.31 19                | 14 12.6) | 9.31 56  | 42 12.41  |
| Number of Metastatic Sites at Enrollment             |                        |                        |          |          |           |
| n (missing)                                          | 265(37)                |                        | 132(19)  |          | 397(56)   |
| Mean (SD)                                            | 2.7 (1.3)              |                        | 2.6(1.2) |          | 2.7 (1.3) |
| Median                                               | 3.0                    |                        | 2.0      |          | 3.0       |
| Min, Max                                             | 1.8                    |                        | 1.7      |          | 1,8       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                                                                                     | Ategolisumab (N=302)                 | Chemotherapy (N=151)    | Total (N=453)   |
|-------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|-------------------------|-----------------|
| Time from Initial Diagnosis Date to Initial Dose Administered (months)                                                              |                                      |                         |                 |
| n (missing)                                                                                                                         | 293(9)                               | 146(5)                  | 439(14)         |
| Mean (SD)                                                                                                                           |                                      | 8.24(15.93)10.65(30.01) | 9.04(21.65)     |
| Hedian                                                                                                                              | 2.10                                 | 1.87                    | 2.04            |
| HeH 'UTN                                                                                                                            | 0.5, 118.2                           | 0.5, 189.1              | 0.5, 189.1      |
| Time from Earliest Date of lst Diag. of Locally Recurrent Disease or Locally Advanced Vnresectable Disease or Metastatic Disease to |                                      |                         |                 |
| Initial Dose Administered (months)                                                                                                  |                                      |                         |                 |
| n (missing)                                                                                                                         | 291 (11)                             | 145(6)                  | 436(17)         |
| Mean (SD)                                                                                                                           | 4.14(10.72)                          | 3.70(7.95)              | 3.99(9.88)      |
|                                                                                                                                     | 1.71                                 | 1.64                    | 1.68            |
|                                                                                                                                     | 0.1, 114.1                           | 0.1, 76.6               | 0.1,114.1       |
| EGFR Mutation', n(t)                                                                                                                |                                      |                         |                 |
| EGrR mutations other than LesiR or exon l9 deletions                                                                                | 0.31                                 | 0.71                    | 2 0.4)          |
| No mutation                                                                                                                         | 269 69.11                            | 131 86.81               | 00 88.31        |
| Not Done                                                                                                                            | 32 10.6)                             | 19 12.6)                | 51 11.31        |
| ALK Rearrangement', n(t)                                                                                                            |                                      |                         |                 |
| No                                                                                                                                  | 266 68.11                            | 130 86.11               | 396 87.41       |
| Not evaluable                                                                                                                       | 3 1.01                               | 1 0.7)                  | 4 0.91          |
| Not Done                                                                                                                            | 33 (10.9)                            | 20(13.2)                | 53 ( 11.7)      |
| Baseline Target Tumor Sum Longest Diameter (mm)                                                                                     |                                      |                         |                 |
| n (missing)                                                                                                                         | 302(0)                               | 151(0)                  | 453(0)          |
| Mean (SD)                                                                                                                           | 91.03(48.65)87.84(48.17)69.97(48.46) |                         |                 |
| Median                                                                                                                              | 83.00                                | 85.00                   | 63.00           |
| Hin, Max                                                                                                                            | 10.0, 317.0                          | 13.0,290.0              | 10.0, 317.0     |
| Baseline Target Tumor Sum Longest Diameter Category. n(t)                                                                           |                                      |                         |                 |
| cMedian                                                                                                                             | 150 (49.7)                           | 73(48.3)                | 223 [49.2]      |
| >=Median                                                                                                                            | 152 ( 50.3)                          | 78 (51.7)               | 230 [ 50.81     |
| Lactate Dehydrogenase, n(e)                                                                                                         |                                      |                         |                 |
| High                                                                                                                                | 116 (38.4)                           | 52 ( 34.41              | 168 [37.1)      |
| Normal                                                                                                                              | 169 56.01                            | 06 59.61                | 259 [ 57.21     |
| Low                                                                                                                                 | 4.31                                 | 13 7 4.6)               | 20 4.41         |
| Missing                                                                                                                             | C 1.31                               | 4 2 1.31                | 6 1.31          |

1 Based on eCRF data.

2 A patient can be counted in more than one location (when multiple locations are checked).

3 Time from &lt;diagnosis&gt; to initial dose administered = (First treatment intake - &lt;diagnosis&gt; date + 1)/30.4375.

4 EGFR &amp; ALK testing was not mandated for patients with squamous NSCLC.

Table 15. Summary of Baseline Disease Characteristics (Platinum-ineligible Population)

|                                                | Atezolizumab (N=268)   | Chemotherapy (N=137)   | Total (N=405)   |
|------------------------------------------------|------------------------|------------------------|-----------------|
| Histology,n(%)                                 |                        |                        |                 |
| Squamous                                       | 120 44.8)              | 58 42.3)               | 178 44.0)       |
| Non-squamous                                   | 148 55.2)              | 79 ( 57.7)             | 227 ( 56.0)     |
| Adenocarcinoma                                 | 133 89.9)              | 74 93.7)               | 207 （ 91.2)     |
| Adenosquamous                                  | 5 ( 3.4)               | 0                      | 5 ( 2.2)        |
| Sarcomatoid                                    | 2 ( 1 . 4)             | 0                      | 2 ( 0.9)        |
| Large cell with neuroendocrine differentiation | 0                      | 1 ( 1.3)               | 1 ( 0.4)        |
| Poorly differentiated                          | 3 ( 2.0)               | 1 ( 1.3)               | 4 ( 1.8)        |
| Mixed (not including small cell)               | 1 ( 0.7)               | 0                      | 1 ( 0.4)        |
| NSCLC/NOS                                      | 4 （ 2.7)               | 3 3.8)                 | 7 （ 3.1)        |
| Initial Diagnosis Staging, n(&)                |                        |                        |                 |
| Stage IA                                       | 12 ( 4.5)              | 3 2.2)                 | 15 3.7)         |
| Stage IB                                       | 4 （ 1.5) 4.5)          | 4 ( 2.9)               | 8 ( 2.0)        |
| Stage IIA                                      | 12                     | 1 0.7)                 | 13 ( 3.2)       |
| Stage IIB                                      | 14 ( 5.2)              | 2 ( 1.5)               | 16 ( 4.0)       |
| Stage IIIA                                     | 13 4.9)                | 11 8.0)                | 24 ( 5.9)       |
| Stage IIIB                                     | 38 14.2)               | 25 18.2)               | 63 （ 15.6)      |
| Stage IV                                       | 162 （ 60.4) 0.4)       | 86 62.8)               | 248 （ 61.2)     |
| Not Done                                       | 1                      | 0                      | 1 （ 0.2)        |
|                                                | （                      | 5 （                    | 17 （ 4.2)       |
| Unknown                                        | 12 4 .5)               | 3.6)                   |                 |
| Current Disease Stage at Enrollment, n()       |                        |                        |                 |
| Stage IIIB                                     | 35 (13.1)              | 20 (14.6)              | 55 (13.6)       |
| Staqe IV                                       | 233 (86.9)             | 117  (85.4)            | 350 (86.4)      |

<div style=\"page-break-after: always\"></div>

| Locations of Metastatic Disease at Enrollment², n(&) Adrenal gland      | 36 ( 13.4)           | 16 ( 11.7)           | 52 12.8)         |
|-------------------------------------------------------------------------|----------------------|----------------------|------------------|
| Bone                                                                    | 61 ( 22.8)           | 21 15.3)             | 82 ( 20.2)       |
| Brain                                                                   | 18 6.7)              | 9 （ 6.6)             | 6.7)             |
| Liver                                                                   | 36 13.4)             | 22 16.1)             | 27 58 14.3)      |
| Lung                                                                    | 180 67.2)            | 06 65.7)             | 270 66.7)        |
| Lymph node                                                              | 151 56.3)            | 80 58.4)             | 231 57.0)        |
| Mediastinum                                                             | 26 9.7)              | 9 4 6.6)             | 35 8.6)          |
| Pleural cavity                                                          | 66 ( 24.6)           | 27 （ 19.7)           | 93 23.0)         |
| Pericardial cavity                                                      | 14 5.2)              | 6 （ 4 .4)            | 20 4 .9)         |
| Skin                                                                    | ( 0.4)               | 1 （ 0.7)             | ( 0.5)           |
| Chest wall                                                              | 1 6 2.2)             | 2 （ 1.5)             | 2 8 2.0)         |
| Bronchus                                                                | 0                    | 1 ( 0.7)             | 1 0.2)           |
| Trachea                                                                 | 4 1.5)               | 1 ( 0.7)             | 5 ( 1.2)         |
|                                                                         | 6 ( 2.2)             | 4 （ 2.9)             | ( 2.5)           |
| Abdominal cavity                                                        |                      |                      | 10               |
| Abdominal wall                                                          | 1 0.4)               | 0 12 ( 8.8)          | 1 ( 0.2) 35 8.6) |
| Other Missing                                                           | 23 8.6) 32 11.9)     | 18 13.1)             | 50 12.3)         |
| Number of Metastatic Sites at Enrollment                                |                      |                      |                  |
| n (missing)                                                             | 236 (32)             | 119 (18)             | 355 (50)         |
| Mean (SD)                                                               | 2.7 (1.3)            | 2.5 (1.2)            | 2.6 (1.3)        |
| Median                                                                  | 3.0                  | 2.0                  | 2.0              |
| Min, Max                                                                | 1,8                  | 1,7                  | 1,8              |
| Time from Initial Diagnosis Date to Initial Dose Administered² (months) |                      |                      |                  |
| n (missing)                                                             | 259(9)               | 134(3)               | 393 (12)         |
| Mean (SD)                                                               | 8.94 (16.74)         | 11.37 (31.23)        | 9.77 (22.73)     |
| Median                                                                  | 2.10 0.5.118.2       | 1.84 0.5.189.1       | 2.04 0.5.189.1   |
|                                                                         | Atezolizumab (N=268) | Chemotherapy (N=137) | Total (N=405)    |
| Time from Earliest Date of 1st Diag.of Locally Recurrent Disease or     |                      |                      |                  |
| Dose Administered (months)                                              | 257 (11)             | 132 (5)              | 389 (16)         |
| n(missing) Mean (SD)                                                    | 4.34 (11.29)         | 3.67 (8.05)          | 4.11 (10.30)     |
| Median                                                                  | 1.71                 | 1.61                 | 1.68             |
| Min, Max                                                                | 0.1, 114.1           | 0.1, 76.8            | 0.1, 114.1       |
| EGFR Mutation，n(%)                                                      |                      |                      |                  |
| EGFR mutations other than L858R or exon 19 deletions                    | 1 ( 0.4)             | 1( 0.7)              | 2 （ 0.5)         |
| No mutation                                                             | 239 89.2)            | 118 86.1)            | 357 （ 88.1)      |
| Not Done                                                                | 28 （ 10.4)           | 18 ( 13.1)           | 46(11.4)         |
| ALK Rearrangement4,n(&)                                                 |                      |                      |                  |
| No                                                                      | 236 88.1)            | 117(85.4)            | 353 (87.2)       |
| Not evaluable                                                           | 3 ( 1.1)             | 1 0.7)               | 4 （ 1.0)         |
| Not Done                                                                | 29 10.8)             | 19 (13.9)            | 48 ( 11.9)       |
| Baseline Target Tumor Sum Longest Diameter (mm)                         |                      |                      |                  |
| n(missing)                                                              | 268 (0)              | 137(0)               | 405 (0)          |
| Mean (SD)                                                               | 88.67 (47.60)        | 85.57 (47.82)        | 87.62 (47.64)    |
| Median                                                                  | 80.50                | 80.00                | 80.00            |
| Min, Max                                                                | 10.0,317.0           | 13.0， 290.0          | 10.0,317.0       |
| <Median >=Median                                                        |                      |                      |                  |
|                                                                         | 137 ( 51.1)          | 70 (51.1)            | 207 (51.1)       |
|                                                                         | 131 48.9)            | 67 (48.9)            | 198 (48.9)       |
| Lactate Dehydrogenase,n(&)                                              |                      |                      |                  |
| High                                                                    | 95 35.4)             | 40 (29.2)            | 135 33.3)        |
| Normal                                                                  | 157 ( 58.6)          | 88 ( 64.2)           | 245 ( 60.5)      |
| Low                                                                     | 13 ( 4.9)            | 7 ( 5.1)             | 20 ( 4.9)        |
| Missing                                                                 | 3 ( 1.1)             | 2 ( 1.5)             | 5 ( 1.2)         |
| Baseline Creatinine Clearance,n()                                       |                      |                      |                  |
| <45 mL/min                                                              | 37 13.8)             | 21 15.3)             | 58 14.3)         |
|                                                                         | 231 （ 86.2)          | （                    | 85.7)            |
| >=45 mL/min                                                             |                      | 116 84.7)            | 347              |

2 A patient can be counted in more than one location (when multiple locations are checked).

Based on eCRF data.

Time from &lt;diagnosis&gt; to initial dose administered =(First treatment intake -&lt;diagnosis&gt; date + 1)/30.4375.

4 EGFR &amp; ALK testing was not mandated for patients with squamous NSCLC.

<div style=\"page-break-after: always\"></div>

Table 16. Baseline PD-L1 Expression Status (SP142, SP263) (ITT Population)

<!-- image -->

|                                        | Atesolisumab (N=302)   | Atesolisumab (N=302)   | Chemotherapy (N=151)   | Chemotherapy (N=151)   | Total (N=453)   | Total (N=453)   |
|----------------------------------------|------------------------|------------------------|------------------------|------------------------|-----------------|-----------------|
| PD-L1 IHC Status by SP142 Ausay. n(e)  |                        |                        |                        |                        |                 |                 |
| Tc3 or 1C3                             | 18                     | 6.0)                   | 10                     | 6.61                   | 28              | 6.21            |
| TC0/1/2and1c0/1/2                      | 269                    | 89.1)                  | 135                    | 1*69                   | 404             | 89.21           |
| (Tc1/2 and 1c0/1/2) or (1c0 and IC1/2) | 112                    | (37.1)                 | 56                     | 37.11                  | 168             | 37.11           |
| TC1/2/3orIC1/2/3                       | 130                    | (43.0)                 | 66                     | 43.71                  | 196             | 43.31           |
| TCO and ICO                            | 157                    | (52.0)                 | 79                     | 52.31                  | 236             | 52.11           |
| Unknown                                | 15                     | 5.01                   | 6                      | 4.01                   | 21              | 19*             |
| PD-L1 IHC Btatus by SP263 Aasay.n(t)   |                        |                        |                        |                        |                 |                 |
| TC3=500                                | 50                     | 16.61                  | 25                     | 16.61                  | 75              | 16.6)           |
| TC 409>                                | 228                    | 75.51                  | 114                    | 75.51                  | 342             | 75.51           |
| 1-494                                  | 77                     | 25.51                  | 53                     | 35.11                  | 130             | 28.71           |
| TC >=1                                 | 127                    | 42.11                  | 78                     | 51.71                  | 205             | 45.31           |
| TC<1                                   | 151                    | 50.01                  | 61                     | 1+*0                   | 212             | 46.81           |
| Unknown                                | 24                     | 7.91                   | 12                     | 7.91                   | 36              | 7.91            |

Table 17. Baseline PD-L1 Expression Status (SP142, SP263) (Platinum-ineligible Population)

|                                        | Atezolizumab (N=268)   | Chemotherapy (N=137)   | Total (N=405)   |
|----------------------------------------|------------------------|------------------------|-----------------|
| PD-L1 IHC Status by SP142 Assay, n(%)  |                        |                        |                 |
| TC3 or IC3                             | 14 5.2)                | 10 7.3)                | 24 5.9)         |
| TC0/1/2andIC0/1/2                      | 243 90.7)              | 121 88.3)              | 364 89.9)       |
| (TC1/2 and IC0/1/2) or (TC0 and IC1/2) | 102 (38.1)             | 50 (36.5)              | 152 (37.5)      |
| TC1/2/3orIC1/2/3                       | 116 43.3)              | 60 43.8)               | 176 43.5)       |
| TCO and ICo                            | 141 52.6)              | 71 （ 51.8)             | 212 52.3)       |
| Unknown                                | 11 4.1)                | 6 4 . 4)               | 17 4.2)         |
| PD-L1 IHC Status by SP263 Assay, n(%)  |                        |                        |                 |
| TC>=50号                                | 39 (14.6)              | 22 (16.1)              | 61 (15.1)       |
| TC<50%                                 | 211 78.7)              | 103 (75.2) 35.0)       | 314 (77.5)      |
| TC 1-49$                               | 73 27.2)               | 48                     | 121 29.9)       |
| TC >= 1$                               | 112 41.8)              | 70 (51.1)              | 182 44 .9)      |
| TC<1%                                  | 138                    | 51.5) 55 40.1)         | 193 47.7)       |
| Unknown                                | 18 6.7)                | 12 8.8)                | 30 7.4)         |

Relevant comorbidities defined as the following HLGTs: Cardiac arrhythmias, Coronary artery disorders, Heart failures, Myocardial disorders, Cardiac valve disorders, Arteriosclerosis, stenosis,vascular insufficiency and necrosis,

Vascular hypertensive disorders, Central nervous system vascular disorders, Mental impairment disorders, Neurological disorders NEC, Peripheral neuropathies, Increased intracranial pressure and hydrocephalus, Encephalopathies,

Nephropathies, Renal disorders (excl nephropathies), Electrolyte and fluid balance conditions, Glucose metabolism disorders (incl diabetes mellitus), Appetite and general nutritional disorders, Bronchial disorders (excl neoplasms), Lower respiratory tract disorders (excl obstruction and infection),Pulmonary vascular disorders.

## Numbers analysed

Intent-to-treat  (ITT)  Population: all  randomised  patients  irrespective  of  whether  the  assigned treatment was actually received. For analyses on ITT, patients will be grouped according to the treatment assigned  at  randomisation.  The  ITT  population  will  be  the  population  for  the  analysis  of  efficacy parameters.  The  ITT patient  population  comprised  453  patients;  302  patients  randomised  to  the atezolizumab arm and 151 patients randomised to the chemotherapy arm.

The platinum-ineligible population (see clarification and definition above, at the beginning of baseline characteristics): A total of 405 patients corresponding to 89% of the ITT population, and of these, 268 patients  were  randomised  to  the  atezolizumab  arm  and  137  patients  were  randomised  to  the chemotherapy arm.

Safety-Evaluable Population: all randomised patients who received any amount of study treatment. For analyses on Safety-Evaluable Population, patients will be grouped according to whether any amount

Assessment report

<div style=\"page-break-after: always\"></div>

of atezolizumab was received, including the case when atezolizumab was received in error. The SafetyEvaluable Population will be the population for the analysis of safety parameters.

The safety-evaluable population included 447 (98.7%) patients who either received at least one dose of atezolizumab (300 patients) or at least one dose of chemotherapy (vinorelbine or gemcitabine) (147 patients).

The study data cut off (CCOD) 30 April 2022.

## Outcomes and estimation

Clarification: Since analyses from the platinum-ineligible population were performed ad hoc, they are presented in the subsequent section (see 'Ancillary analyses').

Table 18. Overview of Efficacy (ITT Population)

<!-- image -->

|                                                        | Atezolizumab N=302        | Chemotherapy N= 151       |
|--------------------------------------------------------|---------------------------|---------------------------|
| Primary Efficacy Endpoint                              |                           |                           |
| Overall Survival                                       |                           |                           |
| No (%) of events                                       | 249 (82.5%)               | 130 (86.1%)               |
| Median (95% Cl) *, months                              | 10.3 (9.4, 11.9)          | 9.2 (5.9, 11.2)           |
| Stratified HR (95% CI) b p-value (Stratified Log-rank) | 0.78 (0.63, 0.97) p=0.028 | 0.78 (0.63, 0.97) p=0.028 |
| Key Secondary Efficacy Endpoints                       |                           |                           |
| Landmark Overall Survival Rates, % (95% CI °)          |                           |                           |
| 6 months                                               | 64.0 (58.6, 69.5)         | 57.5 (49.4, 65.7)         |
| 12 months                                              | 43.7 (37.9, 49.4)         | 38.6 (30.5, 46.7)         |
| 18 months                                              | 31.4 (26.0, 36.8)         | 24.0 (16.8, 31.2)         |
| 24 months                                              | 24.3 (19.3, 29.4)         | 12.4 (6.7, 18.0)          |
| INV-assessed Progression-Free Survival                 |                           |                           |
| No (%) of events                                       | 276 (91.4%)               | 138 (91.4%)               |
| Median (95% Cl) *, months                              | 4.2 (3.7, 5.5)            | 4.0 (2.9, 5.4)            |
| Stratified HR (95% CI) b                               | 0.87 (0.70, 1.07)         | 0.87 (0.70, 1.07)         |
| Objective Response Rate (confirmed)                    |                           |                           |
| ORR, n(%)                                              | 51 (16.9%)                | 12 (7.9%)                 |
| Difference in ORR (95% CI) d                           | 8.9% (2.4, 15.5)          | 8.9% (2.4, 15.5)          |
| Duration of Response (confirmed)                       |                           |                           |
| No (%) of events e                                     | 40 (78.4%)                | 12 (100.0%)               |
| Median (95% Cl) ·, months                              | 14.0 (8.1, 20.3)          | 7.8 (4.8, 9.7)            |

CI = confidence interval; HR = hazard ratio; ORR = objective response rate

a 95% CI computed using the Brookmeyer Crowley method.

b Estimated hazard ratio and 95% CI obtained from Cox model with treatment group as covariate. Stratification factors include histologic subtype, PD-L1 IHC status and brain metastases (Yes/No) (per IxRS data).

c 95% CI computed using linear transformation based on standard errors computed using Greenwood's formula.

d 95% CI of the difference in ORR (atezolizumab - chemotherapy) computed using normal approximation to the binomial distribution.

e Percentages calculated based on number of patients with best overall response of confirmed CR or PR.

## Primary endpoint (OS)

The primary efficacy endpoint of IPSOS was met as the pre-specified final OS analysis alpha boundary (two sided α=0.04295) was crossed in the ITT population.

<div style=\"page-break-after: always\"></div>

Table 19. Overall Survival (ITT Population)

<!-- image -->

|                                                         | Atesolisumab (N=302)   | Chemotherapy (N=151)   |
|---------------------------------------------------------|------------------------|------------------------|
| Kaplan-Meier Estimates of Overall Survival (oS)(months) |                        |                        |
| Events, n(e)                                            | 249 (82.56)            | 130 (86.16)            |
| Censored, n(e)                                          | 53 (17.5+)             | 21 (13.96)             |
| 25th Pctl.(95o C1l)                                     | 3.6 (2.8,5.0)          | 3.9 (3.1,4.9)          |
| Median (95e CI)                                         | 10.3 (9.4,11.9)        | 9.2 (5.9,11.2)         |
| 75th Pctl.(95e CIl)                                     | 24.0(18.6,28.3)        | 17.0 (13.9，21.3)       |
|                                                         | 0.1,51.5               | 0.1, 53.5              |
| Stratified Analysis                                     |                        |                        |
| Hasard ratio (Atesolisumab vs.                          | 0.78                   |                        |
| Chemotherapy12                                          |                        |                        |
| 95+ C12                                                 | (0.63,0.97)            |                        |
| P-value (log-rank)                                      | 0.028                  |                        |
| Unstratified Analysis                                   |                        |                        |
| Hasard ratio (Atesolisumab vs.                          | 0.79                   |                        |
| Chemotherapy12                                          |                        |                        |
| 956 C12                                                 | (0.64,0.97)            |                        |
| P-value (log-rank)                                      | 0.028                  |                        |

1 95% Confidence Interval (CI) computed using the Brookmeyer and Crowley method.

2 Estimated hazard ratio and 95% Confidence Interval (CI) obtained from Cox model with treatment group as covariate.

For the stratified analysis, histologic subtype, PD-L1 IHC status and brain metastases (Yes/No) were added as stratification factors (per IxRS data).

Table 20. Kaplan-Meier Plot of Overall Survival (ITT Population)

<!-- image -->

## Secondary endpoints

## 1) Landmark Overall Survival Rates at 6, 12, 18 and 24 Months (ITT Population)

<div style=\"page-break-after: always\"></div>

Table 21. Overall Survival Rates at the 6, 12, 18 and 24-Month Timepoints (ITT Population)

<!-- image -->

estimatedlusing

## 2) Investigator-Assessed Progression-Free Survival (PFS)

Table 22. Investigator-Assessed PFS per RECIST v1.1 (ITT Population)

<!-- image -->

a normal approximation method.

<div style=\"page-break-after: always\"></div>

Figure 7. Kaplan-Meier Plot of Investigator-Assessed PFS per RECIST v1.1 (ITT Population)

<!-- image -->

P-value obtained from a stratified log-rank test. Stratification factors (per IxRS data) are: histologic subtype, PD-L1 IHC status and brain metastases.

<div style=\"page-break-after: always\"></div>

## 3) Best Overall response

Table 23. Confirmed Best Overall Response per RECIST v1.1 - Investigator (ITT Population)

<!-- image -->

|                                                                                                                                                                                                                  | Atesolisumab (N=302)                                                                                                                                                                                             | Chemotherapy (N=151)                                                                                                                                                                                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Best Overall Response (BoR), n(b)                                                                                                                                                                                |                                                                                                                                                                                                                  |                                                                                                                                                                                                                  |
| Complete Response (cR)                                                                                                                                                                                           | 4(1.3)                                                                                                                                                                                                           | 0(0.0)                                                                                                                                                                                                           |
| 95+ CI1                                                                                                                                                                                                          | (0.4,3.4)                                                                                                                                                                                                        | (NE, NE)                                                                                                                                                                                                         |
| Partial Response (PR)                                                                                                                                                                                            | 47(15.6)                                                                                                                                                                                                         | 12 (7.9)                                                                                                                                                                                                         |
| 95+ C1l                                                                                                                                                                                                          | (11.7, 20.2)                                                                                                                                                                                                     | (4.2, 13.5)                                                                                                                                                                                                      |
| Stable Disease (S0)                                                                                                                                                                                              | 122(40.4)                                                                                                                                                                                                        | 73(48.3)                                                                                                                                                                                                         |
| 95+ CI1                                                                                                                                                                                                          | (34.8,46.2)                                                                                                                                                                                                      | (40.1,56.6)                                                                                                                                                                                                      |
| Progressive Disease (PD)                                                                                                                                                                                         | 67(22.2)                                                                                                                                                                                                         | 36(23.8)                                                                                                                                                                                                         |
| 95+ CI1                                                                                                                                                                                                          | (17.6, 27.3)                                                                                                                                                                                                     | (17.3,31.4)                                                                                                                                                                                                      |
| Non-Evaluable (NE)                                                                                                                                                                                               | 14(4.6)                                                                                                                                                                                                          | 12(7.9)                                                                                                                                                                                                          |
| 95+ CI1                                                                                                                                                                                                          | (2.6,7.7)                                                                                                                                                                                                        | (4.2, 13.5)                                                                                                                                                                                                      |
| Missing                                                                                                                                                                                                          | 48(15.9)                                                                                                                                                                                                         | 18(11.9)                                                                                                                                                                                                         |
| 95+ CI1                                                                                                                                                                                                          | (12.0, 20.5)                                                                                                                                                                                                     | (7.2. 18.2)                                                                                                                                                                                                      |
| Objective Response Rate (oRR) n[t)                                                                                                                                                                               | 51 (16.9)                                                                                                                                                                                                        | 12(7.9)                                                                                                                                                                                                          |
| 95+ CI1                                                                                                                                                                                                          | (12.8, 21.6)                                                                                                                                                                                                     | (4.2,13.5]                                                                                                                                                                                                       |
| Differencein ORR(Atenolisumab- Chemotherapy)                                                                                                                                                                     |                                                                                                                                                                                                                  |                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                  | 8.9                                                                                                                                                                                                              |                                                                                                                                                                                                                  |
| 95+ C12                                                                                                                                                                                                          | (2.4,15.5)                                                                                                                                                                                                       |                                                                                                                                                                                                                  |
| P-value\"                                                                                                                                                                                                         | 0.010                                                                                                                                                                                                            |                                                                                                                                                                                                                  |
| 958 confidence interval (CI) computed using the Clopper-Pearson method. 2950 confidence interval (CI) of the difference in ORR (Atesolisumab - Chemotherapy) computed using normal approrimation to the binomial | 958 confidence interval (CI) computed using the Clopper-Pearson method. 2950 confidence interval (CI) of the difference in ORR (Atesolisumab - Chemotherapy) computed using normal approrimation to the binomial | 958 confidence interval (CI) computed using the Clopper-Pearson method. 2950 confidence interval (CI) of the difference in ORR (Atesolisumab - Chemotherapy) computed using normal approrimation to the binomial |
| distribution. 3 P-value (two-sided) obtained from Chi-square test.                                                                                                                                               |                                                                                                                                                                                                                  |                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

## 4) Duration of response

```
Ategolisumab Chemotherapy (N=302) (N=151) Patients with Best Overall Response (BoR) 51 (16.9) 12(7.9) of CR or PR, n(o) Kaplan-Meier Estimates of Duration of Response (months) Events, n(e)1 40 (78.46) 12 (100.04) Earliest contributing event Death 8 3 Disease Progression 32 9 Censored, n(e)1 11 (21.60) 0 (0.06) 25th Pctl. (95o Ci²) 5.5(4.2,10.2) 4.2 (2.9,8.2) Hedian (95o C1l) 14.0(8.1,20.3) 7.8 (4.8,9.7) 75th Pctl.(95e C1²) 33.8 (18.7,43.3) 10.6 (7.4，12.7) Min, Max 1.4.44.7 2.2.15.7 Stratified Analysis Hagard ratio (Atesolisumab vs. 0.40 Chemotherapy]a 95+ C1(0.19,0.85) P-value (logrrank) 0.014 Unstratified Analysis Haoard ratio (Atesolisumab vs. 0.36 Chemotherapy)4 956 C13 (0.18,0.72) P-value (logrrank) 0.003 Note: Duration of response is defined only for patients with a best overall response (BoR) of Complete Response (cR) or Partial Response [PR). Percentages are calculated based on number of patients with BoR of CR or PR. 2 2 g5t Confidence Interval (cl) computed using the Brookmeyer and Crowley method. model with treatment group as covariate. For the stratified analysis, histologic subtype, PD-Ll Ihc status and brain metastases (Yes/No) were added as stratification factors (per InRs data).
```

Table 24. Summary of Duration of Response (ITT Patients with Confirmed Response per RECIST v1.1)

## Ancillary analyses

## Sensitivity Analyses on Overall Survival (ITT Population)

Sensitivity analyses to confirm the robustness of the primary OS analysis were performed including:

- Unstratified log-rank analysis
- Sensitivity analysis to account for the risk of over-stratification
- Sensitivity analysis to account for potential mis-stratification
- Sensitivity analysis to account for non-proportionality
- Sensitivity analysis to assess the impact of non-protocol anti-cancer immunotherapy (NPT)

## Table 25. Sensitivity Analyses on Overall Survival (ITT Population)

<div style=\"page-break-after: always\"></div>

|                                                            | Atezolizumab N=302                                         | Chemotherapy N=151   |
|------------------------------------------------------------|------------------------------------------------------------|----------------------|
| Primary analysis                                           |                                                            |                      |
| Median (95% Cl) *, months                                  | 10.3 (9.4, 11.9)                                           | 9.2 (5.9, 11.2)      |
| Stratified HR (95% CI) b,c                                 | 0.78 (0.63, 0.97)                                          | 0.78 (0.63, 0.97)    |
| Sensitivity Analyses                                       |                                                            |                      |
| Unstratified analysis                                      |                                                            |                      |
| Median (95% Cl) *, months                                  | 10.3 (9.4, 11.9)                                           | 9.2 (5.9, 11.2)      |
| Unstratified HR (95% Cl)                                   | 0.79 (0.64, 0.97)                                          | 0.79 (0.64, 0.97)    |
| Over-stratification                                        |                                                            |                      |
| Median (95% Cl) *, months                                  | 10.3 (9.4, 11.9)                                           | 9.2 (5.9, 11.2)      |
| Stratified HR (95% Cl) b.d                                 | 0.79 (0.63, 0.97)                                          | 0.79 (0.63, 0.97)    |
| Mis-stratification                                         |                                                            |                      |
| Median (95% Cl) *, months                                  | 10.3 (9.4, 11.9)                                           | 9.2 (5.9, 11.2)      |
| Stratified HR (95% CI) b.e                                 | 0.79 (0.63, 0.98)                                          | 0.79 (0.63, 0.98)    |
| Impact of Non-Protocol-Specified Anti-Cancer Immunotherapy | Impact of Non-Protocol-Specified Anti-Cancer Immunotherapy |                      |
| Rank Preserving Structural Failure Time (RPSFT) Model      |                                                            |                      |
| Median (95% Cl) *, months                                  | 10.3 (9.4, 11.9)                                           | 9.1 (5.9, 10.8)      |
| RPSFT HR  (95% CI)                                         | 0.74 (0.57, 0.97)                                          | 0.74 (0.57, 0.97)    |
| Impact of Non-proportionality Assumption                   |                                                            |                      |
| Non-Proportional Hazard - Restricted Mean Survival Time    |                                                            |                      |
| Estimate (95% Cl), months                                  | 16.1 (14.2, 17.9)                                          | 12.5 (10.5, 14.4)    |
| Difference (95% Cl)                                        | 3.6 (0.9, 6.3)                                             | 3.6 (0.9, 6.3)       |

CI = confidence interval; HR = hazard ratio; ITT = intent to treat

a 95% CI computed using the Brookmeyer Crowley method

b Estimated hazard ratio and 95% CI obtained from Cox model with treatment group as covariate.

c Stratification factors included histologic subtype, PD-L1 IHC status and brain metastases (Yes/No) (per IxRS data).

d Histologic subtype was added as stratification factor (per IxRS data).

e Stratification factors included histologic subtype, PD-L1 IHC status and brain metastases (Yes/No) (per eCRF/Lab data)

f 95% CI calculated using inflation of standard error based on ITT test.

## Subgroup analyses OS (ITT Population)

The consistency of OS results was investigated by estimating the treatment effect in predefined subgroups based on key demographics and baseline prognostic characteristics.

It is important to note that the study was not powered to detect differences in the individual subgroups and that in some subgroups, the small sample size and the wide 95% CIs hampers the ability to draw solid conclusions about the consistency of the treatment effect.

<div style=\"page-break-after: always\"></div>

## Figure 8. Forest Plot - Subgroup Analysis of Overall Survival by Baseline Demographic Characteristics (ITT Population)

|                               |         | Atezolizumab (N=302)   | Atezolizumab (N=302)   | Atezolizumab (N=302)   | Chemotherapy (N=151)   | Chemotherapy (N=151)   | Chemotherapy (N=151)   |              |              |     |                                        |
|-------------------------------|---------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|--------------|--------------|-----|----------------------------------------|
| Subgroups                     | Total n | n                      |                        | Median Events (Months) | n                      |                        | Median Events (Months) | Hazard Ratio | PPM%56 CI    |     | Atezolizumab Chemotherapy betterbetter |
| AllPatients                   | 453     | 302                    | 249                    | 10.3                   | 151                    | 130                    | 9.2                    | 0.79         | (0.64, 0.97) |     |                                        |
| Age                           |         |                        |                        |                        |                        |                        |                        |              |              |     |                                        |
| 65years                       | 65      | 46                     | 34                     | 9.4                    | 19                     | 15                     | 12.1                   | 1.05         | (0.57. 1.93) |     |                                        |
| 65-74years                    | 151     | 100                    | 81                     | 13.5                   | 51                     | 45                     | 9.1                    | 0.60         | (0.41,0.87)  |     |                                        |
| 75-84years                    | 213     | 141                    | 120                    | 9.7                    | 72                     | 61                     | 5.9                    | 0.86         | (0.63,1.18)  |     |                                        |
| >=85years                     | 24      | 15                     | 14                     | 11.0                   | 9                      | 9                      | 11.7                   | 0.80         | (0.33, 1.90) |     |                                        |
| Sex                           |         |                        |                        |                        |                        |                        |                        |              |              |     |                                        |
| Male                          | 328     | 220                    | 177                    | 11.0                   | 108                    | 90                     | 9.4                    | 0.76         | (0.59.0.98)  |     |                                        |
| Female                        | 125     | 82                     | 72                     | 8.5                    | 43                     | 40                     | 5.9                    | 0.86         | (0.58, 1.27) |     |                                        |
| Race                          |         |                        |                        |                        |                        |                        |                        |              |              |     |                                        |
| AmericanIndianorAlaskanNative | 21      | 12                     | 10                     | 5.5                    | 9                      | 9                      | 3.9                    | 0.75         | (0.29, 1.91) |     |                                        |
| Asian                         | 113     | 75                     | 52                     | 15.8                   | 38                     | 25                     | 12.3                   | 0.74         | (0.46, 1.20) |     |                                        |
| Black orAfrican American      | 3       | 2                      | 1                      | NE                     | 1                      | 0                      | NE                     | NE           | (NE,NE)      |     |                                        |
| White                         | 298     | 203                    | 178                    | 9.5                    | 95                     | 89                     | 8.3                    | 0.86         | (0.67,1.11)  |     |                                        |
| Unknown                       | 6       | 4                      | 4                      | 10.7                   | 2                      | 2                      | 4.2                    | 0.17         | (0.02.1.93)  |     |                                        |
| Multiple                      | 12      | 6                      | 4                      | 23.2                   | 6                      | 5                      | 7.1                    | 0.36         | (0.08.1.51)  |     |                                        |
| Ethnicity                     |         |                        |                        |                        |                        |                        |                        |              |              |     |                                        |
| Hispanic or Latino            | 70      | 47                     | 41                     | 7.9                    | 23                     | 22                     | 7.1                    | 0.70         | (0.41. 1.20) |     |                                        |
| Not Hispanic or Latino        | 367     | 242                    | 196                    | 11.0                   | 125                    | 105                    | 9.8                    | 0.80         | (0.63.1.01)  |     |                                        |
| Not Reported / Unknown        | 16      | 13                     | 12                     | 9.5                    | 3                      | 3                      | 5.5                    | 0.46         | (0.12, 1.78) |     |                                        |
| Smoking Status                |         |                        |                        |                        |                        |                        |                        |              |              |     |                                        |
| Never                         | 55      | 35                     | 26                     | 12.0                   | 20                     | 15                     | 12.3                   | 0.70         | (0.37. 1.35) |     |                                        |
| Current                       | 86      | 58                     | 48                     | 10.4                   | 28                     | 24                     | 4.4                    | 0.65         | (0.40, 1.07) |     |                                        |
| Previous                      | 312     | 209                    | 175                    | 10.0                   | 103                    | 91                     | 9.7                    | 0.83         | (0.64, 1.08) |     |                                        |
|                               |         |                        |                        |                        |                        |                        |                        |              |              | 0.2 | 0.5                                    |

NE=Notestimable;MedianSurvivalwasestimatedfromKaplan-Meiermethod.Unstratifiedhazardratiorelativeto Chemotherapyand95%CIforthehazardratiowereestimatedusingCoxregression.Thevertical dashedlineindicates thehazardratioforallpatients.Thediameter of thecircle isproportional to thesquareroot of thetotal number of events. Randomizedtreatmentsaredisplayed.

<div style=\"page-break-after: always\"></div>

## Figure 9. Forest Plot - Subgroup Analysis of Overall Survival by Baseline Disease Characteristics (ITT Population)

|                                 |         | Atezolizumab (N=302)   | Atezolizumab (N=302)   | Atezolizumab (N=302)   | Chemotherapy (N=151)   | Chemotherapy (N=151)   | Chemotherapy (N=151)   |              |              |
|---------------------------------|---------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|--------------|--------------|
| Subgroups                       | Total n | n                      |                        | Median Events (Months) | n                      |                        | Median Events (Months) | Hazard Ratio | PIBM %96 CI  |
| All Patients                    | 453     | 302                    | 249                    | 10.3                   | 151                    | 130                    | 9.2                    | 0.79         | (0.64, 0.97) |
| ECoGPerformanceStatus 0/1       | 75      | 56                     | 47                     | 11.3 9.7               | 19                     | 16                     | 8.3                    | 0.64         | (0.36, 1.13) |
| 2                               | 344     | 228                    | 185                    |                        | 116                    | 99                     | 10.4                   | 0.86         | (0.67.1.10)  |
| 3                               | 34      | 18                     | 17                     | 5.5                    | 16                     | 15                     | 5.3                    | 0.74         | (0.35, 1.57) |
| HistologyfromeCRF               |         |                        |                        |                        |                        |                        |                        |              |              |
| Squamous                        | 193     | 129                    | 110                    | 9.5                    | 64                     | 55                     | 7.2                    | 0.80         | (0.58,1.12)  |
| Non-Squamous                    | 260     | 173                    | 139                    | 11.3                   | 87                     | 75                     | 9.4                    | 0.77         | (0.58,1.03)  |
| Histologyfrom IxRS              |         |                        |                        |                        |                        |                        |                        |              |              |
| Squamous                        | 193     | 129                    | 110                    | 9.7                    | 64                     | 55                     | 7.2                    | 0.80         | (0.58,1.12)  |
| Non-Squamous                    | 260     | 173                    | 139                    | 11.0                   | 87                     | 75                     | 9.4                    | 0.77         | (0.58, 1.02) |
| CurrentDiseaseStageatEnrollment |         |                        |                        |                        |                        |                        |                        |              |              |
| Stage IIIB                      | 62      | 41                     | 35                     | 9.9                    | 21                     | 18                     | 10.3                   | 0.69         | (0.39, 1.24) |
| Stage IV                        | 391     | 261                    | 214                    | 10.3                   | 130                    | 112                    | 9.1                    | 0.81         | (0.64, 1.02) |

NE=Not estimable;MedianSurvival wasestimated fromKaplan-Meier method.Unstratified hazardratiorelative to Chemotherapyand95%CIfor thehazardratiowere estimatedusing Coxregression.Thevertical dashed lineindicates thehazardratioforallpatients.The diameterof thecircle isproportionaltothesquarerootof thetotalnumberofevents. Randomized treatmentsaredisplayed.

<div style=\"page-break-after: always\"></div>

## Figure 10. Forest Plot - Subgroup Analysis of Overall Survival by PD-L1 Status (ITT Population)

|                                  |                               | Atezolizumab (N=302)   | Atezolizumab (N=302)   | Atezolizumab (N=302)   | Chemotherapy (N=151)   | Chemotherapy (N=151)   | Chemotherapy (N=151)   |              |              |
|----------------------------------|-------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|--------------|--------------|
| Subgroups                        | Total n                       | n                      |                        | Median Events (Months) | n                      |                        | Median Events (Months) | Hazard Ratio | PBM %96 CI   |
| AllPatients                      | 453                           | 302                    | 249                    | 10.3                   | 151                    | 130                    | 9.2                    | 0.79         | (0.64, 0.97) |
| PD-L1IHCStatusbySP142fromLab     |                               |                        |                        |                        |                        |                        |                        |              |              |
| TC3orIC3                         | 28                            | 18                     | 11                     | 15.1                   | 10                     | 8                      | 9.2                    | 0.82         | (0.33, 2.06) |
| TC0/1/2and1C0/1/2                | 404                           | 269                    | 227                    | 9.9                    | 135                    | 117                    | 9.7                    | 0.80         | (0.64,1.01)  |
| [TC1/2andIC0/1/2]or[TC0andIC1/2] | 168                           | 112                    | 94                     | 10.2                   | 56                     | 50                     | 11.2                   | 0.89         | (0.63,1.26)  |
| TC1/2/3orIC1/2/3                 | 196                           | 130                    | 105                    | 10.2                   | 66                     | 58                     | 11.0                   | 0.89         | (0.65, 1.23) |
| TCO and ICo                      | 236                           | 157                    | 133                    | 9.7                    | 79                     | 67                     | 8.0                    | 0.73         | (0.54.0.99)  |
| Unknown                          | 21                            | 15                     | 11                     | 13.1                   | 6                      | 5                      | 5.2                    | 0.26         | (0.08, 0.86) |
| PD-L1IHCStatusbySP142fromIxRS    | PD-L1IHCStatusbySP142fromIxRS |                        |                        |                        |                        |                        |                        |              |              |
| TC3orIC3                         | 28                            | 18                     | 11                     | 15.1                   | 10                     | 8                      | 9.2                    | 0.82         | (0.33. 2.06) |
| TC0/1/2 andIC0/1/2               | 405                           | 270                    | 228                    | 9.9                    | 135                    | 117                    | 9.7                    | 0.81         | (0.65,1.01)  |
| Unknown                          | 20                            | 14                     | 10                     | 16.9                   | 6                      | 5                      | 5.2                    | 0.22         | (0.06,0.74)  |
| PD-L1IHCStatusbySP263            | PD-L1IHCStatusbySP263         |                        |                        |                        |                        |                        |                        |              |              |
| TC>=50%                          | 75                            | 50                     | 34                     | 11.0                   | 25                     | 20                     | 13.9                   | 0.87         | (0.50,1.52)  |
| TC<50%                           | 342                           | 228                    | 197                    | 9.5                    | 114                    | 101                    | 8.0                    | 0.80         | (0.63,1.02)  |
| TC 1-49%                         | 130                           | 77                     | 68                     | 8.4                    | 53                     | 49                     | 10.2                   | 0.84         | (0.57, 1.22) |
| TC >=1%                          | 205                           | 127                    | 102                    | 9.4                    | 78                     | 69                     | 10.3                   | 0.84         | (0.62.1.15)  |
| TC<1%                            | 212                           | 151                    | 129                    | 10.3                   | 61                     | 52                     | 7.1                    | 0.81         | (0.58, 1.11) |
| Unknown                          | 36                            | 24                     | 18                     | 16.9                   | 12                     | 9                      | 9.4                    | 0.49         | (0.21, 1.14) |

NE=Notestimable;MedianSurvival wasestimatedfromKaplan-Meiermethod.Unstratified hazardratiorelative to Chemotherapy and 95% CI for the hazard ratio were estimated using Cox regression.The vertical dashed line indicates thehazardratiofor allpatients.The diameterof thecircle isproportionaltothesquareroot of the total numberof events. Randomizedtreatmentsaredisplayed.

## Subsequent treatment

## Table 26. Subsequent Non-Protocol Anti-Cancer Therapies (ITT Population)

| Type of Therapy Medication                                 | Atesolisumab (N=302) n (e)   | Chemotherapy (N=151) n (b)   | Total (N=453) n(e)   |
|------------------------------------------------------------|------------------------------|------------------------------|----------------------|
| Number of Patients with Any Subsequent Anti-Cancer Therapy | 61(20.2)                     | 45(29.8)                     | 106(23.4)            |
| Overall Total Number of Medications                        | 95                           | 62                           | 157                  |
| Chemotherapy                                               | 48 15.91                     | 16 10.61                     | 64 C 14.1)           |
| CARBOPLATIN                                                | 16 5.31                      | 7 4.61                       | 23 C 5.11            |
| PEMETREKED                                                 | 15 5.01                      | 4 2.61                       | 19 4.2)              |
| GEMCITABINE                                                | 16 5.31                      | 2 1.31                       | 18 C 4.01            |
| DOCETAKEL                                                  | 5 1.71                       | 3 2.01                       | 8 C 1.81             |
| VINORELBINE                                                | 7 2.31                       | 1 0.71                       | 8 C 1.81             |
| PACLITAKEL                                                 | 5 1.71                       | 2 1.31                       | 7 1.51               |
| VINORELBINE TARTRATE                                       | 4 1.31                       | 3 2.0)                       | 7 1.51               |
| CISPLATIN                                                  | 3 1.01                       | D ! 0.01                     | 3 C 0.71             |
| ETOPOSIDE                                                  | 2 0.71                       | D 0.01                       | 2 0.41               |
| PEMETREKED DISODIUM                                        | 1 】 0.31                     | 1 0.71                       | 2 0.41               |
| GEMCITABINE HYDROCHLORIDE                                  | 1 0.31                       | 0.01                         | 1 C 0.21             |
| LOBAPLATIN                                                 | 0 0.01                       | 1 0.71                       | 1 C 0.21             |
| Cancer Immunotherapy                                       | 4 1.31                       | 28 18.51                     | 32 C 7.11            |
| NIVOLUMAB                                                  | 1 0.31                       | 13 8.61                      | 14 3.11              |
| ATEZOLIZUMAB                                               | 1 0.31                       | 9 6.01                       | 10 2.21              |
| PEMBROLIZUMAB                                              | D 0.01                       | 5 3.3)                       | 5 1.11               |
| T0R2450                                                    | n 21                         | n71                          | 2 f n 41             |

<div style=\"page-break-after: always\"></div>

| CAMRELIZUMAB                               | 1 0.31   | D 0.01   | 1 0.21   |
|--------------------------------------------|----------|----------|----------|
| TKI                                        | 10 3.31  | 5 3.31   | 15 3.31  |
| CATEQUENTINIB                              | 3 1 1.01 | 1 0.71   | 0.91     |
| ERLOTINIB                                  | 2 0.71   | 1 0.71   | 3 0.71   |
| AFATINIB                                   | 2 0.71   | 0 0.01   | 2 0.41   |
| CATEQUENTINIB HYDROCHLORIDE                | 1 0.31   | 1 0.71   | 2 0.41   |
| AL 2846                                    | 1 1 0.31 | 0.01     | 1 0.21   |
| CRIZOTINIB                                 | 1 1 0.31 | 0 0.0)   | 1 1 0.21 |
| DABRAFENIB                                 | 1 0.0)   | 1 0.71   | 1 0.2)   |
| ERLOTINIB HYDROCHLORIDE                    | D 1 0.01 | 1 0.71   | 1 】 0.21 |
| GEFITINIB                                  | 1 1 0.31 | 0.01     | 1 0.2)   |
| TRAMETINIB                                 | 0 10:0   | 1 0.71   | 1 0.21   |
| Other                                      | 3 1.01   | 1 0.71   | 4 0.91   |
| UNSPECIFIED HERBALAND TRADITIONAL MEDICINE | 1 0.3)   | 1 0.71   | 2 0.4)   |
| ALLOTHERTHERAPEUTIC PRODUCTS               | 1 0.31   | D 0.01   | 1 一 0.2) |
| PHENTOLAMINEMESILATE                       | 1 0.31   | 0 0.01   | 1 0.21   |

Note: At each level of summation, patients reporting more than one subsequent therapy are counted only once. Types of therapy and medications within a type are sorted in descending order of total frequency. Treatments are coded using the WHODrug Global B3 Format dictionary March 1, 2022.

Table 27. Improvement of ECOG Performance Status in Patients with Subsequent Platinum Therapy (ITT Population)

|                                                      | Atezolizumab (N=18)   | Chemotherapy (N=8)   | Total (N=26)   |
|------------------------------------------------------|-----------------------|----------------------|----------------|
| Improvement of EcoG Ps at anytime post-baseline，n(%) |                       |                      |                |
| Yes*                                                 | 10 (55.6)             | 3(37.5)              | 13(50.0)       |
| No                                                   | 8(44.4)               | 5(62.5)              | 13 (50.0)      |

*OnepatientintheAtezolizumabarm(Patient1699)withimprovementinECoGPSpost-baselinewaserroneouslyreportedashavingreceivedplatinumassubsequentanti-cancer therapyatthe time thedatasnapshotwastaken(15June2022);dataentrieshavesincebeencorrected intheeCRFand thispatientreceivedbestsupportivecareonly.

Table 28. Overview of Platinum-Containing Regimens in Subsequent Therapy Lines (ITT Population)

|                                         | Atezolizumab (N=302) n （告)   | Chemotherapy (N=151) n(%)   | Total (N=453) n （告)   |
|-----------------------------------------|------------------------------|-----------------------------|-----------------------|
| Platinum Monotherapy                    | 1 （ 0.3)                     | 0                           | 1 ( 0.2)              |
| Carboplatin                             | 1 0.3)                       | 0                           | 1 0.2                 |
| Platinum in Doublet                     | 16 5.3)                      | 8 5.3)                      | 24 5.3)               |
| Carboplatin + Docetaxel                 | 0                            | 1 0.7)                      | 1 0.2)                |
| Carboplatin + Gemcitabine               | 1 0.3)                       | 1 0.7)                      | 2 （ 0.4)              |
| Carboplatin + Gemcitabine Hydrochloride | 1 0.3)                       | 0                           | 1 0.2)                |
| Carboplatin + Paclitaxel                | 3 1.0)                       | 2 1.3)                      | 5 1.1)                |
| Carboplatin + Pemetrexed*               | 7 2.3)                       | 2 1.3)                      | 9 （ 2.0)              |
| Carboplatin + Pemetrexed Disodium       | 1 0.3)                       | 1 0.7)                      | 2 （ 0.4)              |
| Carboplatin + Vinorelbine               | 1 0.3)                       | 0                           | 1 0.2)                |
| Cisplatin + Gemcitabine                 | 1 0.3)                       | 0                           | 1 （ 0.2)              |
| Cisplatin + Vinorelbine Tartrate        | 1 0.3)                       | 0                           | 1 ( 0.2)              |
| Lobaplatin + Docetaxel                  | 0                            | 1 0.7)                      | 1 （ 0.2)              |
| Platinum in Triplet                     | 1 （ 0.3)                     | 0                           | 1 ( 0.2)              |
| Carboplatin + Cisplatin + Pemetrexed**  | 1 （ 0.3)                     | 0                           | 1 0.2)                |

**Switch from cisplatin to carboplatin after Cvcle 1

*One patient in the Atezolizumab arm was erroneously reported as having received platinum (carboplatin + pemetrexed) as subsequent anti-cancer therapy at the time the data snapshot received best supportive care only.

## Results from the Platinum-ineligible population (N=405)

Baseline demographic characteristics and baseline disease characteristics for the platinum-ineligible population (N=405) are shown in Table 13 and Table 14, respectively.

<div style=\"page-break-after: always\"></div>

Table 29. Duration of Survival Follow-Up (Platinum-ineligible Population)

|                                                | Atesolisumab (N=268)   | Chemotherapy (N=137)   | Tot=l (N=405)   |
|------------------------------------------------|------------------------|------------------------|-----------------|
| Kaplan-Meier Estimates of Duration of Survival |                        |                        |                 |
| Follow-Up(months)                              |                        |                        |                 |
| Events, n(e)                                   | 45(16.8#)              | 17(12.4#)              | 62(15.3)        |
| Censored, n(e)                                 | 223(83.2)              | 120(87.6)              | 343(84.7)       |
| 25th Bxtl(95CI²)                               | 38.2(35.5,40.1)        | 36.5(34.3,39.9)        | 36.8(34.3,39.9) |
| Median (95e CI²)                               | 41.3(40.0,44.2)        | 39.9(36.5,NE)          | 41.0(39.9.44.2) |
| 75th Bx-(95 CI²)                               | 48.0(43.1,49.4)        | 52.7(39.9,NE)          | 48.0(43.1,49.5) |
| Min, Max                                       | 0.1, 51.5              | 0.1, 53.5              | 0.1, 53.5       |

1 95e Confidence Interval (CI) computed using the Brookmeyer and Crowley method.

The inverse Kaplan-Meier methodology as used to estimate the duration of survival follow-up.

Myocardial disorders, Caxdiac valve disordexs, Arteriosclexosis, stenosis, vascular insufficiency and necrosis, Vascular hypertensive disorders, Central nervous system vascular disorders, Mental impairment disorders, Neurological disorders NEc, Pexipheral neuropathies, Increased intracranial pressure and hydrocephalus, Encephalopathies, Deliris (iwsl, confusion] , Psychiatric disorders NEC, Dementia and smmestic conditions, Nephropathies, Renal disorders nephropathies), Electrolyte and fluid balance conditions, xl

Glucose metabolism disorders (incl, diabetes mellitus), Appetite and general nutritional disorders, Bronchial disorders neoplasms); Lower respiratory tract disozders (exsl obstruction and infection), Pulmonary vascular disoxders.

Table 30. Overall Survival (Platinum-ineligible Population)

|                                                          | Atezolizumab (N=268)   | Chemotherapy (N=137)   |
|----------------------------------------------------------|------------------------|------------------------|
| Kaplan-Meier Estimates of Overall Survival (OS) (months) |                        |                        |
| Events, n(e)                                             | 223(83.2)              | 120(87.6)              |
| Censoxed, n (e)                                          | 45(16.8#)              | 17(12.4#)              |
| 25th Bctl(95 CI²)                                        | 3.7 (2.8, 5.1)         | 4.0 (3.1, 5.2)         |
| Median (95e CI²)                                         | 10.3(9.3,12.0)         | 9.4(5.9,11.3)          |
| 75th Bs(95 CI*)                                          | 24.0(18.6, 28.7)       | 17.0(13.9, 20.2)       |
| Min, Max                                                 | 0.1, 51.5              | 0.1, 53.5              |
| Stratified Analysis                                      |                        |                        |
| Hazardratio (Atezolizumab vs. Chemotherapy)a             | 0.79                   |                        |
| 95 CI*                                                   | (0.63, 0.99)           |                        |
| P-value (log-rank)                                       | 0 .041                 |                        |
| Unstratified Analysis                                    |                        |                        |
| Hazard ratio (Atezolizumab vs. Chemothexapy)*            | 0.78                   |                        |
| 95e C1*                                                  | (0.63, 0.98)           |                        |
| P-value (log-rank)                                       | 0 .034                 |                        |

Estimated hazard ratio and 95e Confidence Interval (CI) obtained from Cox model with txeatment group as covariate.

For the stratified analysis, histologic subtype, PD-L1l IHC status and brain metastases (Yes/No) were added ss stratification factors (per IxRS data).

Relevant comorbidities defined as the following HLGTs: Cardiac arrhythmias, Coronary artery disorders, Heart failures, Myocardial disorders, Cardiac valve disordexs, Arteriosclexosis, stenosis, vascular insufficiency and necrosis,

Deliria (jncl, confusion], Psychiatric disorders NEC, Dementia and ammestic conditions, Nephropathies, Renal disorders (exol nephropathies), Electrolyte and fluid balance conditions,

Vascular hypertensive disorders, Central nervous system vascular disorders, Mental impairment disorders, Neurological disoxders NEC, Peripheral neuropathies, Increased intracranial pressure and hydrocephalus, Encephalopathies;

Glucose metabolism disorders (aRcl diabetes mellitus), Appetite and general nutritional disorders, Bzonchial disorders (cxol neoplasms), Lower respiratory txact disozders (axgl obstruction and infection), Pulmonary vascular disoxders.

<div style=\"page-break-after: always\"></div>

Figure 11. Kaplan-Meier Overall Survival (Platinum-ineligible Population)

<!-- image -->

P-value obtained from a stratified log-rank test.Stratification factors(perIxRS data) are:histologic subtype,PD-L1IHC status and brain metastases.

Table 31. Progression Free Survival as per Investigator - RECIST v1.1 (Platinum-ineligible Population)

|                                                                    | Atezolizumab (N=268)   | Chemotherapy (N=137)   |
|--------------------------------------------------------------------|------------------------|------------------------|
| Kaplan-Meier Estimates of Progression Free Survival (PFS) (months) |                        |                        |
| Events, n()                                                        | 245 (91.4)             | 125 (91.28)            |
| Earliest contributing event                                        |                        |                        |
| Death                                                              | 83                     | 44                     |
| Disease Progression                                                | 162                    | 81                     |
| Censored, n(&)                                                     | 23(8.6%)               | 12(8.8%)               |
| 25thRctl.(95% CI1)                                                 | 1.5 (1.4, 2.1)         | 2.5 (1.5, 2.8)         |
| Median (95 CI)                                                     | 4.7(4.0,5.6)           | 4.2(3.0,5.5)           |
| 75thRctl.(95% CI1)                                                 | 9.7 (8.3,12.5)         | 8.4(6.3,10.7)          |
| Min, Max                                                           | 0.0,48.3               | 0.0, 29.1              |
| Stratified Analysis                                                |                        |                        |
| Hazard ratio (Atezolizumab vs. Chemotherapy)2 95%CI2               | 0.85 (0.68, 1.06)      |                        |
| P-value (log-rank)                                                 | 0.151                  |                        |
| Unstratified Analysis                                              |                        |                        |
| Hazard ratio (Atezolizumab vs.Chemotherapy)2                       | 0.82                   |                        |
| 95%CI2                                                             | (0.66, 1.02)           |                        |
| P-value (log-rank)                                                 | 0.076                  |                        |

2 Estimated hazard ratio and 95&amp; Confidence Interval (CI) obtained from Cox model with treatment group as covariate. For the stratified analysis,histologic subtype, PD-L1 IHC status and brain metastases (Yes/No) were added as stratification

195&amp; Confidence Interval (CI) computed using the Brookmeyer and Crowley method.

factors (per IxRS data).

Vascular hypertensive disorders, Central nervous system vascular disorders, Mental impairment disorders, Neurological disorders NEC, Peripheral neuropathies, Increased intracranial pressure and hydrocephalus, Encephalopathies,

Relevant comorbidities defined as the following HLGTs: Cardiac arrhythmias, Coronary artery disorders, Heart failures,Myocardial disorders, Cardiac valve disorders, Arteriosclerosis, stenosis, vascular insufficiency and necrosis,

Deliria (incl confusion), Psychiatric disorders NEC, Dementia and amnestic conditions,Nephropathies, Renal disorders (excl nephropathies)， Electrolyte and fluid balance conditions,

Glucose metabolism disorders (incl diabetes mellitus), Appetite and general nutritional disorders, Bronchial disorders (excl neoplasms)，Lower respiratory tract disorders （excl obstruction and infection),Pulmonary vascular disorders.

<div style=\"page-break-after: always\"></div>

Table 32. Confirmed Best Overall Response per RECIST v1.1 - Investigator (Platinumineligible Population)

|                                                          | Atezolizumab (N=268)   | Chemotherapy (N=137)   |
|----------------------------------------------------------|------------------------|------------------------|
| Best Overall Response (BOR), n(&)                        |                        |                        |
| Complete Response (CR)                                   | 4 (1.5)                | 0 (0.0)                |
| 95&CI1                                                   | (0.4, 3.8)             | (NE，NE)                |
| Partial Response (PR)                                    | 45 (16.8)              | 11 (8.0)               |
| 95%CI1                                                   | (12.5, 21.8)           | (4.1, 13.9)            |
| Stable Disease (SD)                                      | 110 (41.0)             | 69 (50.4)              |
| 95%CI1                                                   | (35.1, 47.2)           | (41.7, 59.0)           |
| Progressive Disease (PD)                                 | 53 (19.8)              | 31 (22.6)              |
| 958CI1                                                   | (15.2, 25.1)           | (15.9, 30.6)           |
| Non-Evaluable (NE)                                       | 11 (4.1)               | 10 (7.3)               |
| 95CI1                                                    | (2.1, 7.2)             | (3.6, 13.0)            |
| Missing                                                  | 45 (16.8)              | 16 (11.7)              |
| 958CI1                                                   | (12.5, 21.8)           | (6.8, 18.3)            |
| Objective Response Rate (ORR) n(&)                       | 49(18.3)               | 11 (8.0)               |
| 95%CI1                                                   | (13.8,23.4)            |                        |
| Difference in ORR (Atezolizumab - Chemotherapy) P-value? |                        | (4.1, 13.9)            |
| 958CI2                                                   | (3.2, 17.3)            |                        |
| &                                                        | 10.3                   |                        |
|                                                          | 0.006                  |                        |

2 95&amp; confidence interval (CI) of the difference in ORR (Atezolizumab - Chemotherapy) computed using normal approximation to the binomialdistribution.

195&amp; confidence interval (CI) computed using the Clopper-Pearson method.

3p-value (two-sided) obtained from Chi-square test.

Table 33. Duration of Confirmed Response as per Investigator - RECIST v1.1 (Platinumineligible Population)

|                                                             | Atezolizumab (N=268)   | Chemotherapy (N=137)   |
|-------------------------------------------------------------|------------------------|------------------------|
| Patients with Best Overall Response (BOR) of CR or PR, n(&) | 49(18.3)               | 11 (8.0)               |
| Kaplan-Meier Estimates of Duration of Response (months)     |                        |                        |
| Events,n(%)1                                                | 38 (77.6%)             | 11 (100.0%)            |
| Earliest contributing event                                 |                        |                        |
| Death                                                       | 8                      | 3                      |
| Disease Progression                                         | 30                     | 8                      |
| Censored, n(&)1                                             | 11 (22.4%)             | Q (0.0%)               |
| 25th Rctl.(95% CI²)                                         | 5.6 (4.2, 10.2)        | 4.8(2.2,8.2)           |
| Median (95 CI)                                              | 14.5 (8.1, 20.3)       | 8.2 (4.8,11.6)         |
| 75th Rctl.(95% CI²)                                         | 33.8 (18.7,43.3)       | 11.6 (8.2, NE)         |
| Min, Max                                                    | 1.4, 44.7              | 2.2, 15.7              |
| Stratified Analysis                                         |                        |                        |
| Hazard ratio (Atezolizumab vs. Chemotherapy)3               | 0.42 (0.19, 0.91)      |                        |
| 95%CI3                                                      |                        |                        |
| P-value (log-rank)                                          | 0.024                  |                        |
| Unstratified Analysis                                       |                        |                        |
| Hazard ratio (Atezolizumab vs. Chemotherapy)3               | 0.37                   |                        |
| 95%CI3                                                      | (0.18,0.75)            |                        |
| P-value (log-rank)                                          | 0.004                  |                        |

1 Percentages are calculated based on number of patients with BOR of CR or PR.

（BoR)of Complete Response(CR)or Partial Response (PR).

295&amp; Confidence Interval(CI)computed using theBrookmeyer and Crowley method.

3Estimated hazard ratio and 95&amp; Confidence Interval (CI) obtained from Cox model with treatment group as covariate. For the stratified analysis, histologic subtype, PD-L1 IHC status and brain metastases (Yes/No) were added as stratification factors (per IxRS data).

## Summary of main study(ies)

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Summary of Efficacy for trial MO29872 (IPSOS)

| Title: A Phase III, open-label, multicenter, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung   | Title: A Phase III, open-label, multicenter, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung   | Title: A Phase III, open-label, multicenter, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung   | Title: A Phase III, open-label, multicenter, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung                                                                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                            | IPSOS Protocol number: MO29872 EudraCT number: 2015-004105-16 NCT number: NCT03191786                                                                                                                                                                                                                       | IPSOS Protocol number: MO29872 EudraCT number: 2015-004105-16 NCT number: NCT03191786                                                                                                                                                                                                                       | IPSOS Protocol number: MO29872 EudraCT number: 2015-004105-16 NCT number: NCT03191786                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                                                                                                      | IPSOS is a Phase III, global, multicenter, open-label, randomised, controlled study                                                                                                                                                                                                                         | IPSOS is a Phase III, global, multicenter, open-label, randomised, controlled study                                                                                                                                                                                                                         | IPSOS is a Phase III, global, multicenter, open-label, randomised, controlled study                                                                                                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                                                                      | Duration of main phase: Duration of                                                                                                                                                                                                                                                                         | Run-in phase:                                                                                                                                                                                                                                                                                               | Patients received atezolizumab until disease progression per RECIST v1.1, unacceptable toxicity, patient or physician decision to discontinue, or death. Patients received vinorelbine or gemcitabine until disease progression per RECIST v1.1, unacceptable toxicity, patient or physician decision to discontinue, or death. not applicable                                                                                                     |
| Hypothesis                                                                                                                                                                                                                                                                                                  | Superiority                                                                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Treatments groups                                                                                                                                                                                                                                                                                           | Atezolizumab                                                                                                                                                                                                                                                                                                | Atezolizumab                                                                                                                                                                                                                                                                                                | 1200 mg by IV infusion on Day 1 of every 21-day cycle                                                                                                                                                                                                                                                                                                                                                                                              |
| Treatments groups                                                                                                                                                                                                                                                                                           | Chemotherapy                                                                                                                                                                                                                                                                                                | Chemotherapy                                                                                                                                                                                                                                                                                                | Vinorelbine: IV infusion at 25-30 mg/m2 on Days 1 and 8 of each 21-day cycle or on Days 1, 8 and 15 of each 28-day cycle. Vinorelbine: oral administration at 60- 80 mg/m2 on Days 1 and 8 of each 21-day cycle or on Days 1, 8 and 15 of each 28-day cycle, with weekly dosing recommended in some labels. Gemcitabine: IV infusion at 1000- 1250 mg/m2 on Days 1 and 8 of each 21- day cycle or on Days 1, 8 and 15 of each 28- day cycle. N=151 |
| Endpoints and definitions                                                                                                                                                                                                                                                                                   | Primary endpoint                                                                                                                                                                                                                                                                                            | overall survival (OS)                                                                                                                                                                                                                                                                                       | defined as the time from randomisation to death from any cause                                                                                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                                                                                                                                                   | Secondary endpoint                                                                                                                                                                                                                                                                                          | landmark OS Rates                                                                                                                                                                                                                                                                                           | OS rates at 6, 12, 18 and 24 months                                                                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                             | investigator- assessed objective response rate (ORR)                                                                                                                                                                                                                                                        | defined as partial response plus complete response (confirmation being required) as determined by the investigator per RECIST v1.1                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                                                                                                       | investigator- assessed progression- free survival (INV-assessed PFS)                                                                                                                  | investigator- assessed progression- free survival (INV-assessed PFS)                                                                                                                  | defined as time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurs first                                    | defined as time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurs first                                    |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 |                                                                                                                                                                                       | investigator- assessed duration of response (DOR)                                                                                                                                     | investigator- assessed duration of response (DOR)                                                                                                                                     | defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. | defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. |
|                                                 |                                                                                                                                                                                       | OS and PFS defined by the Ventana SP263 IHC assay                                                                                                                                     | OS and PFS defined by the Ventana SP263 IHC assay                                                                                                                                     | OS and investigator-assessed PFS according to RECIST v1.1 defined by the Ventana SP263 IHC Assay                                                                                                                           | OS and investigator-assessed PFS according to RECIST v1.1 defined by the Ventana SP263 IHC Assay                                                                                                                           |
| Database lock                                   | CCOD: 30 April 2022                                                                                                                                                                   | CCOD: 30 April 2022                                                                                                                                                                   | CCOD: 30 April 2022                                                                                                                                                                   | CCOD: 30 April 2022                                                                                                                                                                                                        | CCOD: 30 April 2022                                                                                                                                                                                                        |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                  | Results and Analysis                                                                                                                                                                  | Results and Analysis                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                       |
| Analysis description                            | Primary Analysis of OS (ITT Population)                                                                                                                                               | Primary Analysis of OS (ITT Population)                                                                                                                                               | Primary Analysis of OS (ITT Population)                                                                                                                                               | Primary Analysis of OS (ITT Population)                                                                                                                                                                                    | Primary Analysis of OS (ITT Population)                                                                                                                                                                                    |
| Analysis population and time point description  | Of the 453 enrolled patients, 302 patients were randomised to the atezolizumab monotherapy arm and 151 patients were randomised to the chemotherapy (gemcitabine or vinorelbine) arm. | Of the 453 enrolled patients, 302 patients were randomised to the atezolizumab monotherapy arm and 151 patients were randomised to the chemotherapy (gemcitabine or vinorelbine) arm. | Of the 453 enrolled patients, 302 patients were randomised to the atezolizumab monotherapy arm and 151 patients were randomised to the chemotherapy (gemcitabine or vinorelbine) arm. | Of the 453 enrolled patients, 302 patients were randomised to the atezolizumab monotherapy arm and 151 patients were randomised to the chemotherapy (gemcitabine or vinorelbine) arm.                                      | Of the 453 enrolled patients, 302 patients were randomised to the atezolizumab monotherapy arm and 151 patients were randomised to the chemotherapy (gemcitabine or vinorelbine) arm.                                      |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                       | Treatment group                                                                                                                                                                       | Atezolizumab                                                                                                                                                                          | Atezolizumab                                                                                                                                                                                                               | Chemotherapy                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                    | Number of subjects                                                                                                                                                                    | 302                                                                                                                                                                                   | 302                                                                                                                                                                                                                        | 151                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | OS (median, months)                                                                                                                                                                   | OS (median, months)                                                                                                                                                                   | 10.3                                                                                                                                                                                  | 10.3                                                                                                                                                                                                                       | 9.2                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                | 95% CI                                                                                                                                                                                | 9.4, 11.9                                                                                                                                                                             | 9.4, 11.9                                                                                                                                                                                                                  | 5.9, 11.2                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Primary endpoint:                                                                                                                                                                     | Primary endpoint:                                                                                                                                                                     | Comparison groups                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                          | Atezolizumab vs. Chemotherapy                                                                                                                                                                                              |
| Effect estimate per comparison                  |                                                                                                                                                                                       |                                                                                                                                                                                       | Stratified HR                                                                                                                                                                         | Stratified HR                                                                                                                                                                                                              | 0.78                                                                                                                                                                                                                       |
| Effect estimate per comparison                  |                                                                                                                                                                                       |                                                                                                                                                                                       | 95% CI                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                     | 0.63, 0.97                                                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                       |                                                                                                                                                                                       | p-value (Stratified Log- rank)                                                                                                                                                        | p-value (Stratified Log- rank)                                                                                                                                                                                             | 0.028                                                                                                                                                                                                                      |
| Notes                                           | Not applicable                                                                                                                                                                        | Not applicable                                                                                                                                                                        | Not applicable                                                                                                                                                                        | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             |
| Analysis description                            | Key Secondary analysis (ITT Population)                                                                                                                                               | Key Secondary analysis (ITT Population)                                                                                                                                               | Key Secondary analysis (ITT Population)                                                                                                                                               | Key Secondary analysis (ITT Population)                                                                                                                                                                                    | Key Secondary analysis (ITT Population)                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                       | Treatment group                                                                                                                                                                       | Atezolizumab                                                                                                                                                                          | Atezolizumab                                                                                                                                                                                                               | Chemotherapy                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                     | Number of subject                                                                                                                                                                     | 302                                                                                                                                                                                   | 302                                                                                                                                                                                                                        | 151                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Landmark OS rates (%) 6 months                                                                                                                                                        | Landmark OS rates (%) 6 months                                                                                                                                                        | 64.0                                                                                                                                                                                  | 64.0                                                                                                                                                                                                                       | 57.5                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 12 months                                                                                                                                                                             | 12 months                                                                                                                                                                             | 43.7                                                                                                                                                                                  | 43.7                                                                                                                                                                                                                       | 38.6                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 18 months                                                                                                                                                                             | 18 months                                                                                                                                                                             | 31.4                                                                                                                                                                                  | 31.4                                                                                                                                                                                                                       | 24.0                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 24 months                                                                                                                                                                             | 24 months                                                                                                                                                                             | 24.3                                                                                                                                                                                  | 24.3                                                                                                                                                                                                                       | 12.4                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|       | 95% CI                            |                |                |
|-------|-----------------------------------|----------------|----------------|
|       | 6 months                          | 58.6, 69.5     | 49.4, 65.7     |
|       | 12 months                         | 37.9, 49.4     | 30.5, 46.7     |
|       | 18 months                         | 26.0, 36.8     | 16.8, 31.2     |
|       | 24 months                         | 19.3, 29.4     | 6.7, 18.0      |
|       | INV-assessed PFS (median, months) | 4.2            | 4.0            |
|       | 95% CI                            | 3.7, 5.5       | 2.9, 5.4       |
|       | Difference in ORR                 | 8.9%           | 8.9%           |
|       | 95% CI                            | 2.4, 15.5      | 2.4, 15.5      |
|       | DoR (median, months)              | 14.0           | 7.8            |
|       | 95% CI                            | 8.1, 20.3      | 4.8, 9.7       |
| Notes | Not applicable                    | Not applicable | Not applicable |

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## Clinical studies in special populations

No dedicated studies were conducted in special populations.

The number of patients by age category (&lt;65, 65-74, 75-84, &gt;=85) enrolled in IPSOS are shown in Table 12. OS results by age groups are shown in Figure 8.

## Supportive study(ies)

Not applicable.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

Based on data from the pivotal trial IPSOS (MO29872): A Phase III, open-label, multicentre, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naive advanced or recurrent or metastatic non-small cell lung cancer who are deemed ineligible for platinum-containing therapy, the MAH for Tecentriq had initially applied for the following extension of indication:

Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with NSCLC who are ineligible for platinum-based chemotherapy and who do not have EGFR-mutant or ALKpositive NSCLC, who have:

- locally advanced, unresectable NSCLC not amenable for definitive chemoradiotherapy, or

Assessment report

<div style=\"page-break-after: always\"></div>

## · metastatic NSCLC (see section 5.1)

The MAH did not receive CHMP scientific advice before the conduct of this pivotal trial.

The overall study design of study IPSOS (MO29872) and assessment of results by the Independent data monitoring  committee  are  endorsed.  Despite  patients  in  the  atezolizumab  arm  were  allowed  (per protocol)  to  continue  treatment  beyond  progression,  there  is  insufficient  efficacy/safety  evidence  to make this a general recommendation. Therefore, all labelling claims for post-PD treatment were removed from the SmPC.

Per-protocol platinum-ineligibility held a seemingly lax and ambiguous definition at inclusion criteria: instead of specific requirements, it was left to individual investigator judgement to decide whether a patient was unfit for a platinum-doublet. This issue constituted a major objection along the procedure, as  it  was  uncertain  whether  results  from  the  studied  population  could  be  representative  of  patients defined in the proposed therapeutic indication.

From  a  clinical  perspective,  platinum-eligibility  serves  to  dichotomize  patients  into  'fit  enough  for cisplatin or carboplatin' or not, but this definition is better defined in other malignancies, the classical paradigm being metastatic urothelial cancer (Gupta et al. Defining 'platinum-ineligible' patients with metastatic urothelial cancer. J Clin Oncol 2019;37:451), while a set of criteria that define platinumineligibility  in  NSCLC  is  not  yet  defined,  standardised  nor  internationally  applied.  Based  on  the uncertainties  from  the  ambiguous  per-protocol  definition  from  IPSOS,  and  the  need  to  anchor  the indication to specific criteria defining platinum-ineligibility, the MAH assessed that ~89% of the IPSOS ITT population met 'directly evaluable' criteria for platinum ineligibility based on criteria defined in the literature (De Marinis et al., 2015 and  Camerini et al., 2022), i.e., age &gt;80 years, Eastern Cooperative Oncology Group (ECOG) PS ≥3, ECOG PS 2 in combination with relevant comorbidities, or age ≥70 years in combination with relevant comorbidities. Results from this ad hoc analysis are considered supportive of the finally agreed indication.

Control arm: The selection of vinorelbine and gemcitabine as the sole comparators in the chemotherapy arm was also questioned during the procedure, since other relevant treatments (particularly docetaxel and pemetrexed) were not considered. The MAH provided the following arguments: Firstly, historical data presented from 4 clinical trials (see Table 6) showed that OS for patients who had docetaxel or pemetrexed was not superior to those who had vinorelbine or gemcitabine, which were options in the control arm. It should be noted that the included patients in these trials were treated in the first-line setting  of  NSCLC  and  they  were  defined  as  unsuitable,  ineligible,  or  unfit  for  platinum  based chemotherapy by the judgement of the treating physician. Second, it is acknowledged that pemetrexed was added to the ESMO treatment guidelines in October 2018 (Planchard et al. 2018), while the IPSOS study was ongoing, so this option was not added to the control arm to avoid a major amendment during study conduct. Thirdly, RWE from MOON-OSS and data from the CRISP database in Germany support the use of vinorelbine and gemcitabine in the proposed setting (data not shown). In conclusion, for the targeted frail population, who are platinum-ineligible, the options of single-agent chemotherapy with either gemcitabine or vinorelbine are acceptable options, while the reason for not including pemetrexed in the control arm is acknowledged.

Statistical methods: Sample size calculation is sufficiently justified. The choice of endpoints is appropriate to evaluate efficacy in the targeted population and the statistical methods in the analysis are overall adequate.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

A total of 843 patients were screened for entry into the study, 390 patients failed screening, in most cases due to not meeting eligibility criteria, investigator or patient decision, or insufficient tissue for analysis. Patients were recruited from 85 centres across 23 countries covering Europe and the Middle East,  Asia  Pacific,  Central  and  South  America  and  North  America.  The  first  patient  was  recruited  in September 2017.

Of  the  453  enrolled  patients  (ITT  population),  302  patients  were  randomised  to  the  atezolizumab monotherapy arm and 151 patients were randomised to the chemotherapy (gemcitabine or vinorelbine) arm. Of these 453 patients, 405 (i.e.,  89%)  met  the  above-mentioned  ad  hoc  selection  criteria  for platinum-ineligibility (referred as 'Platinum-ineligible population'). As of the CCOD (30 April 2022), 95% of patients in the atezolizumab arm vs. 100% of patients in the chemotherapy arm had discontinued the study and treatment, the majority discontinued treatment due to progressive disease; 50.3% and 51% respectively.

The  treatment  arms  were  generally  well  balanced  with  respect  to  demographic  and  baseline characteristics. The ITT population predominantly comprised White (66%) and male (72%) patients. The median age of patients was 75 years and 73% of patients were aged 70 years or older. The proportion of patients with ECOG PS of 0, 1, 2 and 3 was 1.5%, 15%, 76%, and 7.5%, respectively. Overall, 14% of  patients  had  stage  IIIB  disease  not  amenable  to  multimodality  treatment  and  86%  had  stage  IV disease. The percentage of patients who had tumours with PD-L1 expression TC&lt; 1%, 149% and ≥ 50% as measured by the VENTANA PD-L1 (SP263) assay was 47%, 29% and 16%, respectively, while 8% of patients had an unknown PD-L1 expression status. The distribution between squamous and nonsquamous NSCLC was ~40/60% and slightly different from the ~30/70% distribution that is otherwise observed in the NSCLC population, but this fact is not considered influential on the outcome. The overall baseline and disease characteristics were comparable between the ITT and the ad hoc platinum-ineligible population.

Efficacy  data  are  considered  overall  mature,  with  an  OS  event  rate  of  82.5%  and  86.1%  in  the atezolizumab and the chemotherapy arm, respectively. Median OS in the overall population was 10.3 (95%CI: 9.4-11.9) months in the atezolizumab arm and 9.2 (95%CI: 5.9-11.2) in the chemotherapy arm, stratified HR 0.78 (95%CI: 0.63-0.97). As seen in similar clinical scenarios when anti-PD-1/PD-L1 monotherapy is compared to chemotherapy in the first-line of NSCLC (and some other cancers), an early crossing of the OS KM curves is observed. Investigator-assessed PFS in the overall population was similar for  both  arms,  4.2  (95%CI:  3.7-5.5)  vs  4.0  (95%CI:  2.9-5.4)  months  in  the  atezolizumab  and chemotherapy arms, respectively, HR 0.87 (95%CI: 0.7-1.07). The overall response rate (ORR) was 16.9% vs 7.9%, respectively, while the duration of response (DoR) was 14.0 (95%CI: 8.1, 20.3) vs 7.8 (95%CI: 4.8, 9.7), respectively.

Ad hoc platinum-ineligible population (n=405, 268 in the atezo arm and 137 in the chemo arm):  An exploratory analysis of OS in this population shows a median OS of 10.3 months with atezolizumab monotherapy versus a median of 9.4 months in the chemotherapy arm (unstratified HR=0.78, 95%CI: 0.63, 0.98). Despite the caveats of such post-hoc analyses, this result is consistent with results from the primary  analysis  and  overall  considered  reassuring  and  supportive  of  the  proposed  extension  of indication. From a clinical perspective, the difference of 1 month in OS is considered clinically relevant as  it  is  recognized  that  the  targeted  population  is  by  definition  frail,  and  thus  an  overwhelming improvement of survival was not expected.

For the platinum-ineligible population, data on PFS, ORR and DoR showed comparable results to the primary analysis of the ITT. Hence, for the Atezo vs the chemotherapy group, the median PFS was 4.7

<div style=\"page-break-after: always\"></div>

months vs 4.2 months, while the ORR was 18.3% vs 8%, with a median DoR of 14.5 months vs 8.2 months.

The MAH has convincingly argued that the ad hoc platinum-ineligible population (89% of the ITT) of the pivotal IPSOS study is defined by specific criteria, and is supportive of the requested extension of indication. Efficacy and safety are comparable for the subgroup and the overall population, and the comparators used are found to be acceptable.

The efficacy is considered established in the finally agreed indication, supported by the ad hoc platinum-ineligible population:

Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy (see section 5.1 for selection criteria).

The  further  revised  indication  is  relevant  for  a  targeted  patient  population,  with  locally  advanced, unresectable NSCLC not amenable for definitive chemoradiotherapy, or metastatic NSCLC, in whom the recommended 1 st  line choice of treatment would otherwise (had they not been considered unsuitable for platinum-based chemotherapy) have been platinum-based chemotherapy.

Based on the positive outcome from the Tecentriq X-76 variation (CHMP positive opinion 09 Nov 2023, EC decision 11 Jan 2024), in which the extrapolation of the SC formulation for atezolizumab was found acceptable for all current and future approved indications for atezolizumab IV, the MAH requested to extend the currently pursued indication (platinum-ineligible patients with advanced NSCLC) to its SC formulation. This was considered acceptable.

## 2.4.4. Conclusions on the clinical efficacy

The MAH has applied for an extension of indication for atezolizumab as a 1 st  line treatment in adult patients  with  locally  advanced,  unresectable  or  metastatic  NSCLC,  who  are  considered  ineligible  for platinum-based  chemotherapy,  defining  a  more  frail  patient  population.  For  the  defined  platinumineligible subpopulation, efficacy has been demonstrated in comparison to single-agent chemotherapy with either vinorelbine or gemcitabine in the proposed setting.

## 2.5. Clinical safety

## Introduction

The clinical safety data are based on the data snapshot of the final overall survival analysis (clinical cutoff date [CCOD]: 30 April 2022) from Study MO29872 ('IPSOS').

In  addition,  an  overview  of  the  two  atezolizumab  monotherapy  pools,  consisting  of  safety-evaluable patients (all patients who received any amount of atezolizumab) in monotherapy studies are provided as a reference:

- Single-agent atezolizumab regardless of tumor type (n = 3178); hereinafter referred to as the Atezo Mono 1 population. The Atezo Mono 1 pool comprises safety data which informs the core data sheet (CDS).
- Single-agent atezolizumab regardless of tumor type (n=4739); hereinafter referred to as the Atezo Mono 2 population. The Atezo Mono 2 pool comprises safety data previously reviewed by European  Medicines  Agency  (EMA)  that  informs  the  updated  draft  EU  Summary  of  Product Characteristics (SmPC).

<div style=\"page-break-after: always\"></div>

Safety data from the atezolizumab arm and chemotherapy arm of IPSOS are summarised and displayed side-by-side with the two pooled atezolizumab monotherapy populations described above. These pooled data are not intended for a head-to-head comparison to IPSOS data due to the variation in sample sizes, disease stages, line of therapies, treatment durations, and different indications. However, the pooled populations allow for a comprehensive characterisation of the safety profile of atezolizumab when given as monotherapy.

A list of all twelve studies (including IPSOS) contributing to the safety evaluation is provided in Table 34 below and details on the number of patients in each study contributing to the various monotherapy pooled populations are provided in the Table 35 below.

Table 34. Summary of Studies and Pooled Populations Contributing to Safety Evaluation

| Study No.                      | Study Design                                                            | Population                                                                                                                                                                                                                                                                                                                                                                                                                                       | No. of Patients Evaluable for Safety                                                                                            | Dose,Route,and Regimen         | Data Cutoff Date                 |
|--------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------|----------------------------------|
| Pivotal Study                  | Pivotal Study                                                           | Pivotal Study                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pivotal Study                                                                                                                   | Pivotal Study                  | Pivotal Study                    |
| IPSOS (MO29872)                | Phase Ill, global, multicenter, open-label, randomized, controlled      | Patientswithtreatment-naivelocallyadvanced or metastatic NSCLC not harboring an EGFR mutationorALKtranslocationwhowere deemedunsuitableforanyplatinumdoublet chemotherapy due to their poor performance status (ECOG PS of 2-3) or due to their advanced age (≥70 years) in combination with substantialcomorbiditiesorother contraindicationsforplatinum-doublet chemotherapy in the investigator's opinion, regardless ofPD-L1expressionstatus | Atezo =300 Chemo = 147                                                                                                          | Atezolizumab 1200 mg IV q3w    | Primary analysis: 30 April 2022  |
| AtezolizumabMonotherapyStudies | AtezolizumabMonotherapyStudies                                          | AtezolizumabMonotherapyStudies                                                                                                                                                                                                                                                                                                                                                                                                                   | AtezolizumabMonotherapyStudies                                                                                                  | AtezolizumabMonotherapyStudies | AtezolizumabMonotherapyStudies   |
| OAK (GO28915)                  | Phase Ill, global, open-label, multicenter, randomized study            | Patients with locally advanced, metastatic, or recurrent non-squamous or squamous NSCLC who have failed a prior platinum-containing regimen (2L and 3L). Patients were stratified by PD-L1 status (IC0 vs. IC1 vs. IC2 vs. IC3), number of prior chemotherapy regimens (1 versus 2), histology (non-squamous versus squamous).                                                                                                                   | 609 patients treated with atezolizumab monotherapy                                                                              | Atezolizumab 1200 mg IV q3w    | Primary analysis: 7 July 2016    |
| Study No.                      | Study Design                                                            | Population                                                                                                                                                                                                                                                                                                                                                                                                                                       | No. of Patients Evaluablefor Safety                                                                                             | Dose,Route,and Regimen         | Data CutoffDate                  |
| POPLAR (GO28753)               | Phase Il, global, multicenter, open-label, randomized, controlled trial | Patients with locally advanced,metastatic, or recurrent non-squamous orsquamous NSCLC whohavefailed apriorplatinum-containing regimen (2L and 3L). Patients were stratified by PD-L1 status (IC0 vs.IC1 vs.IC2vs.IC3), number of prior chemotherapy regimens (1 versus 2), histology (non-squamous versus squamous).                                                                                                                             | 142 patients treated with atezolizumab monotherapy                                                                              | Atezolizumab 1200 mg IVq3w     | Updated analysis: 1 December2015 |
| BIRCH (GO28754)                | Phase Il, global, multicenter, three-cohort, single-arm trial           | Patients withlocally advanced ormetastatic NSCLC who were treatment-naive in the metastatic setting (1L), or had progressed during or following treatment with one platinum- based regimen (2L),or had progressed during orfollowingatleast2regimens(3L+),one of which had to have been a platinum-containing regimen for advanced disease.Patients were PD-L1 selected (TC2/3 or IC2/3).                                                        | 659patients treated with atezolizumab monotherapy: Cohort 1(1L)=139 Cohort 2 (2L)= 268 Cohort 3 (3L+) =252                      | Atezolizumab 1200 mg IV q3w    | Updated analysis: 1 December2015 |
| FIR (GO28625)                  | Phase Il, global, multicenter, three-cohort, single-arm trial           | Patientswith locally advanced or metastatic NSCLCwhoweretreatment-naiveinmetastatic setting (1L, Cohort 1) or progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number ofpriortherapies(ie.,2L+;Cohort 2) or 2L+ patients with previously treated brain metastases (Cohort 3). Patients were PD-L1 selected (TC2/3 or IC2/3).                                                        | 137 patients treated with atezolizumab monotherapy: Cohort 1 (1L)=31 Cohort 2 (2L+)=93 Cohort 3 (2L+ with brain metastases) =13 | Atezolizumab 1200 mg IVq3w     | Primary analysis: 7 January2015  |

<div style=\"page-break-after: always\"></div>

| Study No.             | Study Design                                                                | Population                                                                                                                                                                                                                                                                                                                                                                                                                                         | No. of Patients Evaluable for Safety                                                        | Dose,Route,and Regimen                            | Data Cutoff Date                   |
|-----------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------|------------------------------------|
| IMvigor211 (GO29294)  | Phase Ill, global, open-label, multicenter, randomized study                | Patients with locally advanced or metastatic UC whohaveprogressed during or following a platinum-containing regimen (2L/3L). Patients werestratifiedbychemotherapy(vinfluninevs. taxane),PD-L1status(IC0/1vs.IC2/3),number ofriskfactors,andpresenceof liver metastases.                                                                                                                                                                           | 459patientstreated with atezolizumab monotherapy                                            | Atezolizumab 1200 mg IV q3w                       | Primary analysis: 13 March 2017    |
| IMvigor210 (GO29293)  | Phase Il, global, multicenter, two-cohort, single-arm trial                 | Patientswithlocallyadvancedor1Lmetastatic UC (no prior chemotherapy in the metastatic settingandineligibleforcisplatin-based chemotherapy)or2L+patientswithlocally advancedormetastaticUC(patientswhofailed a prior platinum-based therapy or progressed within 12 months of a platinum-containing treatmentadministeredintheneoadjuvantor adjuvant setting).Approximately 30% of the patient population was planned to be PD-L1 selected (Ic2/3). | 429 patients treated with atezolizumab monotherapy: Cohort 1 (1L)= 119 Cohort 2(2L+)=310    | Atezolizumab 1200 mg IV q3w                       | Updated analysis: 4 July 2016      |
| IMmotion150 (WO29074) | Phase Il, multicenter, randomized, open-label study                         | Patients with histologically confirmed, inoperable,locallyadvancedormetastaticrenal cellcarcinoma whohave not received prior systemic therapy either in the adjuvant or metastatic setting.                                                                                                                                                                                                                                                        | 103patients treated with atezolizumab monotherapy                                           | Atezolizumab 1200 mg IV q3w                       | Primary analysis: 17 October 2016  |
| Study No.             | Study Design                                                                | Population                                                                                                                                                                                                                                                                                                                                                                                                                                         | No. of Patients Evaluablefor Safety                                                         | Dose,Route,and Regimen                            | Data Cutoff Date                   |
| PCD4989g (GO27831)    | Phase l, open-label, dose-escalation and dose-expansion stages              | Patientswithlocallyadvancedormetastatic solid tumors (including UC and NSCLC) and hematologic malignancies.                                                                                                                                                                                                                                                                                                                                        | 640 patients treated with atezolizumab monotherapy: UC=95, NSCLC=89, Non- UC +Non NSCLC=456 | Atezolizumab ≤1,3,10,15, 20 mg/kg and 1200 mg q3w | Interim analysis: 31 March 2016    |
| IMpower110 (GO29431)  | Phase Ill, global, randomized, multicenter, open-label study                | PD-L1-selected, chemotherapy-naive patients with Stage IV non-squamous or squamous NSCLC.                                                                                                                                                                                                                                                                                                                                                          | 286patientstreated with atezolizumab monotherapy                                            | Atezolizumab 1200 mg IV q3w                       | Updated analysis: 4February2020    |
| IMpower010 (GO29527)  | Phase Ill, global, randomized, multicenter, open-label study                | PatientswithStageIB(tumors≥4cm)- StageIlIANSCLCfollowingcompleteresection and adjuvant cisplatin-based chemotherapy.                                                                                                                                                                                                                                                                                                                               | Atez0=495 BSC=495                                                                           | Atezolizumab 1200mg IVq3w                         | Primary analysis: 21 January2021   |
| IMvigor010 (WO29636)  | Phase Ill, open-label, randomized study                                     | Patientswithmuscleinvasiveurothelial carcinoma,whoareathighriskforrecurrence following resection                                                                                                                                                                                                                                                                                                                                                   | 390patientstreated with atezolizumab monotherapy                                            | Atezolizumab 1200mg IVq3w                         | Primary analysis: 30 November 2019 |
| Study No.             | Study Design                                                                | Population                                                                                                                                                                                                                                                                                                                                                                                                                                         | No. of Patients Evaluable for Safety                                                        | Dose, Route, and Regimen                          | Data Cutoff Date                   |
| IMmotion010 (WO39210) | Phase Ill, multicenter, randomized, placebo- controlled, double-blind study | Patientswithrenalcellcarcinomaathighriskof developingmetastasisfollowingnephrectomy                                                                                                                                                                                                                                                                                                                                                                | 390 patients treated with atezolizumab monotherapy                                          | Atezolizumab 1200mg IVq3w                         | Final analysis: 03 May 2022        |

1L=first-line; 2L =Second-line; 2L+=Second-line and beyond; 3L =third-line; 3L+ =third-line and beyond; atezo=atezolizumab; AUC=area under the concentration-time curve; BSC=best supportive care; CE=carboplatin+etoposide; CIT=cancer immunotherapy; ECOG=Eastem Cooperative Oncology Group; IC=tumor-infiltrating immune cell; IHC= immunohistochemistry; IV=intravenous; NSCLC=non-small cell lung cancer; OS=overall survival; qw=weekly; q3w=every 3 weeks; PD-L1=programmed death-ligand 1; SC=subcutaneous; SCLC=small cell lung cancer; TC=tumorcell;UC=urothelialcarcinoma

<div style=\"page-break-after: always\"></div>

Table 35. Overview of Pooling Strategy

| Study       |   No. of Safety- EvaluablePatients | Atezo Mono 1 n=3178   | Atezo Mono 2 n=4739   |
|-------------|------------------------------------|-----------------------|-----------------------|
| OAK         |                                609 | X                     | X                     |
| BIRCH       |                                659 | X                     | X                     |
| POPLAR      |                                142 | X                     | X                     |
| FIR         |                                137 | X                     | X                     |
| PCD4989g    |                                640 | X                     | X                     |
| IMvigor210  |                                429 | X                     | X                     |
| IMvigor211  |                                459 | X                     | X                     |
| IMmotion150 |                                103 | X                     | X                     |
| IMpower110  |                                286 |                       | X                     |
| IMpower010  |                                495 |                       | X                     |
| IMvigor010  |                                390 |                       | X                     |
| IMmotion010 |                                390 |                       | X                     |

## Patient exposure

Table 36. Exposure to Atezolizumab at a Dose of 1200 mg Every Three Weeks (SafetyEvaluable Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Exposure to Gemcitabine or Vinorelbine

Table 37. Exposure to Study Treatment (Safety-Evaluable Population)

|                             | Atezolizumab N=300   | Chemotherapy N=147   | Gemcitabine N=63   | Vinorelbine N=84   |
|-----------------------------|----------------------|----------------------|--------------------|--------------------|
| Treatment duration (months) |                      |                      |                    |                    |
| Mean (SD)                   | 8.4 (11.5)           | 3.2 (3.7)            | 2.8 (2.4)          | 3.5 (4.4)          |
| Median                      | 3.5                  | 2.3                  | 2.3                | 1.8                |
| Min - Max                   | 0-51                 | 0-21                 | 0-13               | 0-21               |
| Treatment duration (n, %)   |                      |                      |                    |                    |
| 0 to≤3 months               | 140 (46.7%)          | 101 (68.7%)          | 45 (71.4%)         | 56 (66.7%)         |
| >3to≤6 months               | 43 (14.3%)           | 31 (21.1%)           | 14 (22.2%)         | 17 (20.2%)         |
| >6 to≤12 months             | 52 (17.3%)           | 6 (4.1%)             | 3 (4.8%)           | 3 (3.6%)           |
| >12 months                  | 65 (21.7%)           | 9 (6.1%)             | 1 (1.6%)           | 8 (9.5%)           |
| Dose intensity (%)          |                      |                      |                    |                    |
| Median                      | 99.0                 |                      | 95.5               | 99.7               |
| Min - Max                   | 51-105               |                      | 67 -102            | 57-103             |
| Number of cycles initiated  |                      |                      |                    |                    |
| Median                      | 6.0                  |                      | 4.0                | 3.0                |
| Min - Max                   | 1-73                 |                      | 1-19               | 1-31               |

## Adverse events

## Demographics and Baseline Characteristics

Table 38. Summary of Key Demographic and Baseline Characteristics (Safety-Evaluable Population)

<!-- image -->

|                   | IPSOS                | IPSOS                | Atezo Mono [1] (N=3178)   | IPSOS                  |
|-------------------|----------------------|----------------------|---------------------------|------------------------|
|                   | Chemotherapy (N=147) | Atezolizumab (N=300) | Atezolizumab (N=300)      | Atezo Mono[2] (N=4739) |
| Age (years)       |                      |                      |                           |                        |
| n                 | 147                  | 300                  | 3178                      | 4739                   |
| Mean (SD)         | 73.8 (8.5)           | 73.6 (9.1)           | 63.3 (10.8)               | 63.0 (10.5)            |
| Median            | 75.0                 | 75.0                 | 64.0                      | 64.0                   |
| Min - Max         | 37-89                | 33-94                | 20-92                     | 20-92                  |
| Age Group (years) |                      |                      |                           |                        |
| n                 | 147                  | 300                  | 3178                      | 4739                   |
| <65               | 18 (12.2%)           | 46 (15.3%)           | 1595 (50.2%)              | 2472 (52.2%)           |
| >=65              | 129 (87.8%)          | 254 (84.7%)          | 1583 (49.8%)              | 2267 (47.8%)           |
| Age Group (years) |                      |                      |                           |                        |
| n                 | 147                  | 300                  | 3178                      | 4739                   |
| <65               | 18 (12.2%)           | 46 (15.3%)           | 1595 (50.2%)              | 2472 (52.2%)           |
| 65-74             | 50 (34.0%)           | 100 (33.3%)          | 1105 (34.8%)              | 1645 (34.7%)           |
| 75-84             | 70(47.6%)            | 139 (46.38)          | 458 (14.4%)               | 600 (12.7%)            |
| >=85              | 9( 6.1%)             | 15 (5.0%)            | 20(0.6%)                  | 22 (0.5%)              |

<div style=\"page-break-after: always\"></div>

| Sex                                       | 147                    | 300                   | 3178          | 4739          |
|-------------------------------------------|------------------------|-----------------------|---------------|---------------|
| n Female                                  | 42 (28.6%)             | 81 (27.0%)            | 1146 (36.1%)  | 1582 (33.4%)  |
| Male                                      | 105 (71.4%)            | 219 (73.0%)           | 2032 (63.9%)  | 3157 (66.6%)  |
| Race                                      |                        |                       |               |               |
| n                                         | 147                    | 300                   | 3178          | 4739          |
| American Indian or Alaska Native          | 9(6.1%)                | 12(4.0%)              | 4(0.1%)       | 6(0.1%)       |
| Asian                                     | 34 (23.1%)             | 74 (24.7%)            | 320 (10.1%)   | 598 (12.6%)   |
| Black or African American                 | 1 (0.7%)               | 2 (0.7%)              | 73 (2.3%)     | 91 (1.9%)     |
| Native Hawaiian or other Pacific Islander | 0                      | 0                     | 7 (0.2%)      | 8 (0.2%)      |
| White                                     | 95 (64.68)             | 202 (67.3%)           | 2533 (79.7%)  | 3752 (79.2%)  |
| Other                                     | 0                      | 0                     | 121 (3.8%)    | 127 2.7%)     |
| Multiple                                  | 6 (4.1%)               | 6 2.0%)               | 6 (0.2%)      | 7 0.1%)       |
| Unknowm                                   | 2 (1.4%)               | 4 1.3%)               | 114 (3.6%)    | 150 (3.2%)    |
| Pooled Race Group                         |                        |                       |               |               |
| n                                         | 147                    | 300                   | 3178          | 4739          |
| Asian                                     | 34(23.1%)              | 74(24.7%)             | 320 (10.1%)   | 598 (12.6%)   |
| Black or African American                 | 1(0.7%)                | 2 (0.7%)              | 73(2.3%)      | 91 (1.9%)     |
| White                                     | 95 (64.6%)             | 202 (67.3%)           | 2533(79.7%)   | 3752 (79.2%)  |
| Other                                     | 17 (11.6%)             | 22 (7.3%)             | 252 ( 7.9%)   | 298 (6.38)    |
| Ethnicity                                 |                        |                       |               |               |
| n                                         | 147                    | 300                   | 3178          | 4739          |
| Hispanic or Latino                        | 22 (15.0%)             | 47(15.7%)             | 117(3.7%)     | 200(4.2%)     |
| Not Hispanic or Latino                    | 122 (83.0%)            | 240(80.0%)            | 2774 (87.38)  | 4197 (88.6%)  |
| Not reported                              | 3 (2.0%)               | 9( 3.0%)              | 200 (6.3%)    | 240(5.1%)     |
| Unknowm                                   | 0                      | 4 (1.3%)              | 87 (2.7%)     | 102 (2.2%)    |
| Region                                    |                        |                       |               |               |
| n                                         | 147                    | 300                   | 3178          | 4739          |
| Asia-Pacific                              | 33 (22.4%)             | 70(23.3%)             | 240(7.6%)     | 503 (10.6%)   |
| Australia                                 | 0                      | 0                     | 42 (1.3%)     | 51 (1.1%)     |
| Central and South America                 | 23 (15.6%)             | 38 (12.7%)            | 14 (0.4%)     | 52 (1.1%)     |
| Europe and Middle East                    | 86 (58.58)             | 178 (59.3%)           | 1367 (43.0%)  | 2291 (48.3%)  |
| North America                             | 5 (3.4%)               | 14 (4.7%)             | 1515 (47.7%)  | 1842 (38.9%)  |
| Baseline Weight (kg)                      |                        |                       |               |               |
| n                                         | 147                    | 300                   | 3125          | 4685          |
| Mean (SD)                                 | 66.41 (15.69)          | 65.74 (15.34)         | 75.62 (18.08) | 76.03 (18.11) |
| Median                                    | 65.00                  | 65.00                 | 74.00         | 74.20         |
|                                           | 35.0 -128.5            | 31.0 -130.7           | 34.3-175.8    | 34.3-175.8    |
| Baseline EcoG Performance Score           |                        |                       |               |               |
| n                                         | 147                    | 300                   | 3069          | 4630          |
| 0                                         | 0                      | 7(2.3%)               | 1201 (39.1%)  | 2120 (45.8%)  |
| 1                                         | 19 (12.9%)             | 49 (16.3%)            | 1832 (59.7%)  | 2457(53.1%)   |
| 2 3                                       | 113 (76.9%) 15 (10.2%) | 226 (75.3%) 18 (6.0%) | 36 ( 1.2%) 0  | 53 ( 1.1%) 0  |
| Tobacco Use History                       |                        |                       |               |               |
| n                                         | 147                    | 300                   | 3072          | 4633          |
| Never                                     | 19 (12.9%)             | 35 (11.7%)            | 842 (27.4%)   | 1299 (28.0%)  |
| Current                                   | 26 (17.7%)             | 57 (19.0%)            | 344 (11.2%)   | 588 (12.7%)   |
| Previous                                  | 102 (69.4%)            | 208 (69.3%)           | 1886 (61.4%)  | 2746 (59.3%)  |

Atezo=Atezolizumab.Atezo Mono[1]:Go27831(PCD4989g All Cohorts)

Actual treatment arms are presented.

( (

Clinical cut-off dateS:GO27831:31MAR2016,G028625:07JAN2015，G028753:01DEC2015，G028754:01DEC2015，G028915:07JUL2016,

MO29872:30APR2022.

<div style=\"page-break-after: always\"></div>

## Overview of Safety Profile

Table 39. Overview of Safety (Safety-Evaluable Population)

|                                                                                                   | IPSOS                                      | IPSOS                                      |                                            |                                            |                                            |                                            |
|---------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                                                                                   | Chemotherapy (N-147)                       | Atezolizumab (N-300)                       | Atezo Mono[1] (N-3178)                     | Atezo Mono[1] (N-3178)                     | Atezo Mono[2] (N-4739)                     | Atezo Mono[2] (N-4739)                     |
| Total number of patients with at least one AE                                                     | 143(97.38)                                 | 275 (91.76)                                | 3051 (96.08)                               | 3051 (96.08)                               | 4514(95.38)                                | 4514(95.38)                                |
| Total number of events                                                                            | 1086                                       | 2352                                       | 33377                                      | 33377                                      | 44720                                      | 44720                                      |
| Total number of patients with at least one                                                        | Total number of patients with at least one | Total number of patients with at least one | Total number of patients with at least one | Total number of patients with at least one | Total number of patients with at least one | Total number of patients with at least one |
| Treatment-related AE                                                                              | 118(80.3%)                                 | 171 (57.06)                                |                                            | 2168 (68.2%)                               | 3272                                       | (69.08)                                    |
| Grade 3-4 AE                                                                                      | 71 (48.38)                                 | 136 (45.38)                                |                                            | 1482 (46.66)                               | 1938                                       | (40.98)                                    |
| Treatment-related Grade 3-4 AE                                                                    | 49 133.361                                 | 49 (16.38)                                 |                                            | 496 (15.66)                                | 711                                        | (15.08)                                    |
| Grade 5 AE                                                                                        | 13 (8.86)                                  | 35 (11.74)                                 | 119                                        | (3.78)                                     | 147                                        | (3.14]                                     |
| Treatment-related Grade 5 AE                                                                      | 4 (2.76)                                   | 3 (1.04)                                   | 11                                         | (0.36)                                     | 16                                         | (0.38)                                     |
| Serious AE                                                                                        | 53 (36.16)                                 | 146 (48.7%)                                | 1309                                       | (41.28)                                    | 1678                                       | [35.48)                                    |
| Treatment-related serious AE                                                                      | 23 (15.66)                                 | 35 (11.78)                                 | 353                                        | (11.18)                                    | 494                                        | (10.48)                                    |
| AE leading to any Study Treatment discontinuation                                                 | 20 (13.66)                                 | 66 (13.06)                                 |                                            | 226 ( 7.16)                                | 443                                        | (9.38)                                     |
| AE leading to any Dose modification or Study Treatment interruption                               | 71(48.36)                                  | 96(32.06)                                  |                                            | 882 (27.86)                                |                                            | 1331 (28.14)                               |
| Total number of patients with at least one AE of Special Interest                                 | 27(18.48)                                  | 103 (34.36)                                |                                            | 1132 (35.6%)                               |                                            | 1912 (40.38)                               |
| Total number of events                                                                            | 37                                         | 207                                        | 2250                                       | 2250                                       | 3809                                       | 3809                                       |
| Total mumber of patients with at least one                                                        | Total mumber of patients with at least one | Total mumber of patients with at least one | Total mumber of patients with at least one | Total mumber of patients with at least one | Total mumber of patients with at least one | Total mumber of patients with at least one |
| Treatment-related AE of Special Interest                                                          | 19(12.9%)                                  | 87 (29.08)                                 |                                            | 805 (25.36)                                |                                            | 1456 (30.78)                               |
| Grade 3-4 AE of Special Interest                                                                  | E ( 2.08)                                  | 20 (6.78)                                  | 268                                        | (8.48)                                     | 400                                        | (8.48)                                     |
| Treatment-related Grade 3-4 AE of Special Interest                                                | 2 (1.48)                                   | 17 5.741                                   | 181                                        | (5.78)                                     | 293                                        | 6.241                                      |
| Grade 5 AE of Special Interest                                                                    | 0                                          | 3                                          | (1.08)                                     | 7 (0.28)                                   | 6                                          | 0.281                                      |
| Treatment-related Grade 5 AE of Special Interest                                                  | 0                                          | 2 10.78)                                   | 3                                          | (<0.18)                                    | 5                                          | 0.181                                      |
| Serious AE of Special Interest                                                                    | 2(1.4%)                                    | 20 (6.78] (5.78)                           | 175                                        | 1 5.56)                                    |                                            | 254 ( 5.48)                                |
| Treatment-related Serious AE of Special Interest                                                  | 1 (0.78)                                   | 17                                         | 137                                        | 4.381                                      | 209                                        | (4.48)                                     |
| AE of Special Interest leading to any Study Treatment discontinuation                             | 3( 2.0%)                                   | 17( 5.76)                                  |                                            | 62 ( 2.08)                                 |                                            | 173 ( 3.78)                                |
| AE of Special Interest leading to any Dose modification or                                        | 5( 3.48)                                   | 21( 7.0%)                                  |                                            | 221 ( 7.08)                                |                                            | 389 ( 8.24)                                |
| Study Treatment interruption AE of Special Interest Requiring the Use of Systemic Corticosteroids | 7(4.88)                                    | 34(11.36)                                  |                                            | 251 ( 7.96)                                |                                            | 399( 8.48)                                 |

## Al.

Only events reported in the Adverse Events Form are included.

Imvestigator text for AEs encoded using MedDRA v25.1. Percentages are based on N in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for \"total mumber of events\" row in which multiple occurrences of the same AE are counted separately. All treatment emergent AEs are included. For the counts in the rows by grade, the patients are counted once at the highest grade.

G028754:01DBC2015, G028915:07JUL2016, G029293:04JUL2016, G029294:13MAR2017, G029431:04FEB2020, G029527:21JAN2021, W029074:170CT2016, W029636:30NOV2019, WO39210:03MAY2022, M029872:30APR2022.

<div style=\"page-break-after: always\"></div>

## Common AEs

The most common (≥20% of patients in either arm) SOC in which AEs were reported were (atezolizumab arm and chemotherapy arm, respectively):

- General disorders and administration site conditions (49.7% vs. 49.7%)
- Gastrointestinal disorders (42.3% vs. 53.7%)
- Respiratory, thoracic and mediastinal disorders (49.0% vs. 35.4%)
- Infections and infestations (46.7% vs. 36.1%)
- Metabolism and nutrition disorders (43.3% vs. 31.3%)
- Blood and lymphatic disorders (21.3% vs. 46.3%)
- Investigations (29.3% vs. 29.9%)
- Musculoskeletal and connective tissue disorders (26.0% vs. 27.2%)
- Nervous system disorders (20.7% vs. 18.4%)

The most common (≥10% in either arm) AEs by SOC and PT are shown in Table 40.

Table 40 . Common Adverse Events Reported in ≥10% of Patients in Any Treatment Group (Safety-Evaluable Population)

|                          | IPSOS                | IPSOS   | IPSOS   |                                             |                                             |                        |                        |
|--------------------------|----------------------|---------|---------|---------------------------------------------|---------------------------------------------|------------------------|------------------------|
| MedDRA Preferred Term    | Chemotherapy (N=147) |         |         | Atezo Atezolizumab Mono[1] (N=300) (N=3178) | Atezo Atezolizumab Mono[1] (N=300) (N=3178) | Atezo Mono[2] (N=4739) | Atezo Mono[2] (N=4739) |
| Fatigue                  | 34 (23.1%)           | 57      | (19.0%) | 1142                                        | (35.9%)                                     | 1417                   | (29.9%)                |
| Decreased appetite       | 32 (21.8%)           | 66      | (22.0%) | 810                                         | (25.5%)                                     | 947                    | (20.0%)                |
| Nausea                   | 35 (23.8%)           | 32      | (10.7%) | 747                                         | (23.5%)                                     | 917                    | (19.4%)                |
| Cough                    | 13 (8.8%)            | 59      | (19.7%) | 660                                         | (20.8%)                                     | 859                    | (18.1%)                |
| Diarrhoea                | 24 (16.3%)           | 40      | (13.3%) | 624                                         | (19.6%)                                     | 866                    | (18.3%)                |
| Pyrexia                  | 10 (6.8%)            | 31      | (10.3%) | 639                                         | (20.1%)                                     | 869                    | (18.3%)                |
| Constipation             | 29 (19.7%)           | 47      | (15.7%) | 652                                         | (20.5%)                                     | 794                    | (16.8%)                |
| Dyspnoea                 | 16 (10.9%)           | 60      | (20.0%) | 651                                         | (20.5%)                                     | 777                    | (16.4%)                |
| Arthralgia               | 12 (8.2%)            | 27      | (9.0%)  | 573                                         | (18.0%)                                     | 787                    | (16.6%)                |
| Anaemia                  | 49 (33.3%)           | 49      | (16.3%) | 505                                         | (15.9%)                                     | 660                    | (13.9%)                |
| Asthenia                 | 19 (12.9%)           | 43      | (14.3%) | 461                                         | (14.5%)                                     | 612                    | (12.9%)                |
| Back pain                | 13 (8.8%)            | 25      | (8.3%)  | 480                                         | (15.1%)                                     | 592                    | (12.5%)                |
| Vomiting                 | 23 (15.6%)           | 25      | 8.3%)   | 477                                         | (15.0%)                                     | 565                    | (11.9%)                |
| Pruritus                 | 3 (2.0%)             | 23      | (7.7%)  | 406                                         | (12.8%)                                     | 647                    | (13.7%)                |
| Rash                     | 5 (3.4%)             | 30      | (10.0%) | 358                                         | (11.3%)                                     | 515                    | (10.9%)                |
| Headache                 | 7 （ 4.8%)            | 15      | (5.0%)  | 352                                         | (11.1%)                                     | 498                    | (10.5%)                |
| Urinary tract infection  | 12 (8.2%)            | 29      | (9.7%)  | 338                                         | (10.6%)                                     | 467                    | 9.9%)                  |
| Oedema peripheral        | 6 (4.1%)             | 25      | (8.3%)  | 332                                         | (10.4%)                                     | 414                    | 8.7%)                  |
| Pneumonia                | 16 (10.9%)           | 45      | (15.0%) | 206                                         | (6.5%)                                      | 264                    | 5.6%)                  |
| Neutropenia              | 19 (12.9%)           | 2       | (0.7%)  | 36                                          | (1.1%)                                      | 73                     | 1.5%)                  |
| Neutrophilcountdecreased | 17 (11.6%)           | 1       | （0.3%)  | 5                                           | （0.2%)                                      | 20                     | 0.4%)                  |

+ WO29074(IMMOTIONl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A).

Investigator text for AEs encoded using MedDRA v25.l. Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once at the highest NCI CTCAE grade. All treatment emergent AEs are included.

```
Clinical cut-off dateS: G027831:31MAR2016, G028625:07JAN2015, G028753:01DEC2015, GO28754:01DEC2015, G028915:07JUL2016, G029293:04JUL2016, G029294:13MAR2017, GO29431:04FEB2020,G029527:21JAN2021，WO29074:170CT2016,WO29636:30NOV2019, WO39210:03MAY2022,M029872:30APR2022.
```

<div style=\"page-break-after: always\"></div>

Table 41 . Adverse Events by Preferred Term, with a Difference of at Least 5% between IPSOS Atezolizumab Arm and Chemotherapy Arm (Safety-Evaluable Population)

|                                  | IPSOS                | IPSOS                | IPSOS                | IPSOS                |                        |                        |                        |                        |
|----------------------------------|----------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|------------------------|
| MedDRA Preferred Term            | Chemotherapy (N=147) | Chemotherapy (N=147) | Atezolizumab (N=300) | Atezolizumab (N=300) | Atezo Mono[1] (N=3178) | Atezo Mono[1] (N=3178) | Atezo Mono[2] (N=4739) | Atezo Mono[2] (N=4739) |
| Nausea                           | 35                   | (23.8%)              | 32                   | (10.7%)              | 747                    | (23.5%)                | 917                    | (19.4%)                |
| Cough                            | 13                   | (8.8%)               | 59                   | (19.7%)              | 660                    | (20.8%)                | 859                    | (18.1%)                |
| Dyspnoea                         | 16                   | (10.9%)              | 60                   | (20.0%)              | 651                    | (20.5%)                | 777                    | (16.4%)                |
| Anaemia                          | 49                   | (33.3%)              | 49                   | (16.3%)              | 505                    | (15.9%)                | 660                    | (13.9%)                |
| Vomiting                         | 23                   | (15.6%)              | 25                   | (8.3%)               | 477                    | (15.0%)                | 565                    | (11.9%)                |
| Pruritus                         | 3                    | (2.0%)               | 23                   | (7.7%)               | 406                    | (12.8%)                | 647                    | (13.7%)                |
| Rash                             | 5                    | (3.4%)               | 30                   | (10.0%)              | 358                    | (11.3%)                | 515                    | (10.9%)                |
| Hypothyroidism                   | 0                    |                      | 19                   | 9(6.3%)              | 137                    | (4.3%)                 | 309                    | (6.5%)                 |
| Neutropenia                      | 19                   | (12.9%)              | 2                    | 2(0.7%)              | 36                     | (1.1%)                 | 73                     | 1.5%)                  |
| White blood cell count decreased | 14                   | (9.5%)               |                      | 2 (0.7%)             | 25                     | (0.8%)                 | 41                     | 0.9%)                  |
| Leukopenia                       | 11                   | (7.5%)               | 4                    | (1.3%)               | 9                      | ( 0.3%)                | 24                     | 0.5%)                  |
| Neutrophil count decreased       | 17                   | (11.6%)              |                      | 1 (0.3%)             | 5                      | (0.2%)                 | 20                     | 0.4%)                  |

(

A).

Clinical cut-0ff dateS: G027831:31MAR2016, G028625:07JAN2015, G028753:01DEC2015,

GO28754:01DEC2015, G028915:07JUL2016, G029293:04JUL2016, G029294:13MAR2017,

GO29431:04FEB2020, G029527:21JAN2021, WO29074:170CT2016, W029636:30NOV2019,

WO39210:03MAY2022, MO29872:30APR2022.

s       s included. All counts represent patients. Multiple occurrences of the same AE in one individual are counted once at the highest NCI CTCAE\\_grade.

<div style=\"page-break-after: always\"></div>

Grade 3-4 AEs

Table 42. Summary of Grade 34 Adverse Events with a Difference of at Least 2% between IPSOS Atezolizumab Arm and Chemotherapy Arm by Preferred Term (Safety-Evaluable Population)

|                                  | IPSOS                | IPSOS                | IPSOS                | IPSOS                |                        |                        |                        |                        |
|----------------------------------|----------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|------------------------|
| MedDRAPreferred Term             | Chemotherapy (N=147) | Chemotherapy (N=147) | Atezolizumab (N=300) | Atezolizumab (N=300) | Atezo Mono[1] (N=3178) | Atezo Mono[1] (N=3178) | Atezo Mono[2] (N=4739) | Atezo Mono[2] (N=4739) |
| Anaemia                          | 7                    | (4.8%)               | 8                    | (2.7%)               | 160                    | (5.0%)                 | 178                    | (3.8%)                 |
| Pulmonary embolism               | 5                    | (3.4%)               |                      | 4 (1.3%)             | 59                     | (1.9%)                 | 74                     | (1.6%)                 |
| Hypertension                     | 2                    | (1.4%)               |                      | 14 (4.7%)            | 42                     | (1.3%)                 | 61                     | 1(1.3%)                |
| Pleural effusion                 | 2                    | (1.4%)               | 11                   | (3.7%)               | 37                     | (1.2%)                 | 38                     | (0.8%)                 |
| Neutropenia                      | 14                   | (9.5%)               | 2                    | (0.7%)               | 11                     | (0.3%)                 | 20                     | (0.4%)                 |
| Lymphopenia                      | 5                    | (3.4%)               | 4                    | (1.3%)               | 8                      | (0.3%)                 | 9                      | (0.2%)                 |
| White blood cell count decreased | 7                    | (4.8%)               |                      | 0                    | 5                      | (0.2%)                 | 6                      | (0.1%)                 |
| Neutrophil count decreased       | 11                   | (7.5%)               |                      | 0                    | 2                      | (<0.1%)                | 3                      | (<0.1%)                |
| Leukopenia                       |                      | 4 (2.7%)             | 0                    |                      | 0                      |                        | 4                      | (<0.1%)                |

Atezo = Atezolizumab. Atezo Mono[1]: G027831(PCD4989g Al1 Cohorts) + G028625(FIR)+

+ WO29074(IMMOTIONl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] +

A).

s       s included. All counts represent patients. Multiple occurrences of the same AE in one individual are counted once at the highest NCI CTCAE grade.

GO28754:01DEC2015, G028915:07JUL2016, G029293:04JUL2016, G029294:13MAR2017,

GO29431:04FEB2020, G029527:21JAN2021, WO29074:170CT2016, WO29636:30NOV2019,

WO39210:03MAY2022, MO29872:30APR2022.

<div style=\"page-break-after: always\"></div>

Table 43. Summary of Grade 34 Adverse Events with an Incidence Rate of at Least 5% in Any Treatment Group by System Organ Class and Preferred Term (Safety-Evaluable Population)

| IPSOS                                           | IPSOS                                           | IPSOS                                           | IPSOS                                           | IPSOS                                           | IPSOS                                           | IPSOS                                           | IPSOS                                           |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| MedDRA System Organ Class MedDRA PreferredTerm  | Chemotherapy Atezolizumab (N=147)               | (N=300)                                         | Atezo Mono[1] (N=3178)                          | Atezo Mono[2] (N=4739)                          | Atezo Mono[2] (N=4739)                          |                                                 |                                                 |
| Blood and lymphatic system disorders            |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Anaemia                                         | 7(4.8%)                                         | 8(2.7%)                                         | 160( 5.0%)                                      | 178 (3.8%)                                      |                                                 |                                                 |                                                 |
| Neutropenia                                     | 14 (9.5%)                                       | 2 (0.7%)                                        | 11 (0.3%)                                       | 20(0.4%)                                        |                                                 |                                                 |                                                 |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders |
| Dyspnoea                                        | 7(4.8%)                                         | 15 (5.0%)                                       | 117(3.7%)                                       | 122 ( 2.6%)                                     |                                                 |                                                 |                                                 |
| Infectionsand infestations                      | Infectionsand infestations                      | Infectionsand infestations                      | Infectionsand infestations                      | Infectionsand infestations                      | Infectionsand infestations                      | Infectionsand infestations                      | Infectionsand infestations                      |
| Pneumonia                                       | 10 (6.8%)                                       | 23 (7.7%)                                       | 95（3.0%)                                        | 117 (2.5%)                                      |                                                 |                                                 |                                                 |
| Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              |
| Hyponatraemia                                   | 5(3.4%)                                         | 16 (5.3%)                                       | 98(3.1%)                                        | 111 (2.38)                                      |                                                 |                                                 |                                                 |
| Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  |
| Neutrophil count decreased                      | 11 (7.5%)                                       | 0                                               | 2 (<0.1%)                                       | 3 (<0.1%)                                       |                                                 |                                                 |                                                 |

A).

included. All counts represent patients. Multiple occurrences of the same AE in one individual are counted once at the highest NCI CTCAE grade.

Clinical cut-off dateS: G027831:31MAR2016, G028625:07JAN2015, G028753:01DEC2015, GO28754:01DEC2015, G028915:07JUL2016, G029293:04JUL2016, G029294:13MAR2017, GO29431:04FEB2020, G029527:21JAN2021， WO29074:170CT2016, WO29636:30NOV2019,

WO39210:03MAY2022,MO29872:30APR2022.

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest (AESI)

Three Grade 5 AESIs were reported in the atezolizumab arm (hepatitis, pneumonitis, and myasthenia gravis).

Table 44. Summary of AESIs of Atezolizumab (Safety-Evaluable Population)

|                                                                                         | IPSOS                                        | IPSOS                                        |                                              |                                              |                                              |                                              |
|-----------------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                                                                         | Chemotherapy (N=147)                         | Atezolizumab (N=300)                         | Atezo Mono [1] (N=3178)                      | Atezo Mono [1] (N=3178)                      | Atezo Mono[2] (N=4739)                       | Atezo Mono[2] (N=4739)                       |
| Total number of patients with at least one AE of Special Interest                       | 27(18.48)                                    | 103(34.3%)                                   | 1132 (35.6%)                                 | 1132 (35.6%)                                 | 1912 (40.3)                                  | 1912 (40.3)                                  |
| Total number of events                                                                  | 37                                           | 207                                          | 2250                                         | 2250                                         | 3809                                         | 3809                                         |
| Total number of patients with at least one                                              | Total number of patients with at least one   | Total number of patients with at least one   | Total number of patients with at least one   | Total number of patients with at least one   | Total number of patients with at least one   | Total number of patients with at least one   |
| Treatment-related AE of Special Interest                                                | 19 (12.9)                                    | 87 (29.0号)                                   |                                              | 805 (25.3%)                                  |                                              | 1456(30.7)                                   |
| Grade 3-4 AE of Special Interest                                                        | 3 (2.0号)                                     | 20 6.781                                     | 268                                          | 8.4%)                                        | 400                                          | 141'8                                        |
| Treatment-related Grade 3-4 AE                                                          | 2 (1.48)                                     | 17 5.78)                                     | 181                                          | 5.78)                                        | 293                                          | 6.2%)                                        |
| of Special Interest Grade 5 AE of Special Interest                                      |                                              | 3 1.0号)                                      | 7                                            | 0.2)                                         | 6                                            | 0.2)                                         |
| Treatment-related Grade 5 AE of Special Interest                                        | 0                                            | 2 0.78)                                      | 3                                            | (<0.11)                                      | 5                                            | 0.1:)                                        |
| Serious AE of Special Interest                                                          | 2(1.48)                                      | 20( 6.78)                                    |                                              | 175 ( 5.5%)                                  | 254                                          | 1(5.4)                                       |
| Treatment-related Serious AE of Special Interest                                        | 1( 0.7)                                      | 17 (5.7%)                                    | 137                                          | (4.3%)                                       | 209                                          | (4.4%)                                       |
| AE of Special Interest leading to any Study Treatment discontinuation                   | 3( 2.0)                                      | 17( 5.78)                                    |                                              | 62 ( 2.0%)                                   |                                              | 173 ( 3.78)                                  |
| AE of Special Interest leading to any Dose modification or Study Treatment interruption | 5( 3.4)                                      | 21 ( 7.0)                                    |                                              | 221 ( 7.0)                                   |                                              | 389( 8.28)                                   |
| AE of Special Interest Requiring the Use of Systemic Corticosteroids                    | 7(4.88)                                      | 34(11.38)                                    |                                              | 251 ( 7.9%)                                  |                                              | 399( 8.48)                                   |
| Identified Risks: patients with at least one                                            | Identified Risks: patients with at least one | Identified Risks: patients with at least one | Identified Risks: patients with at least one | Identified Risks: patients with at least one | Identified Risks: patients with at least one | Identified Risks: patients with at least one |
| Immune-Mediated Rash                                                                    | 11 (7.58)                                    | 45 (15.0%)                                   |                                              | 613 (19.3%)                                  |                                              | 949(20.0%)                                   |
| Immune-Mediated Hepatitis (Diagmosis and Lab Abnormalities)                             | 6 6.18)                                      | 32(10.7%)                                    | 343(                                         | (10.8%)                                      |                                              | 564 (11.98)                                  |

<div style=\"page-break-after: always\"></div>

```
Identified Risks: patients with at least one Immune-Mediated Hepatitis (Lab 8(5.4) 27( 9.0%) 315 ( 9.9%) 523 (11.0%) Abnormalities) Immune-Mediated Hypothyroidism 1 0.78) 27 9.0%) 164 (5.2%) 400 (8.45) Immune-Mediated Pneumonitis 6 2.0号) 13 4.3) 91 (2.9%) 138 2.9%) Immune-Mediated Hyperthyroidism m1 2.0) 7 2.38) 30 0.99) 114 2.4:) Immune-Mediated Hepatitis 0.78) 7 2.38) 62 2.0号 81 1.78) (Diagmosis) Infusion-Related Reactions 0 mm 0.7号) 32 1.0号) 82 1.7) Immune-Mediated Colitis 0 1.08) 34 1.1:) 65 1.28) Immune-Mediated Pericardial 0 1 0.38) 45 1.4) 48 1.0号) Disorders Immune-Mediated Pancreatitis 0 ( 1.0号) 18 0.6) 37 0.8号) Immune-Mediated Severe Cutaneous 0 0 22 0.78) 30 0.6%) Reactions Immune-Mediated Myositis 0 0 13 (0.4%) 32 (0.7%) (Myositis+Rhabdomyolysis) Immune-Mediated Diabetes 0 4 ( 1.38) 10 (0.38) 26 ( 0.58) Mellitus Immune-Mediated Adrenal 0 1( 0.38) 12 ( 0.4) 24 (0.58) Insufficiency Immune-Mediated 0 0 14 (0.48) 22 (0.5号) Meningoencephalitis Immune-Mediated Myositis 0 0 8 0.38) 25 0.58) Immune-Mediated Meningitis 0 0 12 0.48) 18 0.48) Immune-Mediated Nephritis 1 (0.78) 0 3 (<0.1号) 11 0.28) Rhabdomyolysis 0 0 0.2 7 0.18) Immune-Mediated Guillain-Barre 0 0 5 (0.28) 6 0.1:) Symdrome Immune-Mediated Hypophysitis 0 0 (<0.1) 5 (0.1号) Immune-Mediated Encephalitis 0 0 (<0.1:) 4 (<0.18) Immune-Mediated Myocarditis 0 1 0.381 0 4 (<0.1号) Immune-Mediated Myasthenia 0 1 0.38) 1 (<0.18) 1 (<0.18) Gravis Identified Risks: patients with at least one Haemophagocytic 0 0 1 (<0.1) 2 (<0.1) Lymphohistiocytosis Immune-Mediatedl Myelitis 0 0 (<0.1号) 1 (<0.1) Immune-Mediated Facial Paresis 0 0 1 (<0.1%) 1 (<0.18) Potential Risks: patients with at least one Immune-Mediated Ocular 0 0 16 ( 0.5) 22 (0.5) Inflammatory Toxicity Immune-Mediated Vasculitis 0 0 7(0.2%) 14 ( 0.3) Autoimmune Hemolytic Anemia 0 0 4( 0.1) 6 ( 0.1) + 181315298709 + 16110400 11h 6686100811881709 81110u01 02311 '991321102311 = 02211 G028753(P0PLAR)+ G028754(BIRCH)+ G028915(0AK)+ G029293(IMVIG0R210)+ G029294(IMVIG0R211) A). Only events reported in the Adverse Events Fom are included. Investigator text for AEs encoded using MedDRA v25.l. Percentages are based on N in the columm headings. Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE by grade, the patients are counted once at the highest grade. G028754:01DEC2015, G028915:07JUL2016, G029293:04JUL2016, G029294:13MAR2017, G029431:04FEB2020, G029527:21JAN2021, W029074:170CT2016, W029636:30N0V2019, W039210:03MAY2022,M029872:30APR2022.
```

<div style=\"page-break-after: always\"></div>

Table 45. Adverse Events of Special Interest for Atezolizumab by Medical Concept (Atezo Mono Pooled) (N=5039)

| Medical concept                                             | Atezo Mono Pooled (N=5039)   |
|-------------------------------------------------------------|------------------------------|
| Immune-Mediated Rash                                        | 994 (19.7%)                  |
| Immune-Mediated Hepatitis (Diagnosis and Lab Abnormalities) | 596 (11.8%)                  |
| Immune-Mediated Hepatitis (Lab Abnormalities)               | 550 (10.9%)                  |
| Immune-Mediated Hypothyroidism                              | 427 ( 8.5%)                  |
| Immune-Mediated Pneumonitis                                 | 151 ( 3.0%)                  |
| Immune-Mediated Hyperthyroidism                             | 121 ( 2.4%)                  |
| Immune-Mediated Hepatitis (Diagnosis)                       | 88 ( 1.7%)                   |
| Infusion-Related Reactions                                  | 84 ( 1.7%)                   |
| Immune-Mediated Colitis                                     | 62 ( 1.2%)                   |
| Immune-Mediated Pericardial Disorders                       | 49 ( 1.0%)                   |
| Immune-Mediated Pancreatitis                                | 40 ( 0.8%)                   |
| Immune-Mediated Myositis (Myositis+Rhabdomyolysis)          | 32 ( 0.6%)                   |
| Immune-Mediated Diabetes Mellitus                           | 30 ( 0.6%)                   |
| Immune-Mediated Severe Cutaneous Reactions                  | 30 ( 0.6%)                   |
| Immune-Mediated Adrenal Insufficiency                       | 25 ( 0.5%)                   |
| Immune-Mediated Myositis                                    | 25 ( 0.5%)                   |
| Immune-Mediated Meningoencephalitis                         | 22 ( 0.4%)                   |
| Immune-Mediated Ocular Inflammatory Toxicity                | 22 ( 0.4%)                   |
| Immune-Mediated Meningitis                                  | 18 ( 0.4%)                   |
| Immune-Mediated Vasculitis                                  | 14 ( 0.3%)                   |
| Immune-Mediated Nephritis                                   | 11 ( 0.2%)                   |
| Rhabdomyolysis                                              | 7 ( 0.1%)                    |
| Autoimmune Hemolytic Anemia                                 | 6 ( 0.1%)                    |
| Immune-Mediated Guillain-Barre Syndrome                     | 6 ( 0.1%)                    |
| Immune-Mediated Hypophysitis                                | 5 (<0.1%)                    |
| Immune-Mediated Myocarditis                                 | 5 (<0.1%)                    |
| Immune-Mediated Encephalitis                                | 4 (<0.1%)                    |
| Haemophagocytic Lymphohistiocytosis                         | 2 (<0.1%)                    |
| Immune-Mediated Myasthenia Gravis                           | 2 (<0.1%)                    |
| Immune-Mediated Facial Paresis                              | 1 (<0.1%)                    |
| Immune-Mediated Myelitis                                    | 1 (<0.1%)                    |

Atezo = Atezolizumab. Atezo Mono Pooled: GO27831(PCD4989g All Cohorts) + GO28625(FIR) + GO28753(POPLAR) + GO28754(BIRCH) + GO28915(OAK) + GO29293(IMVIGOR210) + GO29294(IMVIGOR211) + GO29431(IMPOWER110) + GO29527(IMPOWER010) + MO29872(IPSOS) + WO29074(IMMOTION150 Arm B prior to crossover) + WO29636(IMVIGOR010) + WO39210(IMMOTION010 Arm A).

Investigator text for AEs encoded using MedDRA v25.1. Percentages are based on N in the column headings. For frequency counts by medical concept, multiple occurrences of the same medical concept in an individual are counted only once. All treatment emergent AEs are included.

Clinical cut-off dates: GO27831:31MAR2016, GO28625:07JAN2015, GO28753:01DEC2015,

GO28754:01DEC2015, GO28915:07JUL2016, GO29293:04JUL2016, GO29294:13MAR2017,

GO29431:04FEB2020, GO29527:21JAN2021, MO29872:30APR2022, WO29074:17OCT2016,

WO29636:30NOV2019, WO39210:03MAY2022.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious adverse events

Table 46. Serious Adverse Events with an Incidence Rate of at Least 2% in Any Treatment Arm by System Organ Class and Preferred Term (Safety-Evaluable Population)

|                                                          | IPSOS                | IPSOS                |                        |                        |                        |
|----------------------------------------------------------|----------------------|----------------------|------------------------|------------------------|------------------------|
| MedDRA System Organ Class MedDRA Preferred Term          | Chemotherapy (N=147) | Atezolizumab (N=300) | Atezo Mono[1] (N=3178) | Atezo Mono[2] (N=4739) | Atezo Mono[2] (N=4739) |
| Infections and infestations                              |                      |                      |                        |                        |                        |
| Pneumonia                                                | 11 (7.5%)            | 33 (11.0%)           | 112 (3.5%)             |                        | 141 (3.0%)             |
| Urinary tract infection                                  | 0                    | (0.3%)               | 61 (1.9%)              |                        | 98(2.1%)               |
| Sepsis                                                   | 4 (2.7%)             | 0                    | 41 (1.3%)              |                        | 50 (1.1%)              |
| Lower respiratory tract infection                        | 4 (2.7%)             | 5 (1.7%)             | 15 (0.5%)              |                        | 18 (0.4%)              |
| Respiratory, thoracic and mediastinal disorders          |                      |                      |                        |                        |                        |
| Dyspnoea                                                 | 2 (1.4%)             | 6 (2.0%)             | 89 (2.8%)              | 91                     | (1.9%)                 |
| Pulmonary embolism                                       | (2.0%)               | 3 (1.0%)             | 42 (1.3%)              | 52                     | (1.1%)                 |
| Pleural effusion                                         | (1.4%)               | 9 (3.0%)             | 40 (1.3%)              | 42                     | (0.9%)                 |
| Pneumonitis                                              | (1.4%)               | 8 3(2.7%)            | 35 (1.1%)              | 48                     | (1.0%)                 |
| Chronic obstructive pulmonary disease                    | (1.4%)               | 7(2.3%)              | 10 (0.3%)              |                        | 19 (0.4%)              |
| General disorders and administration site conditions     |                      |                      |                        |                        |                        |
| Pyrexia                                                  | 1 (0.7%)             | 3 (1.0%)             | 79 (2.5%)              |                        | 103 (2.2%)             |
| Death                                                    | 2 (1.4%)             | 7( 2.3%)             | 19 (0.6%)              |                        | 24 (0.5%)              |
| Blood and lymphatic system disorders Febrile neutropenia | 3 (2.0%)             | 0                    | 7 (0.2%)               |                        | 7 (0.1%)               |

```
A). included. All counts represent patients. Multiple occurrences of the same AE in one individual are counted once at the highest NCI CTcAE grade. Clinical cut-off dateS: G027831:31MAR2016, G028625:07JAN2015, G028753:01DEC2015, GO28754:01DEC2015, G028915:07JUL2016, G029293:04JUL2016, G029294:13MAR2017, GO29431:04FEB2020, G029527:21JAN2021, WO29074:170CT2016, W029636:30NOV2019, WO39210:03MAY2022,MO29872:30APR2022.
```

## Deaths

Table 47. Summary of Deaths and Primary Cause of Death

|                        | IPSOS                | IPSOS                | IPSOS                | IPSOS                |                        |                        |                         |
|------------------------|----------------------|----------------------|----------------------|----------------------|------------------------|------------------------|-------------------------|
|                        | Chemotherapy (N=147) | Chemotherapy (N=147) | Atezolizumab (N=300) | Atezolizumab (N=300) | Atezo Mono[1] (N=3178) | Atezo Mono[1] (N=3178) | Atezo Mono [2] (N=4739) |
| Primary cause of death |                      |                      |                      |                      |                        |                        |                         |
| n                      |                      | 129 (87.8%)          | 248                  | (82.7%)              | 1898(59.7%)            |                        | 2345 (49.58)            |
| ADVERSEEVENT           |                      | 13(8.8%)             | 35                   | (11.7%)              | 120 （3.8%）             | 148                    | （3.1%）                  |
| PROGRESSIVEDISEASE     |                      | 103 (70.1%)          | 179                  | (59.7%)              | 1476 (46.4%)           | 1729                   | (36.5%)                 |
| RECURRENCE OF DISEASE  | 0                    |                      | 0                    |                      | 0                      | 88                     | 1.9%)                   |
| OTHER                  |                      | 13 (8.8%)            | 34                   | (11.3%)              | 302（9.5%)              | 380                    | 8.0%)                   |

Other cause of deathis cisplayedverbatim.Death from public recordis classifiedas Other inMo29872(IPsoS).Grade 5 Adverse EventsofDiseaseProgressionCodedas DISEASERECURRENCE/PROGRESSIVE.ApatientinGO29293hadmissingdatafor Other causeof death.

C1inica1cut-off dateS:G027831:31MAR2016,G028625:07JAN2015,G028753:01DEC2015,G028754:01DEC2015，G028915:07JUL2016, GO29293:04JUL2016, G029294:13MAR2017, G029431:04FEB2020, G029527:21JAN2021, W029074:170CT2016, W029636:30NOV2019, W039210:03MAY2022, MO29872:30APR2022.

<div style=\"page-break-after: always\"></div>

Table 48. Summary of Grade 5 Adverse Events (Safety-Evaluable Population)

| MedDRA System Organ Class MedDRA Preferred Term      | Atezolizumab (N=300) n ($)   | Atezolizumab (N=300) n ($)   | Atezolizumab (N=300) n ($)   | Chemotherapy (N=147) n (6)   | Chemotherapy (N=147) n (6)   | Chemotherapy (N=147) n (6)   |
|------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Any Adverse Events                                   |                              |                              | 35  ( 11.7)                  | 13(                          |                              | 8.8)                         |
| Infections and infestations                          |                              |                              |                              |                              |                              |                              |
| -Overall                                             | 14                           |                              | 4.7)                         | 8                            |                              | 5.4)                         |
| Pneumonia                                            | 8                            |                              | 2.7)                         | 2                            |                              | 1.4)                         |
| Sepsis                                               |                              | 0                            |                              | 4                            |                              | 2.7)                         |
| Lower respiratory tract infection                    | 1                            | (                            | 0.3)                         | 2                            | (                            | 1.4)                         |
| Septic shock                                         |                              | (                            | 0.7)                         |                              | 0                            |                              |
| Covid-19                                             | 1                            |                              | 0.3)                         |                              | 0                            |                              |
| Infective exacerbation of chronic                    | 1                            |                              | 0.3)                         |                              | 0                            |                              |
| obstructive airways disease                          |                              |                              |                              |                              |                              |                              |
| Pneumonia aspiration                                 | 1                            | (                            | 0.3)                         |                              | 0                            |                              |
| General disorders and administration site conditions |                              |                              |                              |                              |                              |                              |
| - Overall                                            | 10                           |                              | 3.3)                         | 2                            | (                            | 1.4)                         |
| Death                                                | 7                            | (                            | 2.3)                         | 2                            | (                            | 1.4)                         |
| Sudden cardiac death                                 | 2                            | (                            | 0.7)                         |                              | 0                            |                              |
| General physical health deterioration                | 1                            | (                            | 0.3)                         |                              | 0                            |                              |
| Respiratory, thoracic and mediastinal disorders      |                              |                              |                              |                              |                              |                              |
| -Overall-                                            | 5                            |                              | 1.7)                         | 1                            | (                            | 0.7)                         |
| Chronic obstructive pulmonary disease                | 1                            |                              | 0.3)                         |                              | 0                            |                              |
| Hypoxia                                              |                              | 0                            |                              | 1                            | (                            | 0.7)                         |
| Pneumonitis                                          | 1                            | (                            | 0.3)                         |                              | 0                            |                              |
| Pneumothorax                                         | 1                            | (                            | 0.3)                         |                              | 0                            |                              |
| Respiratory arrest                                   | 1                            |                              | 0.3) 0.31                    |                              | 0                            |                              |
| Cardiac disorders                                    |                              |                              |                              |                              |                              |                              |
| -Overall                                             | 4                            |                              | 1.3)                         |                              | 0                            |                              |
| Acute left ventricular failure                       | 1                            |                              | 0.3)                         |                              | 0                            |                              |
| Acute myocardial infarction                          | 1                            |                              | 0.3)                         |                              | 0                            |                              |
| Cardiac arrest                                       | 1                            |                              | 0.3)                         |                              | 0                            |                              |
| Cardiac disorder                                     | 1                            |                              | 0.3)                         |                              | 0                            |                              |
| Nervous system disorders                             |                              |                              |                              |                              |                              |                              |
| -Overall                                             | 1                            |                              | 0.3)                         |                              |                              | 0.7)                         |
| Cerebrovascular accident                             |                              | 0                            |                              |                              |                              | 0.7)                         |
| Myasthenia gravis                                    | 1                            | (                            | 0.3)                         |                              | 0                            |                              |
| Blood and lymphatic system disorders                 |                              |                              |                              |                              |                              |                              |
| - Overall -                                          |                              | 0                            |                              | 1(                           |                              | 0.7)                         |
| Febrile neutropenia                                  |                              | 0                            |                              |                              | 1(                           | 0.7)                         |
| Hepatobiliary disorders                              |                              |                              |                              |                              |                              |                              |
| - Overall-                                           | 1(                           |                              | 0.3)                         |                              | 0                            |                              |
| Immune-mediated hepatitis                            | 1                            |                              | 0.3)                         |                              | 0                            |                              |

&lt;

Investigator text for AEs encoded using MedDRA version 25.0. All counts represent patients. Multiple occurrences of the same AE in one individual are counted once.

AEs started on or after first dose of study drug are included.

<div style=\"page-break-after: always\"></div>

## Deaths from Other Causes

Deaths due to causes other than progressive disease (PD) or which occurred after the AE reporting period and were not considered related to previous study treatment were reported as 'Deaths due to other causes'.

Thirty-four deaths in the Atezolizumab arm and 13 deaths in the Chemotherapy arm were reported under the category of 'other'. The 'other' causes of death were: a) deaths that occurred after the end of the AE reporting period and were assessed by the investigator as unrelated to study treatment and not due to  disease  progression  (Atezolizumab  21,  8.5%  vs.  Chemotherapy:  11,  8.5%),  and  b)  post-study reporting  of  death , i.e.,  reports  of  death  identified  through  public  records  for  patients  who  were discontinued from the study prematurely prior to their death and where the cause of death was not collected (Atezolizumab 13, 5.2% vs. Chemotherapy: 2, 1.6%). For the former, investigators provided the condition that resulted in the patient's death, if known, as free text in the database. The majority of these conditions reported by investigators were single-event occurrences and did not indicate a clinically meaningful pattern. The most common (n ≥ 2) causes of death that occurred after the AE reporting period were 'unknown' (Atezolizumab arm:  n = 8 vs.  Chemotherapy  arm:  n = 5), 'unexplained death' (Atezolizumab arm: n = 2), heart failure (Atezolizumab arm: n = 2), septic shock (Chemotherapy: n = 2) and Covid/ Covid-19 (Chemotherapy arm: n = 2).

## Adverse drug reactions

At the time of the primary analysis of OS (CCOD 30 April 2022) for IPSOS, no new adverse drug reactions (ADRs) with atezolizumab monotherapy treatment were identified.

The methodology used to identify any new ADRs in IPSOS is outlined in Figure 12. The exposure-adjusted analysis for certain AE preferred terms (PTs) is also described below.

Figure 12. Methodology to Identify ADRs to Atezolizumab in IPSOS

<!-- image -->

The pooled atezolizumab monotherapy population in the Tecentriq SmPC has been updated with IPSOS data, corresponding to a pool of 5039 patients (Atezo Mono 2 + IPSOS). The previously identified

<div style=\"page-break-after: always\"></div>

ADRs (including the ADR table) associated with atezolizumab monotherapy were updated if they met any of the following parameters:

- For all events, if the frequency category for the ADR escalated (e.g., from common to very common), or de-escalated (e.g., from very common to common). No ADRs met this criterion of a frequency categorisation change.
- Other factors considered: Time to onset, duration, and severity were also reviewed for inclusion of the events even if the category remained unchanged (i.e., the criteria from the bullet above was not met) and the information was updated accordingly when considered representative of new safety information requiring communication to health care providers and patients. The SmPC section, Description of Selected Adverse Reactions, was updated accordingly .

Table 49. Adverse Drug Reactions by Medical Concept (Atezo Mono Pooled) (N=5039)

| Medical concept            | Atezo Mono Pooled (N=5039)   |
|----------------------------|------------------------------|
| Fatigue                    | 1474 (29.3%)                 |
| Decreased Appetite         | 1013 (20.1%)                 |
| Rash                       | 994 (19.7%)                  |
| Nausea                     | 949 (18.8%)                  |
| Cough                      | 918 (18.2%)                  |
| Diarrhoea                  | 910 (18.1%)                  |
| Pyrexia                    | 900 (17.9%)                  |
| Dyspnoea                   | 837 (16.6%)                  |
| Arthralgia                 | 814 (16.2%)                  |
| Pruritus                   | 670 (13.3%)                  |
| Asthenia                   | 655 (13.0%)                  |
| Back Pain                  | 617 (12.2%)                  |
| Vomiting                   | 590 (11.7%)                  |
| Urinary Tract Infection    | 555 (11.0%)                  |
| Headache                   | 513 (10.2%)                  |
| Musculoskeletal Pain       | 448 ( 8.9%)                  |
| Nasopharyngitis            | 442 ( 8.8%)                  |
| Hypothyroidism             | 427 ( 8.5%)                  |
| Abdominal Pain             | 357 ( 7.1%)                  |
| AST increased              | 314 ( 6.2%)                  |
| ALT increased              | 313 ( 6.2%)                  |
| Blood creatinine increased | 296 ( 5.9%)                  |
| Chills                     | 266 ( 5.3%)                  |
| Dry Skin                   | 263 ( 5.2%)                  |
| Influenza Like Illness     | 257 ( 5.1%)                  |
| Dry Mouth                  | 228 ( 4.5%)                  |
| Hyponatraemia              | 228 ( 4.5%)                  |
| Hypokalaemia               | 191 ( 3.8%)                  |
| Oropharyngeal Pain         | 188 ( 3.7%)                  |
| Hyperglycaemia             | 177 ( 3.5%)                  |
| Thrombocytopenia           | 172 ( 3.4%)                  |
| Pneumonitis                | 151 ( 3.0%)                  |

Assessment report

Error! Unknown document property name.

<div style=\"page-break-after: always\"></div>

| Nasal Congestion                                                            | 135 ( 2.7%)   |
|-----------------------------------------------------------------------------|---------------|
| Hypotension                                                                 | 129 ( 2.6%)   |
| Hyperthyroidism                                                             | 121 ( 2.4%)   |
| Infusion Related Reaction (includes Hypersensitivity+Anaphylatic Reactions) | 109 ( 2.2%)   |
| Dysphagia                                                                   | 102 ( 2.0%)   |
| Hepatitis (Diagnosis)                                                       | 88 ( 1.7%)    |
| Hypoxia                                                                     | 85 ( 1.7%)    |
| Colitis                                                                     | 62 ( 1.2%)    |
| Pericardial Disorders                                                       | 49 ( 1.0%)    |
| Pancreatitis                                                                | 40 ( 0.8%)    |
| Psoriasis                                                                   | 35 ( 0.7%)    |
| Myositis                                                                    | 32 ( 0.6%)    |
| Diabetes Mellitus                                                           | 30 ( 0.6%)    |
| Severe Cutaneous Reactions                                                  | 30 ( 0.6%)    |
| Adrenal Insufficiency                                                       | 25 ( 0.5%)    |
| Meningoencephalitis                                                         | 22 ( 0.4%)    |
| Nephritis                                                                   | 11 ( 0.2%)    |
| Guillain-Barre Syndrome                                                     | 6 ( 0.1%)     |
| Hypophysitis                                                                | 5 (<0.1%)     |
| Myocarditis                                                                 | 5 (<0.1%)     |
| Uveitis                                                                     | 3 (<0.1%)     |
| Haemophagocytic Lymphohistiocytosis                                         | 2 (<0.1%)     |
| Myasthenic Syndrome                                                         | 2 (<0.1%)     |
| Facial Paresis                                                              | 1 (<0.1%)     |
| Myelitis                                                                    | 1 (<0.1%)     |
| Pemphigoid                                                                  | 1 (<0.1%)     |

Atezo = Atezolizumab. Atezo Mono Pooled: GO27831(PCD4989g All Cohorts) + GO28625(FIR) + GO28753(POPLAR) + GO28754(BIRCH) + GO28915(OAK) + GO29293(IMVIGOR210) + GO29294(IMVIGOR211) +

GO29431(IMPOWER110) + GO29527(IMPOWER010) + MO29872(IPSOS) + WO29074(IMMOTION150 Arm B prior to crossover) + WO29636(IMVIGOR010) + WO39210(IMMOTION010 Arm A).

Investigator text for AEs encoded using MedDRA v25.1. Percentages are based on N in the column headings. For frequency counts by medical concept, multiple occurrences of the same medical concept in an individual are counted only once. All treatment emergent AEs are included.

Clinical cut-off dates: GO27831:31MAR2016, GO28625:07JAN2015, GO28753:01DEC2015, GO28754:01DEC2015, GO28915:07JUL2016, GO29293:04JUL2016, GO29294:13MAR2017, GO29431:04FEB2020, GO29527:21JAN2021, MO29872:30APR2022, WO29074:17OCT2016, WO29636:30NOV2019, WO39210:03MAY2022.

## Laboratory findings

## All laboratory safety parameters

The frequency of clinically relevant shifts in hematology parameter abnormalities was: low neutrophils (0.9%  atezolizumab  vs.  19.8%  chemotherapy),  low  white  blood  cells  (1.1%  vs.  14.1%)  and  low lymphocytes (11.1% vs. 18.5%) in the chemotherapy and in the atezolizumab arm, respectively.

Among biochemistry laboratory parameter abnormalities, the frequency of clinically relevant shifts was similar between the arms except for a higher ( ≥ 2%) incidence of low sodium levels (13.5% vs. 5.3%) and high potassium levels (2.6% vs. 0%) in the atezolizumab arm compared with the chemotherapy arm (data not shown).

## Thyroid function

<div style=\"page-break-after: always\"></div>

Blood samples for thyroid function assessment were collected routinely (every 4 cycles).

Overall,  the  majority  of  patients  with  baseline  and  non-missing  post-baseline  thyroid  stimulating hormone (TSH) measurements maintained normal TSH levels during the study. Treatment-emergent TSH  laboratory  abnormalities  (defined  as  normal  at  baseline  and  abnormal  at  post-baseline)  were reported in a similar percentage of patients in both treatment arms (TSH low: 7.3% atezolizumab vs. 4.1% chemotherapy, TSH high: 7.0% vs. 6.1%.

## Hy's Law

Two patients in the atezolizumab arm fulfilled the laboratory criteria suggestive for Hy's law with an elevated ALT or AST &gt; 3×baseline value in combination with an elevated total bilirubin [ &gt; 2×ULN]). The first patient experienced elevated liver function tests at the onset of immune-mediated hepatitis with positive hepatitis B core antibody detection, which resulted in death. The second patient experienced elevated liver function tests at the onset of biliary cholangitis. The patient's symptoms were resolved, and liver function tests parameters returned to normal following treatment. This patient also experienced hyperbilirubinaemia approximately 15 months later; this event did not qualify for instances of elevation in transaminase with simultaneous elevation in bilirubin and therefore did not meet the definition of Hy's law per protocol.

## Electrocardiography

At baseline, 8 patients (2.7%) in the atezolizumab arm and 7 patients (4.8%) in the chemotherapy arm had a clinically significant electrocardiogram (ECG) abnormality.

Post-baseline, 28 patients (9.3%) on atezolizumab and 5 patients (3.4%) on chemotherapy had clinically significant  ECG  abnormalities.  Of  the  28  patients  in  the  atezolizumab  arm,  15  patients  experienced cardiac  AEs  associated  with  the  clinically  significant  ECG  abnormalities.  One  of  the  15  patients experienced a Grade 5 cardiac AE (acute left ventricular failure), which was assessed as related to study treatment.

Of the remaining 14 patients, 11 experienced Grade 1 or Grade 2 cardiac AEs; in 4 patients the cardiac AEs  were  considered  related  to  study  treatment  (Grade  1  events  of  cardiac  failure,  ventricular extrasystoles, atrioventricular block first degree, and conduction disorder). Three patients experienced a Grade 3 cardiac AE, all of which were events of atrial fibrillation and were considered unrelated to study treatment by the investigator.

At the time of the CCOD, the cardiac events were resolved in 7/14 patients.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Age

## Table 50. Overview of Safety by Age (Safety-Evaluable Population)

Overall Summary of Adverse Events, by Aqe Group for Chemotherapy Safety-Evaluable Population

|                                                                     | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   |
|---------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                                     | <65 (N=18)             | >= 65 (N=129)          | 65-74 (N=50)           | 75-84 (N=70)           | >= 85 (N=9)            |
| Total number of patients with at least one AE                       | 15 ( 83.3)             | 128 (99.2)             | 50 (100.0)             | 69(98.6)               | 9 (100.0)              |
| Total number of events                                              | 166                    | 920                    | 392                    | 489                    | 39                     |
| Total number of patients with at least one                          |                        |                        |                        |                        |                        |
| Treatment-related AE                                                | 11  ( 61.1)            | 107 (82.9)             | 42 (84.0)              | 57(81.4)               | 8(88.9)                |
| Grade 3-4 AE                                                        | 7(38.9)                | 64(49.6)               | 28 (56.0)              | 33(47.1)               | 3(33.3)                |
| Treatment-related Grade 3-4 AE                                      | 6(33.3)                | 43( 33.3)              | 21 (42.0)              | 20(28.6)               | 2(22.2)                |
| Grade 5 AE                                                          | 5.6)                   | 12（ 9.3)               | 6 (12.0)               | 5 (7.1)                | 1 (11.1)               |
| Treatment-related Grade 5 AE                                        | 0                      | （ 3.1)                 | 2 (4.0)                | 2（ 2.9)                | 0                      |
| Serious AE                                                          | 2 (11.1)               | 51 ( 39.5)             | 21 ( 42.0)             | 28(40.0)               | 2(22.2)                |
| Treatment-related serious AE                                        | 1 (5.6)                | 22 (17.1)              | 12 (24.0)              | 9(12.9)                | 1 ( 11.1)              |
| AE leading to any Study Treatment                                   | 2 ( 11.1)              | 18 (14.0)              | 4 8.0)                 | 12 ( 17.1)             | 2(22.2)                |
| discontinuation                                                     |                        |                        |                        |                        |                        |
| AE leading to any Dose modification or Study Treatment interruption | 9( 50.0)               | 62(48.1)               | 31 (62.0)              | 28(40.0)               | 3(33.3)                |

Overall Summary of AcverseEvents,by Aqe Group for Atezolizumab Safety-EvaluablePopulation

|                                             | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   |
|---------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                             | <65 (N=46)             | >= 65 (N=254)          | 65-74 (N=100)          | 75-84 (N=139)          | >= 85 (N=15)           |
| Totalnumber of patients withat least one AE | 39(84.8)               | 236 ( 92.9)            | 93 (93.0)              | 128 (92.1)             | 15 (100.0)             |
| Total number of events                      | 229                    | 2123                   | 793                    | 1189                   | 141                    |
| Total number of patients with at least one  |                        |                        |                        |                        |                        |
| Treatment-related AE                        | 18 (39.1)              | 153 (60.2)             | 61 ( 61.0)             | 84 (60.4)              | 8 (53.3)               |
| Grade 3-4 AE                                | 18 (39.1)              | 118 (46.5)             | 45 45.0)               | 65 46.8)               | 8 (53.3)               |
| Treatment-related Grade 3-4 AE              | 9 (19.6)               | 40 (15.7)              | 17 (17.0)              | 21 (15.1)              | 2 (13.3)               |
| Grade5 AE                                   | 4 8.7)                 | 31(12.2)               | 13 (13.0)              | 17 (12.2)              | 1 (6.7)                |
| Treatment-related Grade 5 AE                | 0                      | 3(1.2)                 | 1 1.0)                 | 2 1.4)                 | 0                      |
| Serious AE                                  | 16 (34.8)              | 130 ( 51.2)            | 54 (54.0)              | 69 (49.6)              | 7 (46.7)               |
| Treatment-related serious AE                | 8 (17.4)               | 27 (10.6)              | 12 (12.0)              | 13 9.4)                | 2 (13.3)               |
| AE leading to any Study Treatment           | 6 (13.0)               | 33 (13.0)              | 8 8.0)                 | 22 (15.8)              | 3 (20.0)               |
| discontinuation                             |                        |                        |                        |                        |                        |
| AE leading to anyDose modification or       | 11 ( 23.9)             | 85 (33.5)              | 28 (28.0)              | 52 ( 37.4)             | 5(33.3)                |
| Study Treatment interruption                |                        |                        |                        |                        |                        |

AEs started on or after first dose of study drug are included.

<div style=\"page-break-after: always\"></div>

## Gender

Table 51. Overview of Safety by Gender (Safety-Evaluable Population)

Overall Suummary of Adverse Events, by Sex Safety-Evaluable Population

|                                                                     | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   |
|---------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                                     | Male (N=105)           | Female (N=42)          | Male (N=219)           | Female (N=81)          |
| Totalnumber of patients with at least one AE                        | 103 (98.1)             | 40 (95.2)              | 198 (90.4)             | 77( 95.1)              |
| Total number of events                                              | 725                    | 361                    | 1701                   | 651                    |
| Totalnumber of patients with at least one                           |                        |                        |                        |                        |
| Treatment-related AE                                                | 86  ( 81.9)            | 32(76.2)               | 128 (58.4)             | 43(53.1)               |
| Grade3-4 AE                                                         | 47(44.8)               | 24 ( 57.1)             | 93(42.5)               | 43 (53.1)              |
| Treatment-related Grade 3-4 AE                                      | 36 (34.3)              | 13 (31.0)              | 38 (17.4)              | 11 (13.6)              |
| Grade 5 AE                                                          | 9 8.6)                 | 4 9.5)                 | 25 5 (11.4)            | 10 (12.3)              |
| Treatment-related Grade 5 AE                                        | 2 （ 1.9)               | 2 4.8)                 | 2 (0.9)                | 1 (1.2)                |
| Serious AE                                                          | 38(36.2)               | 15 (35.7)              | 101 ( 46.1)            | 45 (55.6)              |
| Treatment-related serious AE                                        | 17 (16.2)              | 6 (14.3)               | 27 (12.3)              | 8 (9.9)                |
| AE leading to any Study Treatment                                   | 15 (14.3)              | 5 （ 11.9)              | 24 ( 11.0)             | 15 (18.5)              |
| discontinuation                                                     |                        |                        |                        |                        |
| AE leading to any Dose modification or Study Treatment interruption | 50 (47.6)              | 21  ( 50.0)            | 65 (29.7)              | 31 ( 38.3)             |

AEs started on or after first dose of study drug are included.

## Race

## Table 52. Overview of Safety by Race (Safety-Evaluable Population)

Overall Summary of Adverse Events, by Race for Chemotherapy Safety-Evaluable Population

|                                              | Chemotherapy (N=147)                   | Chemotherapy (N=147)   | Chemotherapy (N=147)            | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   |
|----------------------------------------------|----------------------------------------|------------------------|---------------------------------|------------------------|------------------------|------------------------|
|                                              | American Indian or Alaska Native (N=9) | Asian (N=34)           | Black or African American (N=1) | White (N=95)           | Multiple (N=6)         | Unknown (N=2)          |
| Totalnumber of patients with at least one AE | 8(88.9)                                | 34 (100.0)             | 1 (100.0)                       | 92 (96.8)              | 6 (100.0)              | 2 (100.0)              |
| Total number of events                       | 101                                    | 258                    | 14                              | 586                    | 110                    | 17                     |
| Total number of patients with at least one   |                                        |                        |                                 |                        |                        |                        |
| Treatment-related AE                         | 8 (88.9)                               | 28 (82.4)              | 1 (100.0)                       | 75 (78.9)              | 4(66.7)                | 2 (100.0)              |
| Grade3-4AE                                   | 4 44.4)                                | 15 (44.1)              | 1 (100.0)                       | 48 (50.5)              | 2(33.3)                | 1 (50.0)               |
| Treatment-related Grade 3-4 AE               | 4 44.4)                                | 15 ( 44.1)             | 1 (100.0)                       | 28 (29.5)              | 1 (16.7)               | 0                      |
| Grade5AE                                     | 0                                      | 4(11.8)                | 0                               | 7.4)                   | 1 (16.7)               | 1 ( 50.0)              |
| Treatment-related Grade 5 AE                 | 0                                      | 0                      | 0                               | 3 3.2)                 | 1 (16.7)               | 0                      |
| Serious AE                                   | 0                                      | 13( 38.2)              | 0                               | 35 （ 36.8)             | 3(50.0)                | 2 (100.0)              |
| Treatment-related serious AE                 | 0                                      | 9(26.5)                | 0                               | 12 12.6)               | 2 (33.3)               | 0                      |
| AE leading to any Study Treatment            | 0                                      | 5 (14.7)               | 0                               | 15 (15.8)              | 0                      | 0                      |
| discontinuation                              |                                        |                        |                                 |                        |                        |                        |
| AEleading to any Dosemodification or         | (22.2)                                 | 19 (55.9)              | 0                               | 45 (47.4)              | 4(66.7)                | 1 (50.0)               |
| Study Treatment interruption                 |                                        |                        |                                 |                        |                        |                        |

AEs started on or after first dose of study drug are included.

<div style=\"page-break-after: always\"></div>

|                                              | Atezolizumab (N=300)                    | Atezolizumab (N=300)   | Atezolizumab (N=300)            | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   |
|----------------------------------------------|-----------------------------------------|------------------------|---------------------------------|------------------------|------------------------|------------------------|
|                                              | American Indian or Alaska Native (N=12) | Asian (N=74)           | Black or African American (N=2) | White (N=202)          | Multiple (N=6)         | Unknown (N=4)          |
| Totalnumber of patients with at least one AE | 6 (50.0)                                | 71 (95.9)              | 2 (100.0)                       | 186 (92.1)             | 6 (100.0)              | 4 (100.0)              |
| Total number of events                       | 63                                      | 572                    | 37                              | 1536                   | 105                    | 39                     |
| Totalnumber of patients with at least one    |                                         |                        |                                 |                        |                        |                        |
| Treatment-related AE                         | 5 (41.7)                                | 44 (59.5)              | 1 (50.0)                        | 113 ( 55.9)            | 4 (66.7)               | 4 (100.0)              |
| Grade3-4 AE                                  | 2 (16.7)                                | 37 50.0)               | 2 2 (100.0)                     | 90 44.6)               | 3 50.0)                | 2 (50.0)               |
| Treatment-related Grade 3-4 AE               | 0                                       | 16 21.6)               | 0                               | 29 14.4)               | 1 16.7)                | 3 (75.0)               |
| Grade5 AE                                    | 0                                       | 5 6.8)                 | 0                               | 27 13.4)               | 2 33.3)                | 1 (25.0)               |
| Treatment-related Grade 5 AE                 | 0                                       | 1 1.4)                 | 0                               | 2 1.0)                 | 0                      | 0                      |
| Serious AE                                   | 2 (16.7)                                | 36 (48.6)              | (50.0)                          | 101 (50.0)             | 3 50.0)                | 3 (75.0)               |
| Treatment-related serious AE                 | 1 8.3)                                  | 17 (23.0)              | 0                               | 15 7.4)                | 1 16.7)                | 1 (25.0)               |
| AE leading to any Study Treatment            | 0                                       | (10.8)                 | (50.0)                          | 27 13.4)               | 0                      | 3 (75.0)               |
| discontinuation                              |                                         |                        |                                 |                        |                        |                        |
| AE leading to any Dose modification or       | 3(25.0)                                 | 19( 25.7)              | 0                               | 70(34.7)               | 1 (16.7)               | 3 (75.0)               |
| Study Treatment interruption                 |                                         |                        |                                 |                        |                        |                        |

AEs started on or after first dose of study drug are included.

## Hepatic Impairment

Hepatic  impairment  was  defined  using  National  Cancer  Institute  Organ  Dysfunction  Working  Group criteria.

Table 53. Overview of Safety by Hepatic Impairment (Safety-Evaluable Population)

Overall Summary\\_ of Adverse Events,by Hepatic Impairment Safety-Evaluable Population

|                                                                                  | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   |
|----------------------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                                                  | Normal (N=132)         | Mild (N=13)            | Moderate (N=2)         | Normal (N=273)         | Mild (N=24)            | Moderate (N=2)         |
| Total number of patients with at least one AE                                    | 129 ( 97.7)            | 12 ( 92.3)             | 2 (100.0)              | 251 ( 91.9)            | 21 ( 87.5)             | 2 (100.0)              |
| Total number of events                                                           | 984                    | 86                     | 16                     | 2180                   | 150                    | 11                     |
| Totalnumber of patientswith at least one                                         |                        |                        |                        |                        |                        |                        |
| Treatment-related AE                                                             | 108 (81.8)             | 8 (61.5)               | 2 (100.0)              | 158 ( 57.9)            | 10 ( 41.7)             | 2 (100.0)              |
| Grade3-4AE                                                                       | 66 ( 50.0)             | 5 ( 38.5)              | 0                      | 123 (45.1)             | 11 (45.8)              | 1 ( 50.0)              |
| Treatment-related Grade 3-4 AE                                                   | 46 (34.8)              | 3(23.1)                | 0                      | 43 (15.8)              | 4 (16.7)               | 1 (50.0)               |
| Grade5AE                                                                         | 13 9.8)                | 0                      | 0                      | 32(11.7)               | 3 (12.5)               | 0                      |
| Treatment-related Grade 5 AE                                                     | 4 3.0)                 | 0                      | 0                      | 2(0.7)                 | 1 4.2)                 | 0                      |
| Serious AE                                                                       | 49 (37.1)              | 3(23.1)                | 1 ( 50.0)              | 135 ( 49.5)            | 9 (37.5)               | 1 (50.0)               |
| Treatment-related serious AE                                                     | 22 (16.7)              | 1 (7.7)                | 0                      | 31 (11.4)              | 2 8.3)                 | 1 ( 50.0)              |
| AE leading to any Study                                                          | 19 (14.4)              | 0                      | 1 ( 50.0)              | 36(13.2)               | 3 (12.5)               | 0                      |
| Treatment discontinuation AE leading to any Dose modification or Study Treatment | 65(49.2)               | 5(38.5)                | 1 ( 50.0)              | 87 (31.9)              | 8(33.3)                | 0                      |

One patient with missing AsT value and normal bilirubin value at baseline could not be assigned to any category of hepatic impairment.

AEs started on or after first dose of study drug are included.

## Renal Impairment

For renal impairment, the following estimated glomerular filtration rate (eGFR) values were used to define each group: Normal = eGFR ≥90 mL/min/1.73 m2, Mild = eGFR ≥60 and &lt;90 mL/min/1.73 m2, Moderate = eGFR ≥30 and &lt;60 mL/min/1.73 m2, and Severe = eGFR &lt;30 mL/min/1.73 m2.

<div style=\"page-break-after: always\"></div>

Table 54. Overview of Safety by Renal Impairment (Safety-Evaluable Population)

Overall Sumary of Adverse Events, by Renal Impairment Safety-Evaluable Population

|                                                                                               | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   |
|-----------------------------------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                                                               | Normal (N=48)          | Mild (N=72)            | Moderate (N=27)        | Normal (N=92)          | Mild (N=154)           | Moderate (N=53)        | Severe (N=1)           |
| Total number of patients with at least one AE                                                 | 44 ( 91.7)             | 72 (100.0)             | 27 (100.0)             | 81 (88.0)              | 143 ( 92.9)            | 50 ( 94.3)             | 1 (100.0)              |
| Total number of events                                                                        | 370                    | 519                    | 197                    | 615                    | 1266                   | 463                    | 8                      |
| Total number of patients with at least one                                                    |                        |                        |                        |                        |                        |                        |                        |
| Treatment-related AE                                                                          | 35  (72.9)             | 61 (84.7)              | 22 (81.5)              | 45 ( 48.9)             | 91 (59.1)              | 34 (64.2)              | 1 (100.0)              |
| Grade3-4 AE                                                                                   | 23 3(47.9)             | 38 (52.8)              | 10 (37.0)              | 41 (44.6)              | 64 (41.6)              | 30(56.6)               | 1 (100.0)              |
| Treatment-related Grade 3-4 AE                                                                | 19 (39.6)              | 24 (33.3)              | 6(22.2)                | 18 (19.6)              | 22 (14.3)              | 9(17.0)                | 0                      |
| Grade 5AE                                                                                     | 5 (10.4)               | 5 6.9)                 | 3 (11.1)               | 11  (12.0)             | 21 (13.6)              | 3 (5.7)                | 0                      |
| Treatment-related Grade 5 AE                                                                  | 2 (4.2)                | 1 1.4)                 | 1(3.7)                 | 1 (1.1)                | (1.3)                  | 0                      | 0                      |
| Serious AE                                                                                    | 15 ( 31.3)             | 26 (36.1)              | 12 (44.4)              | 44(47.8)               | 72 (46.8)              | 30(56.6)               | 0                      |
| Treatment-related serious AE                                                                  | 10 (20.8)              | 6 (12.5)               | 4 (14.8)               | 13 (14.1)              | 19 (12.3)              | 3 (5.7)                | 0                      |
| AE leading to any Study                                                                       | 6(12.5)                | 8(11.1)                | 6(22.2)                | 12  (13.0)             | 21 (13.6)              | 6 ( 11.3)              | 0                      |
| Treatment discontinuation AE leading to any Dose modification or Study Treatment interruption | 25 (52.1)              | 33(45.8)               | 13 (48.1)              | 21 (22.8)              | 53( 34.4)              | 22 ( 41.5)             | 0                      |

AEs started on or after first dose of study drug are included.

## Tobacco Use History

Table 55. Overview of Safety by Tobacco Use History (Safety-Evaluable Population)

Overall Summary of Adverse Events, by Tobacco Use History Safety-Evaluable Population

|                                                  | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   |
|--------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                  | Never (N=19)           | Current (N=26)         | Previous (N=102)       | Never (N=35)           | Current (N=57)         | Previous (N=208)       |
| Total number of patients with at least one AE    | 19 (100.0)             | 25 (96.2)              | 99 (97.1)              | 31 (88.6)              | 50 (87.7)              | 194 ( 93.3)            |
| Total number of events                           | 120                    | 208                    | 758                    | 275                    | 401                    | 1676                   |
| Totalnumber of patients with at least one        |                        |                        |                        |                        |                        |                        |
| Treatment-related AE                             | 15 (78.9)              | 19 (73.1)              | 84(82.4)               | 17(48.6)               | 37 (64.9)              | 117 ( 56.3)            |
| Grade3-4AE                                       | 6 (31.6)               | 13 (50.0)              | 52 (51.0)              | 17 (48.6)              | 26( (45.6)             | 93 (44.7)              |
| Treatment-related Grade 3-4 AE                   | 6(31.6)                | 6 (23.1)               | 37 ( 36.3)             | 4 (11.4)               | 14 (24.6)              | 31 (14.9)              |
| Grade 5 AE                                       | 3(15.8)                | 3 (11.5)               | 7 6.9)                 | 4( 11.4)               | 9 (15.8)               | 22 (10.6)              |
| Treatment-related Grade 5 AE                     | 0                      | 2 (7.7)                | 2（ 2.0)                | 0                      | 1（ 1.8)                | 2 (1.0)                |
| Serious AE                                       | 7(36.8)                | 13 (50.0)              | 33(32.4)               | 17 ( 48.6)             | 27(47.4)               | 102 (49.0)             |
| Treatment-related serious AE                     | 3(15.8)                | 5 (19.2)               | 15 (14.7)              | 3 (8.6)                | 8(14.0)                | 24 (11.5)              |
| AE leading to any Study                          | 2 (10.5)               | 5 (19.2)               | 13 (12.7)              | 4 (11.4)               | 8 (14.0)               | 27 (13.0)              |
| Treatment discontinuation AE leading to any Dose |                        | 14 (53.8)              | 48 (47.1)              | 14 (40.0)              | 18 (31.6)              | 64 (30.8)              |
| modification or Study Treatment interruption     | 9(47.4)                |                        |                        |                        |                        |                        |

AEs started on or after first dose of study drug are included.

<div style=\"page-break-after: always\"></div>

## ECOG PS

Table 56. Overview of Safety by ECOG (Safety-Evaluable Population)

Overall Summary of Adverse Events, By Baseline ECoG PS Safety-Evaluable Population

|                                                        | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Chemotherapy (N=147)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezolizumab (N=300)   |
|--------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                        | ECOG PS 1 (N=19)       | ECOG PS 2 (N=113)      | ECOG PS 3 (N=15)       | ECOG PS 0 (N=7)        | ECOG PS 1 (N=49)       | ECOG PS 2 (N=226)      | ECOG PS 3 (N=18)       |
| Total number of patients with at least one AE          | 19 (100.0)             | 110 ( 97.3)            | 14 ( 93.3)             | 7 (100.0)              | 44 (89.8)              | 208 (92.0)             | 16 (88.9)              |
| Total number of events                                 | 186                    | 816                    | 84                     | 87                     | 446                    | 1667                   | 152                    |
| Total number of patients with at least one             |                        |                        |                        |                        |                        |                        |                        |
| Treatment-related AE                                   | 18 3(94.7)             | 68 (78.8)              | 11 (73.3)              | 6(85.7)                | 31 (63.3)              | 124 ( 54.9)            | 10 (55.6)              |
| Grade 3-4AE                                            | 9(47.4)                | 54 (47.8)              | 8(53.3)                | 5 (71.4)               | 16( 32.7)              | 109 (48.2)             | 6 (33.3)               |
| Treatment-related Grade 3-4 AE                         | 4 (21.1)               | 40 (35.4)              | 5(33.3)                | 0                      | 8(16.3)                | 36 (15.9)              | 5 (27.8)               |
| Grade5 AE                                              | 2 (10.5)               | 10 8.8)                | 1 (6.7)                | 0                      | 2 (4.1)                | 29 (12.8)              | 4 (22.2)               |
| Treatment-related Grade 5 AE                           | 0                      | 4 3.5)                 | 0                      | 0                      | 1 (2.0)                | 2 (0.9)                | 0                      |
| Serious AE                                             | 8(42.1)                | 41 36.3)               | 4 (26.7)               | 3 (42.9)               | 18 (36.7)              | 117 ( 51.8)            | 8 (44.4)               |
| Treatment-related serious AE                           | 0                      | 21 18.6)               | 2 (13.3)               | 0                      | 5(10.2)                | 27 (11.9)              | 3 (16.7)               |
| AE leading to any Study                                | 4 ( 21.1)              | 15 (13.3)              | 1(6.7)                 | 0                      | 10 (20.4)              | 27 (11.9)              | 2 (11.1)               |
| Treatment discontinuation                              |                        |                        |                        |                        |                        |                        |                        |
| AE leading to any Dose modification or Study Treatment | 9(47.4)                | 54(47.8)               | 8(53.3)                | 2(28.6)                | 19 (38.8)              | 68 ( 30.1)             | 7 (38.9)               |

AEs started on or after first dose of study drug are included.

## Use in pregnancy and lactation

There were no pregnancies in IPSOS.

There are no clinical studies of atezolizumab in pregnant women. Atezolizumab is not recommended during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus.

No  reproductive  or  teratogenicity  studies  in  animals  have  been  conducted  with  atezolizumab.  The programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) signaling pathway is well established as essential in maternal / fetal tolerance and embryo-fetal survival during gestation. Administration of atezolizumab is expected to have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo lethality.

It is not known whether atezolizumab is excreted in human breast milk. No studies have been conducted to assess the impact of atezolizumab on milk production or its presence in breast milk.

## Overdose

In the atezolizumab Phase Ia dose-escalation Study PCD4989g, the highest dose per unit weight to which patients  have  been  exposed  was  20  mg/kg  IV  q3w.  There  is  no  information  on  overdose  with atezolizumab in IPSOS.

## Drug abuse

No information is available. However, on the basis of its pharmacological properties, the risk of abuse or misuse of atezolizumab is considered to be low.

## Withdrawal and rebound

No information is available. However, based on the mechanism of action, atezolizumab does not affect pathways that are associated with withdrawal or rebound effects.

## Effects on ability to drive or operate machinery or impairment of mental ability

No  studies  of  the  effects  on  the  ability  to  drive  and  to  use  machines  have  been  performed  for atezolizumab. Atezolizumab may have a minor influence on the ability to drive and use machines.

Assessment report

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No formal pharmacokinetic drug-drug interaction studies have been conducted with atezolizumab.

## Discontinuation due to adverse events

## Treatment discontinuations

At  the  CCOD,  in  the  safety-evaluable  population  of  IPSOS,  the  proportion  of  patients  who  had discontinued from treatment was 95.0% for the atezolizumab arm vs. 100.0% for the chemotherapy arm, with the main reasons being progressive disease (50.3% vs. 51.0%) and death (20.0% vs. 12.2%).

Comparison between IPSOS and Atezo Mono Pooled Populations

Table 57. Patient Status: Overview of Frequency and Reasons for Treatment Discontinuation from Atezolizumab (Safety-Evaluable Population)

|                                  | Atezolizumab (N=300)   | Atezolizumab (N=300)   | Atezo Mono[1] (N=3178)   | Atezo Mono[1] (N=3178)   | Atezo Mono[2] (N=4739)   | Atezo Mono[2] (N=4739)   |
|----------------------------------|------------------------|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Patients Discontinued from Atezo |                        |                        |                          |                          |                          |                          |
| All Reasons                      | 285                    | (95.0%)                | 2627                     | (82.7%)                  |                          | 3364 (71.0%)             |
| Adverse event                    | 38                     | (12.7%)                | 213                      | 6.7%)                    | 431                      | (9.1%)                   |
| Death                            | 60                     | (20.0%)                | 15                       | (0.5%)                   | 52                       | (1.1%)                   |
| Progressive disease              | 151                    | (50.3%)                | 1862                     | (58.6%)                  | 1862                     | (39.3%)                  |
| Progression of disease           | 0                      |                        | 371                      | (11.7%)                  | 505                      | (10.7%)                  |
| Lost to follow-up                | 1                      | 0.3%)                  | 2                        | (<0.1%)                  | 3                        | (<0.1%)                  |
| Other                            | 1                      | 0.3%)                  | 10                       | 0.3%)                    | 28                       | (0.6%)                   |
| Physician decision               | 3                      | (1.0%)                 | 34                       | 1.1%)                    | 55                       | (1.2%)                   |
| Protocolviolation                | 0                      |                        | 14                       | 0.4%)                    | 14                       | (0.3%)                   |
| Protocol Deviation               | 0                      |                        | 0                        |                          | 2                        | (<0.1%)                  |
| Withdrawal by subject            | 27                     | (9.0%)                 | 94                       | (3.0%)                   | 161                      | (3.4%)                   |
| Non-compliance                   | 3                      | (1.0%)                 | 8                        | 0.3%)                    | 9                        | (0.2%)                   |
| Symptomatic Deterioration        | 0                      |                        | 4                        | 0.1%)                    | 23                       | (0.5%)                   |
| Disease relapse                  | 0                      |                        | 0                        |                          | 219                      | (4.6%)                   |
| Study terminated bysponsor       | 1                      | (0.3%)                 | 0                        |                          | 0                        |                          |

+ Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A).

Clinical cut-off dates: G027831:31MAR2016, G028625:07JAN2015, G028753:01DEC2015, GO28754:01DEC2015,G028915:07JUL2016,G029293:04JUL2016,G029294:13MAR2017, GO29431:04FEB2020, G029527:21JAN2021, W029074:170CT2016, W029636:30NOV2019, WO39210:03MAY2022, M029872:30APR2022.

Actual treatment arms are presented.

<div style=\"page-break-after: always\"></div>

## Study discontinuations

Comparison between IPSOS and Atezo Mono Pooled Populations

Table 58. Patient Status: Overview of Frequency and Reasons for Withdrawal from Study (Safety-Evaluable Population)

|                                                                                                                            | Chemotherapy (N=147)                                                                                                       | Chemotherapy (N=147)                                                                                                       | Atezolizumab (N=300)                                                                                                       | Atezolizumab (N=300)                                                                                                       | Atezo Mono[1] (N=3178)                                                                                                     | Atezo Mono[1] (N=3178)                                                                                                     | Atezo Mono[2] (N=4739)                                                                                                     | Atezo Mono[2] (N=4739)                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Study Status                                                                                                               |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| n                                                                                                                          |                                                                                                                            | 147(100%)                                                                                                                  |                                                                                                                            | 300(100%)                                                                                                                  |                                                                                                                            | 3178(100%)                                                                                                                 |                                                                                                                            | 4739(100%)                                                                                                                 |
| Ongoing                                                                                                                    | 0                                                                                                                          |                                                                                                                            | 15                                                                                                                         | (5.0%)                                                                                                                     |                                                                                                                            | 1108(34.9%)                                                                                                                |                                                                                                                            | 2134(45.0%)                                                                                                                |
| Discontinued study                                                                                                         | 147                                                                                                                        | (100%)                                                                                                                     | 285                                                                                                                        | (95.0%)                                                                                                                    |                                                                                                                            | 2070(65.1%)                                                                                                                |                                                                                                                            | 2605 (55.0%)                                                                                                               |
| Reason for Study Discontinuation                                                                                           | Reason for Study Discontinuation                                                                                           |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| All Reasons                                                                                                                | 147                                                                                                                        | (100%)                                                                                                                     | 285                                                                                                                        | (95.0%)                                                                                                                    |                                                                                                                            | 2070(65.1%)                                                                                                                | 2605                                                                                                                       | (55.0%)                                                                                                                    |
| Death                                                                                                                      | 127                                                                                                                        | (86.4%)                                                                                                                    | 235                                                                                                                        | (78.3%)                                                                                                                    | 1887                                                                                                                       | (59.4%)                                                                                                                    | 2317                                                                                                                       | (48.9%)                                                                                                                    |
| Progressive disease                                                                                                        | 0                                                                                                                          |                                                                                                                            | 0                                                                                                                          |                                                                                                                            | 3                                                                                                                          | (<0.1%)                                                                                                                    | 3                                                                                                                          | (<0.1%)                                                                                                                    |
| Lost to follow-up                                                                                                          | 3                                                                                                                          | (2.0%)                                                                                                                     | 9                                                                                                                          | (3.0%)                                                                                                                     | 70                                                                                                                         | (2.2%)                                                                                                                     | 84                                                                                                                         | (1.8%)                                                                                                                     |
| Other                                                                                                                      | 0                                                                                                                          |                                                                                                                            | 0                                                                                                                          |                                                                                                                            | 1                                                                                                                          | (<0.1%)                                                                                                                    | 4                                                                                                                          | (<0.1%)                                                                                                                    |
| Physician decision                                                                                                         | 0                                                                                                                          |                                                                                                                            | 1                                                                                                                          | 0.3%)                                                                                                                      | 1                                                                                                                          | (<0.1%)                                                                                                                    | 1                                                                                                                          | (<0.1%)                                                                                                                    |
| Protocol violation                                                                                                         | 0                                                                                                                          |                                                                                                                            | 0                                                                                                                          |                                                                                                                            | 11                                                                                                                         | (0.36)                                                                                                                     | 11                                                                                                                         | (0.2%)                                                                                                                     |
| Protocol Deviation                                                                                                         | 0                                                                                                                          |                                                                                                                            | 0                                                                                                                          |                                                                                                                            | 0                                                                                                                          |                                                                                                                            | 1                                                                                                                          | (<0.1%)                                                                                                                    |
| Withdrawal by subject                                                                                                      | 12                                                                                                                         | (8.2%)                                                                                                                     | 25                                                                                                                         | (8.3%)                                                                                                                     | 97                                                                                                                         | (3.1%)                                                                                                                     | 182                                                                                                                        | (3.8%)                                                                                                                     |
| Disease relapse                                                                                                            | 0                                                                                                                          |                                                                                                                            | 0                                                                                                                          |                                                                                                                            | 0                                                                                                                          |                                                                                                                            | 2                                                                                                                          | (<0.1%)                                                                                                                    |
| Study terminated by sponsor                                                                                                | 5                                                                                                                          | (3.4%)                                                                                                                     | 15                                                                                                                         | (5.0%)                                                                                                                     | 0                                                                                                                          |                                                                                                                            | 0                                                                                                                          |                                                                                                                            |
| + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. | + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. | + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. | + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. | + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. | + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. | + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. | + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. | + Wo29074(IMMoTIoNl50 Arm B prior to crossover); Atezo Mono [2]: Atezo Mono [1] + A). Actual treatment arms are presented. |

## Adverse Events that Led to Withdrawal of Study Treatment

The proportion of patients experiencing AEs leading to discontinuation of study treatment was similar in the atezolizumab arm (13.0%) and chemotherapy arm (13.6%).

The most frequent AEs ( ≥ 1% of patients) leading to withdrawal of atezolizumab were pneumonitis (3.0% atezolizumab  vs.  1.4%  chemotherapy)  and  pneumonia  (1.0%  vs.  0.7%).  All  other  AEs  leading  to atezolizumab treatment discontinuation were single occurrences.

The most frequent AEs ( ≥ 1% of patients) leading  to  withdrawal  of  chemotherapy  were  fatigue  (0% atezolizumab vs. 2.7% chemotherapy), pneumonitis (3.0% vs. 1.4%), diarrhea (0% vs. 1.4%) and vomiting (0% vs. 1.4%). Other AEs leading to discontinuation of chemotherapy were single occurrences.

The proportion of patients with AEs leading to discontinuation of study treatment was higher in the atezolizumab arm of IPSOS (13.0%) than the Atezo Mono pooled populations (7.1%-9.3%).

Across all populations, the only AEs leading to withdrawal that were reported in ≥ 1% of patients were pneumonitis (IPSOS atezolizumab arm: 3.0% vs. Atezo Mono pools: 0.3%-0.5%) and pneumonia (1.0% vs. 0.3%-0.4%).

## Adverse Events that Led to Dose Modification/Interruption

Dose modifications of atezolizumab were not permitted per protocol but interruptions or delays of the administration were allowed.

<div style=\"page-break-after: always\"></div>

The proportion of patients experiencing AEs leading to dose modification/interruption was lower in the atezolizumab arm (32.0%) compared with the chemotherapy arm (48.3%).

The most frequently reported AEs ( ≥ 2%) leading to atezolizumab dose modification/interruption were pneumonia (3.0% atezolizumab vs. 7.5% chemotherapy) and dyspnea (2.3% vs 2.7%).

In the chemotherapy arm, the most frequently reported AEs ( ≥ 2%) leading to dose modification/interruption  were  hematologic  toxicities  including  neutropenia  (0.7%  atezolizumab  vs. 10.9% chemotherapy), neutrophil count decreased (0% vs. 6.1%), white blood cell count decreased (0% vs. 6.1%), anemia (0.3% vs. 4.8%), and leukopenia (0% vs. 4.1%), as well as the events of pneumonia (3.0% vs. 7.5%), dyspnea (2.3% vs. 2.7%), fatigue (1.0% vs. 2.7%), decreased appetite (0.7% vs. 2.7%), bronchitis (0.3% vs. 2.0%), constipation (0% vs. 2.0%), and weight decreased (0% vs. 2.0%).

The proportions of patients with AEs leading to atezolizumab dose interruption were comparable between the atezolizumab arm of IPSOS (32.0%) and the Atezo Mono pooled populations (27.8%-28.1%).

## Post marketing experience

Since the International Birth Date (18 May 2016) through 17 May 2023, an estimated cumulative total of 433,872 patients have received TECENTRIQ (atezolizumab) from marketing experience (149,664 patients in the United States, 129,404 patients in the European Economic Area, 50,233 patients in Japan, and 104,572 patients in Rest of the World). Among these, 36,459 (8%) patients received atezolizumab for the treatment of 1L NSCLC (11,827 patients in the European Economic Area; 5,772 patients in the United States, 10,927 patients in Japan, and 7,934 patients in Rest of the World). A further 112,262 (26%) patients received atezolizumab for the treatment of 2L+ NSCLC (50,995 patients in the European Economic Area; 19,060 patients in the United States, 6,796 patients in Japan, and 35,411 patients in Rest of the World).

Safety signals were identified during the latest PBRER reporting interval. The new important identified risks that include immune-mediated pericardial disorders, immune-mediated myelitis and facial paresis, and haemophagocytic lymphohistiocytosis were based on comprehensive review of clinical trial data, literature and post-marketing exposure. Review of the safety results from all completed and ongoing clinical studies during the reporting period suggest that the atezolizumab risk profile remains consistent with the current reference safety information, and the new information did not alter the overall benefit-risk profile of atezolizumab (Periodic Benefit Risk Evaluation Report).

## 2.5.1. Discussion on clinical safety

The randomised safety-evaluable population for IPSOS includes all treated patients i.e., all randomised patients  who  received  at  least  one  dose  of  atezolizumab  (n=300)  and  all  randomised  patients  who received at least one dose in the control arm (single-agent vinorelbine or gemcitabine per investigator's choice, n=147).

During  the  randomisation  phase,  patients  randomised  to  the  atezolizumab  arm  received  1200  mg atezolizumab by IV infusion on Day 1 of every 21-day cycle.

Single-agent atezolizumab regardless of tumour type has been evaluated in a total of 4739 patients, referred to as the pooled population (Atezo mono 2). When adding the 300 patients that were treated with atezolizumab in the IPSOS study this amounts to 5039 patients which is the reference pooled safety population reflected in the section 4.8 of the SmPC.

<div style=\"page-break-after: always\"></div>

The median duration of survival follow-up in the IPSOS study was 41.0 months. The median number of doses of atezolizumab treatment in IPSOS was 6.

Comparison between IPSOS and Atezo Mono Pooled Populations - The patient demographics and baseline characteristics in the atezolizumab arm of IPSOS were generally comparable with the Atezo Mono pooled populations, except for the following: there were more men enrolled in IPSOS compared with the Atezo Mono populations; more Asian and Hispanic/Latino patients, as well as patients from Asia-Pacific and Central/South America in IPSOS; fewer patients from North America in IPSOS; more patients with ECOG PS 2 and 3; and fewer patients with ECOG PS 0 and 1 in IPSOS; IPSOS enrolled older patients (median age: 75 years) compared to the Atezo Mono pooled populations (median age: 64 years). There were more patients 75-84 years of age and ≥ 85 years of age in IPSOS; IPSOS included more patients with a history of tobacco use.

These differences are due to the countries IPSOS was open in and the fact that IPSOS included patients who were deemed unsuitable for platinum-doublet chemotherapy either due to their poor performance status (ECOG PS of 2 or 3) or, for patients with an ECOG PS of 0 or 1, due to older age ( ≥ 70 years) in combination with substantial comorbidities or other contraindication(s) for platinumdoublet chemotherapy, whereas other studies have typically excluded patients with ECOG PS ≥ 2. The discussion of the comparison between IPSOS and atezo mono pooled populations is generally supported.

In the atezolizumab arm of IPSOS (n=300), common AEs were reported for ≥10% of patients including decreased appetite (22.0%), dyspnoea (20.0%), cough (19.7%), fatigue (19.0%), anaemia (16.3%), constipation  (15.7%),  pneumonia  (15.0%),  asthenia  (14.3%),  diarrhoea  (13.3%),  nausea  (10.7%), pyrexia (10.3%) and rash (10.0%). In the pooled population (Atezo mono 2, n=4739) the most common AEs were fatigue, decreased appetite, nausea, cough, diarrhoea, pyrexia, constipation, arthralgia and dyspnoea (all &gt;15%) which is expected in a patient population with primarily advanced cancer disease. Typical chemotherapy-related AEs (nausea, vomiting, anaemia, neutropenia) were, as expected, more common in the chemotherapy arm. Cough, dyspnoea, pruritus, rash and hypothyroidism were more common in the atezolizumab  arm.  This  is  consistent  with  the  known  AE  profile  of  these  respective treatments.

In IPSOS, the proportion of patients with Grade 3-4 AEs in the atezolizumab arm (45.3%) was similar to that in the chemotherapy arm (48.3%). The most common Grade 34 AEs by PT (≥5% of patients in either  arm)  were  (atezolizumab  vs.  chemotherapy,  respectively):  pneumonia  (7.7%  vs.  6.8%), dyspnoea (5.0% vs. 4.8%), hyponatremia (5.3% vs. 3.4%), neutropenia (0.7% vs. 9.5%), anaemia (2.7% vs. 4.8%), and neutrophil count decreased (0% vs. 7.5%).

A similar proportion of patients (45.3%) in the atezolizumab arm of IPSOS experienced Grade 3-4 AEs compared with the Atezo Mono pooled populations (40.9%-46.6%). The most common Grade 3-4 AEs by  PT  (≥5%  of  patients  in  either  arm)  were  (atezolizumab  vs.  At ezo  Mono  pooled  populations, respectively): pneumonia (7.7% vs. 2.5-3.0%), dyspnea (5.0% vs. 2.6-3.7%), hyponatremia (5.3% vs. 2.3-3.1%), anaemia (2.7% vs. 3.8-5.0%), and neutrophil count decreased (0% vs. &lt; 0.1% each).

Adverse events of special interest ( AESI ) for atezo were selected based on its mechanism of action. Overall,  the  proportion  of  patients  who  experienced  AESIs  was  34.3%  in  the  atezolizumab  arm  and 18.4% in the chemotherapy arm. The majority of AESIs were of Grade 1-2 severity. Among the atezo arm of IPSOS (n=300) the most frequent (&gt;2%) AESIs were immune-mediated rash (15.0%), immunemediated  hepatitis  (lab  abnormalities)  (9.0%),  immune-mediated  hypothyroidism  (9.0%),  immunemediated  pneumonitis  (4.3%),  immune-mediated  hyperthyroidism  (2.3%)  and  immune-mediated hepatitis (diagnosis) (2.3%). Grade 3-4 AESIs were reported in 6.7% (20 patients) of patients in the atezolizumab arm and 2.0% (3 patients) in the chemotherapy arm. Three Grade 5 AESIs were reported

Assessment report

<div style=\"page-break-after: always\"></div>

in the atezolizumab arm (hepatitis, pneumonitis, and myasthenia gravis). The proportion of patients in the atezolizumab arm who experienced AESIs leading to treatment discontinuation and dose interruption was 5.7% and 7.0%, respectively. The proportion of  patients  who  experienced  AESIs  that  required systemic  corticosteroid  treatment  was  11.3%  (34  patients)  in  the  atezolizumab  arm  and  4.8%  (7 patients) in the chemotherapy arm.

Overall, the proportion of patients who experienced AESIs in the IPSOS atezolizumab arm (34.3%) was lower compared to the Atezo Mono 2 pooled population (40.3%).

The proportion of patients with at least one SAE was higher in the atezolizumab arm (48.7%) than in the chemotherapy arm (36.1%). The only SAE with a ≥2% higher incidence in the atezolizumab arm compared with the chemotherapy arm was pneumonia (11.0% vs. 7.5%). The proportions of patients with  SAEs  was  also  higher  compared  to  the  Atezo  Mono  2  pooled  population  (41.2%).  This  could potentially be related to the fact that the population targeted in IPSOS was more frail and thus prone to SAEs.

The proportion of patients in the safety-evaluable population who died in the atezolizumab arm (82.7% [248/300 patients]) was lower than that in the chemotherapy arm (87.8% [129/147 patients]). The causes of death were progressive disease (atezolizumab: 59.7% vs. chemotherapy: 70.1%), adverse event (11.7% vs. 8.8%), and 'other' causes (11.3% vs. 8.8%). The frequency of deaths due to AE was higher in the atezo arm of IPSOS than compared with the atezo mono 2 pooled population (11.7% vs. 3.1%). The frequency of deaths was higher in the atezolizumab arm of IPSOS (82.7%) compared to the Atezo Mono 2 pooled population (49.5%), with the leading cause of death being disease progression in all populations. This is likely due to the longer observation period in IPSOS and the overall health status (PS ≥2) of the elderly patient population in IPSOS compared to the Mono pools.

Pneumonia was the most common adverse event that led to death in the atezolizumab arm (2.7%) with overall infections and infestations being the cause in 4.7% of cases. Respiratory, thoracic and mediastinal disorders was the cause in 1.7% of cases. Cardiac disorder (overall) was the cause of death in 1.3% of cases. Sudden cardiac death is listed as cause of death in 0.6% of cases. Myasthenia gravis and immunemediated hepatitis was each cause of death in one case respectively (0.3% and 0.3%).

It is acknowledged that the patient population in IPSOS was older and more frail in comparison with most other atezolizumab monotherapy trials. This is regarded as the most likely explanation behind the higher  occurrence  of  AE  related  deaths  in  the  IPSOS  trial.  Regarding  causality,  the  pattern  of respiratory/thoracic/mediastinal disorders with or without underlying infection as death cause, follows what is expected in this disease setting.

In comparison to the Atezo Mono 2 pool (n=4739), the updated Atezo monotherapy pool (n=5039) for ADRs includes patients from the safety population from IPSOS treated with atezolizumab (n=300). At the time of the primary analysis of OS (CCOD 30 April 2022) for IPSOS, no new adverse drug reactions (ADRs) with atezolizumab monotherapy treatment were identified. The proportions of ADRs in the updated pool are justified and appropriately reflected in section 4.8 of the SmPC.

Laboratory findings: Overall, the percentage of patients in the atezolizumab arm who experienced clinically relevant shifts from baseline (defined as shifts from Grade 0, 1, or 2 at baseline to Grade 3 or 4 post baseline) in any laboratory safety test parameter during study treatment was low. The frequency of  clinically  relevant  shifts  in  hematology  parameter  abnormalities  including  low  neutrophils  (0.9% atezolizumab vs. 19.8% chemotherapy), low white blood cells (1.1% vs. 14.1%) and low lymphocytes (11.1%  vs.  18.5%)  was  higher  in  the  chemotherapy  arm  than  in  the  atezolizumab  arm.  Among biochemistry laboratory parameter abnormalities, the frequency of clinically relevant shifts was similar between the arms except for a higher (≥2%) incidence of low sodium le vels (13.5% vs. 5.3%) and high potassium  levels  (2.6%  vs.  0%)  in  the  atezolizumab  arm  compared  with  the  chemotherapy  arm.

Error! Unknown document property name.

<div style=\"page-break-after: always\"></div>

Treatment-emergent TSH laboratory abnormalities (defined as normal at baseline and abnormal at postbaseline) were reported in patients in both treatment arms (TSH low: 7.3% atezolizumab vs. 4.1% chemotherapy. TSH high: 7.0% vs. 6.1%).

Since the majority of patients were over 65 years old, subgroup analyses by age were only meaningful for the 65 -74, and 75 -84 year old subgroups. Between arms, there was no noteworthy difference in the safety profile for these two subgroups. Within each arm, there was no noteworthy difference in the safety profile between the subgroups with the exception of AEs leading to any study treatment discontinuation (atezolizumab  arm:  65-74:  8.0%  vs.  75-84:  15.8%;  chemotherapy  arm:  65-74:  8.0%  vs.  75-84: 17.1%) and AEs leading to any dose modification or study treatment interruption (atezolizumab arm: 65-74: 28.0% vs. 75-84: 37.4%; chemotherapy arm: 65-74: 62.0% vs. 75-84: 40.0%) which were more common in the 75-84 year subgroup, although the relatively small sample size precludes any meaningful clinical interpretations. This information has been added to the section 4.8 of the SmPC.

Between arms, there was no clinically relevant difference in the safety profile by gender .

Due to low numbers of patients in subgroups other than White and Asian, subgroup analyses by race are not considered meaningful.

The majority of patients (approximately 90%) in both treatment arms had 'normal' hepatic function at baseline. No meaningful conclusions can be drawn comparing the safety data for the relatively small subgroup of patients with mild (N=24) or moderate (N=2) hepatic impairment versus normal (N=273) in the atezolizumab arm.

No meaningful conclusions can be drawn comparing the safety data for the small subgroup of patients with severe renal impairment (n=1) versus the other subgroups in the atezolizumab arm. Although higher  rates  of  Grade  3-4  AEs  and  SAEs  were  noted  in  the  subgroups  of  moderate  vs.  mild  renal impairment  within  the  atezolizumab  arm,  the  relatively  small  sample  size  of  the  moderate  renal impairment  subgroup  precludes  any  meaningful  clinical  interpretation.  Similarly,  higher  rates  of treatment  interruptions  due  to  AEs  were  noted  for  the  subgroup  with  moderate  renal  impairment compared to that with normal renal function in the atezolizumab arm; however the sample size of each of these subgroups were too small to draw any clinically relevant conclusions.

Between arms, the safety profile was generally balanced for previous smokers. Since the majority of patients were previous smokers, subgroup analyses by tobacco use history within each arm are not considered meaningful.

The overall safety profile of atezolizumab was generally similar irrespective of baseline ECOG PS status .

At the CCOD, in the safety-evaluable population, the proportion of patients who had discontinued from treatment  was  comparable  between  the  two  treatment  arms  (95.0%  atezolizumab  vs.  100.0% chemotherapy), with the main reasons being progressive disease (50.3% vs. 51.0%) and death (20.0% vs.  12.2%).  The  proportion  of  patients  treated  with  atezolizumab  in  IPSOS  that  discontinued atezolizumab (95.0%) was higher compared to the Atezo Mono pooled populations (71.0%-82.7%). Progressive  disease  was  the  leading  cause  of  treatment  discontinuation  across  all  populations. Discontinuations due to death were higher in IPSOS (20.0%) than the Atezo Mono pooled populations (0.5-1.1%).

As of the CCOD, in the safety-evaluable population, the proportion of patients that had discontinued from the study was comparable between the treatment arms (Atezo: 95.0% vs. Chemo: 100%; Table 6). The reasons for study discontinuation were generally balanced between the treatment arms, except for 'death' where a lower percentage of patients in the atezolizumab arm discontinued the study due to death  (78.3%)  compared  with  the  chemotherapy  arm  (86.4%).  The  proportion  of  patients  that

<div style=\"page-break-after: always\"></div>

discontinued from study in IPSOS (95.0%) was higher compared to the Atezo Mono pooled populations (55-65.1%), with 'death' being the leading cause across all populations.

The proportion of patients experiencing AEs leading to discontinuation of study treatment was 13.0% in the atezolizumab arm.  The most frequent AEs ( ≥ 1% of patients) leading to withdrawal of atezolizumab were  pneumonitis  (3.0%)  and  pneumonia  (1.0%).  All  other  AEs  leading  to  atezolizumab  treatment discontinuation were single occurrences. The proportion of patients with AEs leading to discontinuation of study treatment was higher in the atezolizumab arm of IPSOS (13.0%) than the Atezo Mono pooled populations (7.1%-9.3%).

## 2.5.2. Conclusions on clinical safety

The safety data of atezolizumab in the IPSOS study were generally consistent with the established safety profile of anti-PD/PD-L1 agents and no new ADRs were observed. Common AEs, SAEs and AESIs were observed  at  rates  consistent  with  previous  studies.  Rates  of  death  due  to  AE  and  AEs  leading  to discontinuation was higher in the IPSOS trial compared to the atezo mono pooled populations. However, the  target  population  of  the  IPSOS  study  was  older  and  more  frail  than  the  atezo  mono  pooled populations.

In conclusion, for the targeted population, the safety profile of atezolizumab monotherapy is considered acceptable and no new safety issues have been raised during the safety assessment.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 29.1 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 29.1 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                               |
|------------------------------|----------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related adverse reactions Infusion-related reactions                                              |
| Important potential risks    | Attenuated efficacy or reduced tolerability in patients with anti-drug antibodies Embryo-foetal toxicity |
| Missing information          | None                                                                                                     |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| There are no Required additional pharmacovigilance activities                                                                                                                                                              | There are no Required additional pharmacovigilance activities                                                                                                                                                              | There are no Required additional pharmacovigilance activities                                                                                                                                                              | There are no Required additional pharmacovigilance activities                                                                                                                                                              | There are no Required additional pharmacovigilance activities                                                                                                                                                              |

## Risk minimisation measures

| Safety concern                    | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                      |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-mediated adverse reactions | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Relevant information for patient in PIL Additional risk minimization measures: Patient cards (all immune- mediated adverse reactions excluding SCARs) SCARs: A one-off DHPC was disseminated in March 2021 to | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: SCARs: Metrics on the distribution and receipt of the DHPC were taken to assess the effectiveness of this risk minimization activity. |

<div style=\"page-break-after: always\"></div>

|                                                                                   | inform healthcare professionals that immune-mediated SCARs, which were previously known to be potentially associated with use of Tecentriq (atezolizumab), are now considered to be an identified risk.                                                                                                                                  |                                                                                                                                                  |
|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Infusion-Related Reactions                                                        | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Relevant information for patient in PIL Additional risk minimization measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Attenuated efficacy or reduced tolerability in patients with anti-drug antibodies | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.8 Undesirable effects No additional risk minimization measures                                                                                                                                              | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities:      |
| Embryo-fetal toxicity                                                             | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.6 Fertility, pregnancy and lactation                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities:      |

<div style=\"page-break-after: always\"></div>

| Section 5.3 Preclinical safety data Relevant information for patient in PIL No additional risk minimization measures   | None   |
|------------------------------------------------------------------------------------------------------------------------|--------|

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC have been updated.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- For the proposed extension, no changes to the package leaflet were made that affected key safety messages.
- The posology proposed in this application is the same as for the currently approved indications.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The finally agreed wording for Tecentriq's new extension of indication is:

Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy (see section 5.1 for selection criteria).

## 3.1.2. Available therapies and unmet medical need

Lung cancer remains the leading cause of cancer deaths worldwide; it is the most common cancer in men (together with prostate cancer) and the third most common cancer in women (after breast and colorectal cancer). It accounted for approximately 11% of all new cancers in 2020 with an estimated 2.2 million new cancer cases and 1.8 million deaths (Sung et al. 2021).

Half of all newly diagnosed NSCLC patients present with advanced disease (Stage IIIb or IV) (SEER 2023). In addition to advanced disease at diagnosis, patients could present with poor performance status (PS), advanced age and a history of unintentional weight loss (Bailey et al. 2023).

<div style=\"page-break-after: always\"></div>

Platinum-based chemotherapy regimens are an efficacious standard of care, but in some patients with substantial comorbidities or specific contraindications, they may not be tolerated and are therefore not an available treatment option (Quoix et al. 2011). For this reason, treatment tolerability is an important factor in treatment decisions for patients.

## 3.1.3. Main clinical studies

This application is based on the results from the single pivotal trial IPSOS (MO29872): A Phase III, open-label, multicenter, randomised 2:1 study to investigate the efficacy and safety of atezolizumab compared with chemotherapy (vinorelbine or gemcitabine) in patients with treatment-naïve advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed ineligible for platinum-containing therapy.

Patients were randomised at a 2:1 ratio to receive either atezolizumab 1200 mg IV q3w or single-agent vinorelbine oral or IV (dosing per local principal investigator) or gemcitabine IV (dosing per local principal investigator). No crossover was allowed between treatment arms. Eligible patients were stratified by: histologic subtype (non-squamous vs. squamous), presence/absence of brain metastases, PD-L1 IHC status  by  VENTANA  PD-L1  (SP142)  assay  (IC3  or  TC3  vs.  IC0/1/2  and  TC0/1/2  vs.  unknown).  The primary  endpoint  was  overall  survival.  Patients  were  recruited  globally.  Overall,  453  patients  were enrolled, and of these a total of 405 patients met the platinum-ineligibility criteria (ad hoc platinum ineligible  population),  corresponding  to  89%  of  the  ITT  population.  Efficacy  data  in  this  subgroup population  is  comparable  to  the  one  of  the  overall  population,  and  is  therefore  supportive  of  the requested extension of indication.

## 3.2. Favourable effects

As of the CCOD (30 April 2022) and with a median follow-up of 41.0 months in the overall population, efficacy data are considered overall mature.

- Median OS was 10.3 months with atezolizumab monotherapy versus a median of 9.2 months in the chemotherapy arm (stratified HR=0.78, 95% CI 0.63, 0.97).
- The  median  PFS  was  4.2  months  vs  4.0  months  in  the  patients  treated  with  atezolizumab  vs chemotherapy, respectively,  while the ORR was 16.9% vs 7.9%, with a median DoR of 14.0 months vs 7.8 months.

## 3.3. Uncertainties and limitations about favourable effects

There are some uncertainties and limitations to be considered when interpreting the results of the pivotal IPSOS study and the relevant platinum-ineligible subgroup reflecting the applied indication:

- The  definition  of  platinum-ineligibility  is  not  based  on  validated  criteria  from  international guidelines, as they do not exist for the targeted disease of advanced NSCLC. The wording of the indication  has  been  revised  to  make  reference  to  section  5.1  of  the  SmPC,  where  specific platinum-ineligible criteria have been defined, i.e. patients &gt;80 years of age, or with an ECOG PS of 3, or patients with an ECOG PS 2 in combination with relevant comorbidities, or of older age (≥70 years) in combination with relev ant comorbidities. Efficacy results from the ad hoc platinum ineligible population were considered supportive of the agreed indication.
- The control arm included two options of single-agent chemotherapy (vinorelbine or gemcitabine) and current standard of care options include more options, so it remains uncertain whether

Assessment report

Error! Unknown document property name.

<div style=\"page-break-after: always\"></div>

inclusion of pemetrexed or docetaxel as additional possibilities in the control arm would have led to different study results. The applicant provided arguments for not having included docetaxel and pemetrexed as treatment options (see 'Discussion on clinical efficacy'), and therefore this uncertainty was not further pursued.

## 3.4. Unfavourable effects

- In  the  atezolizumab  arm  of  IPSOS  (n=300),  common  AEs  were  reported  for  ≥10%  of  patients including  decreased  appetite  (22.0%),  dyspnoea  (20.0%),  cough  (19.7%),  fatigue  (19.0%), anaemia  (16.3%),  constipation  (15.7%),  pneumonia  (15.0%),  asthenia  (14.3%),  diarrhoea (13.3%), nausea (10.7%), pyrexia (10.3%) and rash (10.0%).
- The most common Grade 34 AEs by PT (≥5% of patients in either arm) were (atezolizumab vs. chemotherapy, respectively): pneumonia (7.7% vs. 6.8%), dyspnoea (5.0% vs. 4.8%), hyponatremia (5.3% vs. 3.4%), neutropenia (0.7% vs. 9.5%) and neutrophil count decreased (0% vs. 7.5%).
- The proportion of patients who experienced AESIs was 34.3% in the atezolizumab arm and 18.4% in the chemotherapy arm. The majority of AESIs were of Grade 1-2 severity. Among the atezo arm of IPSOS (n=300) the most frequent (&gt;2%) AESIs were immune-mediated rash (15.0%), immunemediated hepatitis (lab abnormalities) (9.0%), immune-mediated hypothyroidism (9.0%), immunemediated pneumonitis (4.3%), immune-mediated hyperthyroidism (2.3%) and immune-mediated hepatitis (diagnosis) (2.3%).
- Grade 3-4 AESIs were reported in 6.7% (20 patients) of patients in the atezolizumab arm and 2.0% (3 patients) in the chemotherapy arm.
- The proportion of patients with at least one SAE was higher in the atezolizumab arm (48.7%) than in the chemotherapy arm (36.1%). The only SAE with a ≥2% higher incidence in the atezolizumab arm compared with the chemotherapy arm was pneumonia (11.0% vs. 7.5%).
- The proportion of patients experiencing AEs leading to discontinuation of study treatment was 13.0% in  the  atezolizumab  arm.    The  most  frequent  AEs  ( ≥ 1%  of  patients)  leading  to  withdrawal  of atezolizumab  were  pneumonitis  (3.0%)  and  pneumonia  (1.0%).  All  other  AEs  leading  to atezolizumab treatment discontinuation were single occurrences.
- The proportion of patients in the safety-evaluable  population who died in the atezolizumab arm (82.7%  [248/300  patients])  was  lower  than  that  in  the  chemotherapy  arm  (87.8%  [129/147 patients]). The causes of death were progressive disease (atezolizumab: 59.7% vs. chemotherapy: 70.1%), adverse event (11.7% vs. 8.8%), and 'other' causes (11.3% vs. 8.8%).

## 3.5. Uncertainties and limitations about unfavourable effects

None.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 59. Effects Table for IPSOS study, Tecentriq (atezolizumab). Data cut-off: 30 April 2022

| Effect                                                     | Short descrip tion                                         | Unit                                                       | Treatment Atezolizumab mono                                | Control Vinorelbin or gemcitabine                          | Hazard Ratio (CI)                                          | Uncertainties / Strength of evidence                       | Ref                                                        |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Favourable Effects in ITT population of IPSOS, N=453       | Favourable Effects in ITT population of IPSOS, N=453       | Favourable Effects in ITT population of IPSOS, N=453       | Favourable Effects in ITT population of IPSOS, N=453       | Favourable Effects in ITT population of IPSOS, N=453       | Favourable Effects in ITT population of IPSOS, N=453       | Favourable Effects in ITT population of IPSOS, N=453       | Favourable Effects in ITT population of IPSOS, N=453       |
|                                                            |                                                            |                                                            | N=302                                                      | N=151                                                      |                                                            |                                                            |                                                            |
| OS in ITT                                                  | Overall survival                                           | Months (95%CI)                                             | 10.3 (9.4-11.9)                                            | 9.2 (5.9-11.2)                                             | 0.78 (0.63- 0.97)                                          | Censoring for OS/mature data, final analysis               | Clinical efficacy section                                  |
| Effect                                                     | Short descrip tion                                         | Unit                                                       | Treatment Atezolizumab mono                                | Control Chemotherap y                                      |                                                            | Uncertainties / Strength of evidence                       | Ref                                                        |
| Unfavourable Effects in the ITT population of IPSOS, N=447 | Unfavourable Effects in the ITT population of IPSOS, N=447 | Unfavourable Effects in the ITT population of IPSOS, N=447 | Unfavourable Effects in the ITT population of IPSOS, N=447 | Unfavourable Effects in the ITT population of IPSOS, N=447 | Unfavourable Effects in the ITT population of IPSOS, N=447 | Unfavourable Effects in the ITT population of IPSOS, N=447 | Unfavourable Effects in the ITT population of IPSOS, N=447 |
|                                                            |                                                            |                                                            | N=300                                                      | N=147                                                      |                                                            |                                                            |                                                            |
| Gr 3-4                                                     | AE                                                         | %                                                          | 45.3                                                       | 48.3                                                       |                                                            |                                                            | Clinical safety section                                    |
| SAEs                                                       | AE                                                         | %                                                          | 48.7                                                       | 36.1                                                       |                                                            |                                                            |                                                            |
| AEs leading to discont.                                    | AE                                                         | %                                                          | 13.0                                                       | 13.6                                                       |                                                            |                                                            |                                                            |
| Death AE                                                   | AE                                                         | %                                                          | 11.7                                                       | 8.8                                                        |                                                            |                                                            |                                                            |

Abbreviations: Abbreviations: NA = not available, NE: not evaluable, HR: hazard ratio, CI: confidence interval, SAE = serious adverse events.

Notes: not applicable.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

There exists a high unmet medical need for the targeted frail patient population with advanced NSCLC, who are ineligible for platinum-based chemotherapy.

The primary endpoint of OS in the ITT population shows a median OS of 10.3 months with atezolizumab monotherapy versus a median of 9.2 months in the chemotherapy arm (stratified HR=0.78, 95% CI 0.63, 0.97). From a clinical perspective, the difference of 1 month in OS is considered clinically relevant as  it  is  recognised  that  the  targeted  population  is  frail  by  definition,  and  thus  an  overwhelming improvement of survival was not expected. Response rates and duration of responses also appeared superior in the atezolizumab monotherapy arm in comparison to the chemotherapy choices. The results from the ad hoc platinum ineligible population are supportive of the agreed indication.

There remain some uncertainties and limitations to be considered when interpreting the results of the pivotal IPSOS study, including the definition of platinum-ineligibility, which is not based on validated criteria from international guidelines, as they do not exist for the targeted disease of advanced NSCLC and the limited choices of treatments in the control arm. The control arm included two options of singleagent chemotherapy (vinorelbine or gemcitabine) and the current standard of care options include also pemetrexed and docetaxel, so it remains uncertain whether inclusion of additional possibilities in the

<div style=\"page-break-after: always\"></div>

control arm would have led to different study results. However, this issue cannot be further pursued in a concluded trial.

Regarding safety, the toxicity profile of atezolizumab is known and no new ADRs were observed. The higher rate of discontinuation and deaths due to AE in the IPSOS study compared with the atezolizumab monotherapy 2 pooled populations is likely due to the inclusion of older and frailer patients in the IPSOS study.

In conclusion, the Applicant has convincingly argued that a relevant and large subpopulation (89%) of the pivotal IPSOS study can be considered platinum-ineligible from specific criteria, and this is adequately reflected in section 5.1 of the SmPC. Efficacy and safety are comparable for the subgroup and the overall population, and the comparators used are found to be acceptable. Considering the totality of the data, the B/R is positive for the claimed indication.

## 3.7.2. Balance of benefits and risks

The balance of benefits and risks is positive for the applied indication.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall B/R of Tecentriq for the applied indication is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I                  |

Extension of indication to include first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for platinum-based therapy (see section 5.1 for selection criteria), for TECENTRIQ, based on final results from study MO29872 (IPSOS); this is a phase 3, openlabel, multicenter, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment naive advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic (stage IV) NSCLC who are deemed unsuitable for platinumcontaining therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The new indication has been reflected in the SmPC for the IV and the SC formulations. Version 29.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor

Assessment report

<div style=\"page-break-after: always\"></div>

editorial changes to the PI.

The variation leads to amendments to the Summary of Product Characteristics and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and to the Risk Management Plan are recommended.